Original Article
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
N Engl J Med 1999; 341:1565-1571November 18, 1999
- Abstract
Background
Patients with myeloma who relapse after high-dose chemotherapy have few therapeutic options. Since increased bone marrow vascularity imparts a poor prognosis in myeloma, we evaluated the efficacy of thalidomide, which has antiangiogenic properties, in patients with refractory disease.
Methods
Eighty-four previously treated patients with refractory myeloma (76 with a relapse after high-dose chemotherapy) received oral thalidomide as a single agent for a median of 80 days (range, 2 to 465). The starting dose was 200 mg daily, and the dose was increased by 200 mg every two weeks until it reached 800 mg per day. Response was assessed on the basis of a reduction of the myeloma protein in serum or Bence Jones protein in urine that lasted for at least six weeks.
Results
The serum or urine levels of paraprotein were reduced by at least 90 percent in eight patients (two had a complete remission), at least 75 percent in six patients, at least 50 percent in seven patients, and at least 25 percent in six patients, for a total rate of response of 32 percent. Reductions in the paraprotein levels were apparent within two months in 78 percent of the patients with a response and were associated with decreased numbers of plasma cells in bone marrow and increased hemoglobin levels. The microvascular density of bone marrow did not change significantly in patients with a response. At least one third of the patients had mild or moderate constipation, weakness or fatigue, or somnolence. More severe adverse effects were infrequent (occurring in less than 10 percent of patients), and hematologic effects were rare. As of the most recent follow-up, 36 patients had died (30 with no response and 6 with a response). After 12 months of follow-up, Kaplan–Meier estimates of the mean (±SE) rates of event-free survival and overall survival for all patients were 22±5 percent and 58±5 percent, respectively.
Conclusions
Thalidomide is active against advanced myeloma. It can induce marked and durable responses in some patients with multiple myeloma, including those who relapse after high-dose chemotherapy.
Media in This Article
Figure 2
Kaplan–Meier Estimates of Overall Survival and Event-free Survival.Figure 1
Times to Various Paraprotein Responses.Article Activity
- Article
Multiple myeloma accounts for approximately 1 percent of all cancers and 10 percent of hematologic cancers. It is incurable with conventional chemotherapy.1 Melphalan-based high-dose chemotherapy with hematopoietic stem-cell support increases the rate of complete remission and extends event-free and overall survival.2-4 However, many patients still relapse, and options for salvage therapy are limited.5,6
Angiogenesis is important in embryogenesis, wound healing, diabetic retinopathy, and tumor progression.7,8 The immunomodulatory drug thalidomide can inhibit angiogenesis and induce apoptosis of established neovasculature in experimental models.9,10 For these reasons, angiogenesis-inhibiting drugs such as thalidomide may be useful for treating cancers that depend on neovascularization.
Prominent bone marrow vascularization occurs in multiple myeloma. It correlates positively with a high plasma-cell–labeling index (a poor prognostic sign) and disease activity and independently confers a poor prognosis.11-16 Plasma levels of various angiogenic cytokines, such as basic fibroblast growth factor and vascular endothelial growth factor, are elevated in patients with active myeloma.11-13,16 In 1965, Olson et al. reported slowing of disease progression in one patient who was treated with thalidomide.17 These considerations led us to administer thalidomide to five patients with end-stage myeloma through a compassionate-use protocol. One patient with a large tumor burden (as indicated by an IgA level of 8.4 g per deciliter, the presence of more than 95 percent plasma cells in bone marrow, and the need for transfusion), who had had no response to two cycles of high-dose chemotherapy followed by multiple salvage therapies, had a nearly complete remission within three months after the initiation of thalidomide therapy. This observation prompted a phase 2 investigation of thalidomide in patients with advanced and refractory myeloma.
Methods
Patients and Treatments
Between December 1997 and June 1998, 84 consecutive, eligible patients with previously treated and progressive myeloma began treatment with oral thalidomide as a single agent after providing written informed consent. No patients were excluded on the basis of renal or cardiopulmonary function, whereas patients could be excluded if the results of liver-function tests were more than twice the upper limit of normal levels. All patients were treated at a single center according to a phase 2 protocol approved by the institutional review board and the Food and Drug Administration (FDA).
Thalidomide was supplied in 50-mg capsules by Celgene (Warren, N.J.) and was administered nightly at a dose of 200 mg. The dose was increased by 200 mg every two weeks for six weeks, so that the final dose was 800 mg per day. Data were analyzed as of June 17, 1999, when the duration of treatment ranged from 2 to 465 days (median, 80) and the median follow-up of surviving patients was 13 months.
Table 1Table 1
Characteristics of the Patients. summarizes the characteristics of the patients and details of prior therapy. Seventy-six patients (90 percent) had received at least one cycle of high-dose chemotherapy with autologous hematopoietic stem-cell support, and 58 (69 percent) had received two or more cycles of intensive chemotherapy. The median time from the last course of high-dose chemotherapy to the beginning of treatment with thalidomide was 14 months. A high-risk cytogenetic abnormality (deletion of chromosome 13) was present in 35 patients (42 percent).20 One patient had received an allograft as a second intervention, with evidence of full donor-type chimerism in normal lymphohematopoietic cells. At the time of enrollment, all patients had progressive disease, with an increase in paraprotein levels of at least 25 percent or at least 50 percent plasma cells in bone marrow. Approximately half the patients had been retreated with dexamethasone or other regimens, but the disease had progressed before thalidomide treatment was begun.Evaluation
The pretreatment evaluation included complete blood counts, tests of renal and liver function, serum and urine protein electrophoresis, and measurements of serum levels of immunoglobulins, beta2-microglobulin, and C-reactive protein. Bone marrow aspirates were obtained and biopsies were performed to determine the percentage of plasma cells in bone marrow, to identify karyotypic abnormalities (Giemsa-banded cells in metaphase), and to assess the proliferative activity in plasma cells according to the bromodeoxyuridine method to derive the plasma-cell–labeling index.18 Follow-up studies included a weekly estimation of paraprotein levels — the myeloma protein in serum and Bence Jones protein in urine — for the first two months, followed thereafter by monthly measurements. Whenever possible, bone marrow was examined at the time of the maximal response or when patients with no response left the study.
The microvascularity of bone marrow was studied in a semiquantitative fashion in biopsy samples that were obtained with a trephine and stained with an anti-CD34 monoclonal antibody (prediluted Clone QBEnd/10, Cell Marque, Austin, Tex.). The results were expressed as the number of vessels per high-power field (400×).
Assessment of Response
The primary end point of the study was the finding of a decline in the level of paraprotein in serum or urine of at least 25 percent, 50 percent, 75 percent, or 90 percent on two occasions at least six weeks apart. Among patients with detectable levels of both urine and serum paraprotein, the response was judged on the basis of the component showing the smaller decline. Patients with a reduction of less than 25 percent and those who discontinued treatment before a response could be assessed were considered to have had no response to thalidomide. Thus, the results were evaluated on an intention-to-treat basis. In patients with a response, an increase in serum or urine paraprotein levels by more than 25 percent above the nadir value was considered evidence of relapse. In patients who had a complete remission, evidence of reemergence of the monoclonal protein (determined by immunofixation) on at least two occasions was considered to indicate a relapse. In patients who had a complete remission or a nearly complete remission (≥90 percent reduction in serum or urine paraprotein levels), a bone marrow response was defined as the finding of less than 5 percent plasma cells in the biopsy specimen or aspirate. For the remaining patients with a paraprotein response, the percentage of plasma cells had to decrease by at least 50 percent to qualify as a bone marrow response.
Assessment of Adverse Effects
All patients, irrespective of the duration of therapy, were included in the evaluation of adverse effects. All patients received diaries after providing informed consent, and 83 patients (99 percent) reported having adverse effects. A comprehensive checklist of the adverse effects associated with thalidomide therapy was provided by Celgene; it was based on previous experience in treating patients with leprosy and had been reviewed by the FDA. The data were verified by the patients by direct or telephone interviews. Hematologic values and other laboratory-based measures of adverse effects were assessed at least monthly by the data-management office.
Statistical Analysis
The primary end point for this phase 2 study was a diminution in the plasma level of the myeloma protein or the urine level of Bence Jones protein. Other end points included the time to a response, the time to disease progression, event-free survival, overall survival, the microvascularity of bone marrow, and improvements in other laboratory values. Response was treated as a categorical variable. Comparisons of the response according to other categorical variables were assessed with use of the chi-square test or Fisher's exact test, as appropriate. The times to response and disease progression were calculated with the use of the competing-risk methods.21 The time to response was defined as the interval between the start of therapy and a given response (i.e., a decline in the serum or urine level of paraprotein of at least 25 percent, 50 percent, 75 percent, or 90 percent or a complete remission). Competing risks with respect to the time to response included discontinuation of treatment because of progression or a lack of response, an inability to tolerate thalidomide, or death or personal reasons. The time to progression was calculated only for patients with a paraprotein response and was defined as the time from the start of therapy to disease progression. Competing risks with respect to the time to progression included discontinuation of treatment because of adverse effects or death or for personal reasons. Event-free survival and overall survival were estimated according to the method of Kaplan and Meier.22 Event-free survival was calculated from the start of therapy to disease progression, removal from the study for any reason, death from any cause, or the last follow-up visit, whichever occurred first. Overall survival was calculated from the start of therapy to death from any cause or the last follow-up visit. Data on patients who had not had an event by the time of the last follow-up were censored at that time with respect to times to response and progression, event-free survival, and overall survival. Survival was compared with use of the log-rank test.23 Univariate and multivariate (stepwise) logistic-regression methods were used to evaluate the prognostic importance of various characteristics with respect to the likelihood of achieving at least a 25 percent or 50 percent reduction in serum or urine paraprotein levels. Univariate and multivariate (stepwise) proportional-hazards regression analyses were used to evaluate the prognostic importance of various characteristics with respect to event-free survival and overall survival.
Since the microvascular density of bone marrow was used as a measure of the antiangiogenic action of thalidomide, this variable was extensively modeled. To account for the need for multiple measurements of each patient over time and missing data, we used mixed-models repeated-measures analysis of variance to evaluate the microvascular density of bone marrow.24 The use of compound symmetry and first-order autoregressive covariance structures was compared, and the results were found to be similar according to Akaike's criterion. Therefore, the values obtained with the compound-symmetry models are reported. Measurements of the microvascular density of bone marrow were grouped according to the length of treatment, and values were measured every 50 days for a total of seven times, including the pretreatment value. The natural logarithm of the values for the microvascular density of bone marrow was used in the analysis. Estimates for patients with no response and patients with a complete or nearly complete response (≥90 percent reduction in serum or urine paraprotein levels) were used to predict the response in terms of the microvascular density of bone marrow over time.
Improvements in important clinical measures were evaluated on the basis of the percent change from base line to the time of the maximal response or, for those without a response, the time at which treatment was discontinued. Spearman correlations were used to assess whether the changes within response groups were significant. For variables with no significant correlations, the signed-rank test was used to test the hypothesis within response groups that the change was significantly different from zero. All statistical tests were two-sided.
Results
Decline in Paraprotein Levels
Timely escalations in the daily dose of thalidomide to 400 mg, 600 mg, and 800 mg were possible in 83 percent, 62 percent, and 47 percent of the patients, respectively; the proportions of patients who eventually reached these levels were 86 percent, 68 percent, and 55 percent, respectively (Table 1). In 27 patients (32 percent), the serum or urine paraprotein level declined by at least 25 percent, including 7 (8 percent) with a decline of at least 50 percent, 6 (7 percent) with a decline of at least 75 percent, and 6 (7 percent) with a decline of at least 90 percent; 2 patients had a complete remission (Table 2Table 2
Paraprotein Response and Bone Marrow Response.). The median interval between the start of treatment and a decrease in the paraprotein level of at least 25 percent was 29 days (range, 4 days to 6 months) (Figure 1Figure 1Times to Various Paraprotein Responses.). Seventy-eight percent of the responses of this magnitude were apparent within two months; they were observed within four months in all but two patients with a response. More marked reductions in paraprotein, by at least 50 percent and 75 percent, occurred after a median of two and three months of therapy, respectively.A low plasma-cell–labeling index (assessed as a continuous variable) was the only statistically significant variable associated with a response among both the group with at least a 25 percent decrease in paraprotein levels (P=0.01) and the group with at least a 50 percent decrease (P=0.01). Using the median plasma-cell–labeling index of 0.2 percent as a cutoff value, we found that 46 percent of patients with values below the median had a reduction in paraprotein levels of at least 25 percent, as compared with 9 percent of patients with higher values (P<0.05). On univariate analysis, deletion of chromosome 13 was predictive of an unfavorable response, but not on multivariate analysis.
Bone Marrow Response
Bone marrow samples were obtained after one to nine months of therapy (median, three) in 48 patients. A paraprotein response was associated with a bone marrow response in 81 percent of the patients who could be evaluated (Table 2). In seven of the eight patients with at least a 90 percent reduction in paraprotein levels, the concurrently examined bone marrow specimens contained less than 5 percent plasma cells. A decline in the percentage of plasma cells in bone marrow by at least 50 percent occurred in only 4 of 27 patients with no paraprotein response (15 percent) who had follow-up bone marrow examinations.
Microvascular Density of Bone Marrow
The microvascular density of bone marrow was scheduled to be assessed every 50 days for a total of seven measurements, including the pretreatment value. At least one measurement of the microvascular density of bone marrow was made in 74 patients (88 percent); two or more measurements were made in 37 patients (44 percent). In all, measurements were made in 69 patients before treatment and (in 50-day increments) in 17 at time 2, in 22 at time 3, in 11 at time 4, in 12 at time 5, in 4 at time 6, and in 3 at time 7. The microvascular density of bone marrow and the percentage of plasma cells in bone marrow correlated significantly at all times except the last (r>0.5, P≤0.01). Although the microvascular density of bone marrow decreased markedly in some patients with a complete or nearly complete remission, estimates of the slope were not significantly different from zero among those with a response (P=0.39) and those without a response (P=0.22).
Other Changes
The percent changes from base line to the time of the maximal response among patients with a response and the time of the last follow-up visit among those without a response were assessed for beta2-microglobulin, C-reactive protein, lactic dehydrogenase, creatinine, albumin, and hemoglobin levels and the platelet count. Hemoglobin levels increased only in patients with a response (median increase, 11 percent; P<0.001 for the comparison with base-line values). Serum levels of beta2-microglobulin rose (median increase, 43 percent; P<0.001) and serum albumin levels fell (median decrease, 4 percent; P<0.001) significantly in patients with no response. Serum creatinine levels did not change significantly in patients with a response, and they increased by a median of 13 percent in those without a response (P<0.001).
Adverse Effects
Side effects reported by at least 10 percent of patients at most dose levels are listed in Table 3Table 3
Incidence of Grade 1 or 2 Adverse Effects.. Most adverse effects were mild or moderate (grade 1 or 2 according to the system of classification of the World Health Organization). Constipation, weakness or fatigue, and somnolence occurred in one third or more of the patients. Reports of grade 3 or 4 adverse effects were infrequent (less than 10 percent in all cases). One quarter of the patients had no appreciable side effects at the 200-mg dose, whereas virtually all patients had adverse effects of grade 1 or 2 at higher doses. Fewer than 5 percent of patients had grade 1 or 2 leukopenia at any dose, and grade 3 or 4 thrombocytopenia or anemia occurred in only three patients. In most of the patients who had no response, pretreatment anemia or thrombocytopenia did not worsen, whereas significant increases in the hemoglobin levels occurred in patients with a response. Nine patients could not tolerate thalidomide (four with a response and five with no response) and discontinued treatment after a median of 36 days (range, 10 to 241). In eight patients, an increase in serum creatinine levels of more than 50 percent was related to progressive disease, with increasing Bence Jones proteinuria. One of the patients with a response died suddenly on day 37 of treatment. The death was thought to be related to sepsis, although a possible contribution of thalidomide could not be ruled out.Time to Progression, Event-Free Survival, and Overall Survival
Of the 27 patients with a decrease in paraprotein levels of at least 25 percent, 12 had a recurrence of the disease. After a median follow-up of 14.5 months (range, 12 to 16), the median time to progression had not been reached. The disease in a mean (±SE) of 44±10 percent of patients was judged to have progressed at 12 months. The median event-free survival for all 84 patients was three months (Figure 2Figure 2
Kaplan–Meier Estimates of Overall Survival and Event-free Survival.). After 12 months of follow-up, 22±5 percent of the 84 patients remained event-free and 58±5 percent were alive. Nineteen patients were still receiving thalidomide 4 to 15 months after starting the treatment (median, 13), including 15 patients with a response and 4 with no response who had had some improvement in various disease indicators but who had not had a decrease in paraprotein levels of at least 25 percent. Multivariate analysis indicated that increases in lactic dehydrogenase levels (P=0.001), the plasma-cell–labeling index (P=0.006), and C-reactive protein levels (P=0.007) were all predictive of a brief period of event-free survival, whereas low albumin levels (P<0.001), the deletion of chromosome 13 (P=0.004), and high numbers of plasma cells in bone marrow (P=0.05) were associated with a relatively short overall survival.Thalidomide was discontinued after a median of 52 days (range, 2 to 286) because of a lack of response in 53 patients (4 patients continued to receive the drug without a response) and because of relapse in 12 patients who had had a response. One patient who had a decrease in the paraprotein level of at least 25 percent and who had not previously received high-dose therapy subsequently underwent autologous stem-cell transplantation at his own request. As of June 17, 1999, 36 patients had died, including 30 patients without a response who died of progressive disease or complications of subsequent salvage therapy, as well as 6 patients with a response who subsequently relapsed and died of progressive disease (3) or toxicity from salvage therapy (3).
Discussion
We found that thalidomide had substantial antitumor activity in patients with advanced myeloma. Ten percent of patients had complete or nearly complete remission, and 32 percent had a reduction in serum or urine paraprotein levels of at least 25 percent. In most patients, the decline in paraprotein levels was accompanied by a reduction in the percentage of plasma cells in bone marrow and an increase in hemoglobin levels, both of which are consistent with the presence of a true antitumor effect. Although not examined quantitatively, bone pain decreased markedly in patients with a response. We did not evaluate lytic bone lesions, which seldom heal, even in patients with a sustained complete remission.
Thalidomide has a number of properties that could explain its activity in myeloma; it can alter the expression of adhesion molecules,25 suppress the production of tumor necrosis factor α,26 increase the production of interleukin-10,27 and enhance cell-mediated immunity by directly stimulating cytotoxic T cells.28 Its interactions with type 1 and type 2 helper T cells produce complex effects on the levels of cytokines such as interleukin-4, interleukin-5, and interferon-γ.29 Thalidomide also increases the total number of lymphocytes as well as CD8+ and CD4+ T-cell counts, along with substantially increasing mean plasma levels of soluble interleukin-2 receptor.29
Thalidomide has been shown to inhibit angiogenesis induced by fibroblast growth factor and vascular endothelial growth factor in a rabbit-cornea micropocket assay9 and a murine model of corneal vascularization.10 It has also been shown to cause apoptosis of established tumor-associated angiogenesis in experimental models.10 The bone marrow of patients with hematologic cancers shows extensive vascularity,12,13 which has prognostic implications in myeloma.14 The apparent lack of a consistent decrease in the microvascular density of bone marrow in patients in whom thalidomide had a marked antitumor effect requires further study. The persistence of extensive vascularization in some patients with a response is consistent with the finding of persistent neovascularity in patients with multiple myeloma who had a response to high-dose chemotherapy.15 The production of angiogenic cytokines such as fibroblast growth factor and vascular endothelial growth factor by undetectable residual myeloma cells may sustain the increased microvascular density of bone marrow in patients considered to be in remission on the basis of bone marrow findings. The persistence of extensive vascularization in patients with a response makes it seem likely that the antimyeloma action of thalidomide depends on more than one of the actions of the drug outlined above. The mouse model of severe combined immunodeficiency, which can be used for the in vivo growth of primary human myeloma cells, is ideally suited to study the mechanisms by which thalidomide induces responses in myeloma.30
The antitumor properties of thalidomide are being evaluated in various malignant diseases,31-35 although only limited efficacy data are available so far. Prolonged responses to thalidomide in some patients with advanced refractory disease suggest that the mechanism of action of thalidomide is distinctly different from that of the other agents active against myeloma. The absence of myelosuppressive and other important adverse effects suggests that thalidomide could be an ideal agent for use in combination with chemotherapy. Indeed, a complete remission has been achieved with such an approach in several patients with myeloma who had no response to treatment with either regimen alone.36 This approach has also been shown to have greater antitumor activity than chemotherapy alone in a murine model of breast cancer.37
In our study, most patients had adverse effects, but the majority of these reactions were mild or moderate. Reducing the dose of thalidomide alleviated the effects in most cases, and only nine patients discontinued therapy altogether. The gradual reduction in drowsiness and fatigue in some patients with continued treatment at the same dose (data not shown) suggests the occurrence of tachyphylaxis.
We conclude that thalidomide is active against multiple myeloma, even in patients who relapsed after repeated cycles of high-dose chemotherapy. Larger studies of thalidomide, its analogues, and other inhibitors of angiogenesis are therefore warranted in patients with myeloma and other cancers. We are currently evaluating thalidomide in combination with chemotherapy for patients with newly diagnosed multiple myeloma.
Supported in part by a grant from the National Cancer Institute (CA55819). Celgene Corporation contributed to the data collection and analysis and provided the study drug free of cost.
Dr. Zeldis is an employee of Celgene Corporation, and Drs. Mehta and Singhal own stock in Celgene, which manufactures thalidomide.
We are indebted to Beth Wolmer for her persistence in recommending the clinical evaluation of thalidomide in the treatment of multiple myeloma; to the members of the myeloma data-management team for their dedication; and to Caran Swanson for her excellent secretarial assistance. This article is dedicated to the memory of Ira Wolmer, M.D.
Source Information
From the Myeloma and Lymphoma Program, South Carolina Cancer Center, University of South Carolina, Columbia (S.S., J.M.); the Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock (R.D., D.A., P.R., P.E., N.M., E.A., C.W., J.Z., B.B.); and the Laboratory of Cellular Physiology and Immunology, Rockefeller University, New York (M.D.).
Address reprint requests to Dr. Barlogie at the Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, 4301 W. Markham, Slot 623, Little Rock, AR 72205.
Other authors were David Siegel, M.D., Ph.D., University of Arkansas for Medical Sciences, Little Rock, and John Crowley, Ph.D., Fred Hutchinson Cancer Research Center, Seattle.
- References
References
1
Alexanian R ,Dimopoulos M . The treatment of multiple myeloma. N Engl J Med 1994;330:484-489
Full Text | Web of Science | Medline2
Barlogie B . Advances in therapy of multiple myeloma: lessons from acute leukemia. Clin Cancer Res 1997;3:2605-2613
Web of Science | Medline3
Attal M ,Harousseau J-L ,Stoppa A-M , et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-97
Full Text | Web of Science | Medline4
Barlogie B ,Jagannath S ,Vesole DH , et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997;89:789-793
Web of Science | Medline5
Tricot G ,Jagannath S ,Vesole DH ,Crowley J ,Barlogie B . Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant 1995;16:7-11
Web of Science | Medline6
Singhal S ,Tricot G ,Jagannath S , et al. Outcome of relapse after transplantation in myeloma. Blood 1996;88:Suppl 1:611a-611a abstract.7
Battegay EJ . Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 1995;73:333-346
CrossRef | Web of Science | Medline8
Folkman J . Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31
CrossRef | Web of Science | Medline9
D'Amato RJ ,Loughnan MS ,Flynn E ,Folkman J . Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91:4082-4085
CrossRef | Web of Science | Medline10
Kenyon BM ,Browne F ,D'Amato RJ . Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997;64:971-978
CrossRef | Web of Science | Medline11
Vacca A ,Ribatti D ,Roncali L , et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503-508
CrossRef | Web of Science | Medline12
Vacca A ,Di Loreto M ,Ribatti D , et al. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules: LFA-1, VLA-4, LAM-1, and CD44. Am J Hematol 1995;50:9-14
CrossRef | Web of Science | Medline13
Vacca A ,Ribatti D ,Roncali L ,Dammacco F . Angiogenesis in B cell lymphoproliferative diseases: biological and clinical studies. Leuk Lymphoma 1995;20:27-38
CrossRef | Web of Science | Medline14
Munshi N ,Wilson CS ,Penn J , et al. Angiogenesis in newly diagnosed multiple myeloma: poor prognosis with increased microvessel density (MVD) in bone marrow biopsies. Blood 1998;92:Suppl 1:98a-98a abstract.
Web of Science15
Rajkumar SV ,Fonseca R ,Witzig TE ,Gertz MA ,Greipp PR . Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia 1999;13:469-472
CrossRef | Web of Science | Medline16
Vacca A ,Ribatti D ,Presta M , et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999;93:3064-3073
Web of Science | Medline17
Olson KB ,Hall TC ,Horton J ,Khung CL ,Hosley HF . Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer. Clin Pharmacol Ther 1965;6:292-297
Web of Science | Medline18
Greipp PR ,Witzig TE ,Gonchoroff NJ , et al. Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc 1987;62:969-977
Web of Science | Medline19
Bartl R ,Frisch B ,Fateh-Moghadam A ,Kettner G ,Jaeger K ,Sommerfeld W . Histologic classification and staging of multiple myeloma: a retrospective and prospective study of 674 cases. Am J Clin Pathol 1987;87:342-355
Web of Science | Medline20
Tricot G ,Barlogie B ,Jagannath S , et al. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995;86:4250-4256
Web of Science | Medline21
Gaynor JJ ,Feuer EJ ,Tan CC , et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc 1993;88:400-409
CrossRef | Web of Science22
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science23
Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170
Medline24
Jennrich RI ,Schluchter MD . Unbalanced repeated-measures models with structured covariance matrices. Biometrics 1986;42:805-820
CrossRef | Web of Science | Medline25
Geitz H ,Handt S ,Zwingenberger K . Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996;31:213-221
CrossRef | Web of Science | Medline26
Sampaio EP ,Sarno EN ,Galilly R ,Cohn ZA ,Kaplan G . Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991;173:699-703
CrossRef | Web of Science | Medline27
Corral LG ,Muller GW ,Moreira AL , et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med 1996;2:506-515
Web of Science | Medline28
Haslett PAJ ,Corral LG ,Albert M ,Kaplan G . Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998;187:1885-1892
CrossRef | Web of Science | Medline29
McHugh SM ,Rifkin IR ,Deighton J , et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995;99:160-167
CrossRef | Web of Science | Medline30
Yaccoby S ,Barlogie B ,Epstein J . Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 1998;92:2908-2913
Web of Science | Medline31
Minchinton AI ,Fryer KH ,Wendt KR ,Clow KA ,Hayes MM . The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs 1996;7:339-343
CrossRef | Web of Science | Medline32
Figg WD ,Bergan R ,Brawley O , et al. Randomized phase II study of thalidomide in androgen-independent prostate cancer (AIPC). Proc Am Soc Clin Oncol 1997;16:333a-333a abstract.33
Fine HA ,Loeffler JS ,Kyritsis A , et al. A phase II trial of the anti-angiogenic agent, thalidomide, in patients with recurrent high-grade gliomas. Proc Am Soc Clin Oncol 1997;16:385a-385a abstract.34
Long G ,Vredenburgh J ,Rizzeri DA , et al. Pilot trial of thalidomide post-autologous peripheral blood progenitor cell transplantation (PBPC) in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 1998;17:181a-181a abstract.35
Eisen T ,Boshoff C ,Vaughan MM , et al. Anti-angiogenic treatment of metastatic melanoma, renal cell, ovarian and breast cancers with thalidomide: a phase II study. Proc Am Soc Clin Oncol 1998;17:441a-441a abstract.36
Barlogie B ,Desikan R ,Munshi N , et al. Single course D.T. PACE anti-angiochemotherapy effects CR in plasma cell leukemia and fulminant multiple myeloma (MM). Blood 1998;92:Suppl 1:273b-273b abstract.
Web of Science37
Nguyen M ,Tran C ,Barsky JR , et al. Thalidomide and chemotherapy combination: preliminary results of preclinical and clinical studies. Int J Oncol 1997;10:965-969
Web of Science | Medline
- Citing Articles (796)
Citing Articles
1
Sonia Vallet, Mathias Witzens-Harig, Dirk Jaeger, Klaus Podar. (2012) Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies. Expert Opinion on Pharmacotherapy1-22
CrossRef2
Mahmoud R Gaballa, Jacob P Laubach, Robert L Schlossman, Katherine Redman, Kimberly Noonan, Constantine S Mitsiades, Irene M Ghobrial, Nikhil Munshi, Kenneth C Anderson, Paul G Richardson. (2012) Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Review of Hematology 5:1, 51-68
CrossRef3
Fengjuan Fan, Alexander Schimming, Dirk Jaeger, Klaus Podar. (2012) Targeting the Tumor Microenvironment: Focus on Angiogenesis. Journal of Oncology 2012, 1-16
CrossRef4
Katsuyuki Shirai, Michael R. Siedow, Arnab Chakravarti. (2012) Antiangiogenic Therapy for Patients with Recurrent and Newly Diagnosed Malignant Gliomas. Journal of Oncology 2012, 1-12
CrossRef5
Christian M. Zechmann, Lisa Traine, Tobias Meißner, Barbara Wagner-Gund, Frederik L. Giesel, Hartmut Goldschmidt, Stefan Delorme, Jens Hillengass. (2012) Parametric Histogram Analysis of Dynamic Contrast-enhanced MRI in Multiple Myeloma. Academic Radiology 19:1, 100-108
CrossRef6
S. Vincent Rajkumar. (2012) Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. American Journal of Hematology 87:1, 78-88
CrossRef7
E. Shannon, F. Sandoval, N. Greig, P. Stagg. (2012) Lenalidomide alone or lenalidomide plus dexamethasone significantly inhibit IgG and IgM in vitro…A possible explanation for their mechanism of action in treating multiple myeloma. International Immunopharmacology
CrossRef8
Y. Cao, J. Arbiser, R. J. D'Amato, P. A. D'Amore, D. E. Ingber, R. Kerbel, M. Klagsbrun, S. Lim, M. A. Moses, B. Zetter, H. Dvorak, R. Langer. (2011) Forty-Year Journey of Angiogenesis Translational Research. Science Translational Medicine 3:114, 114rv3-114rv3
CrossRef9
Satadal Chatterjee, Shobhan Gaddameedhi. 2011. In-Depth Look: Anti-TNF-α Therapies. .
CrossRef10
Hakan Kaya, Benjamin Peressini, Irfan Jawed, Danko Martincic, Ameer L. Elaimy, Wayne T. Lamoreaux, Robert K. Fairbanks, Kevin A. Weeks, Christopher M. Lee. (2011) Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients. International Journal of Hematology
CrossRef11
Sung-Hsin Kuo, Ann-Lii Cheng, Chung-Wu Lin, Chih-Hung Hsu, Ming-Shiang Wu, Kun-Huei Yeh, Yi-Shin Tzeng, Li-Tzong Chen. (2011) t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement. Cancer Chemotherapy and Pharmacology 68:6, 1387-1395
CrossRef12
Giovanni Germano, Alberto Mantovani, Paola Allavena. (2011) Targeting of the innate immunity/inflammation as complementary anti-tumor therapies. Annals of Medicine 43:8, 581-593
CrossRef13
Anne Ormerod, Christopher A. Fausel, Rafat Abonour, Patrick J. Kiel. (2011) Observations of Second Primary Malignancy in Patients With Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia
CrossRef14
F. Elice, F. Rodeghiero. (2011) Hematologic malignancies and thrombosis. Thrombosis Research
CrossRef15
Youssef L. Bennani. (2011) Drug discovery in the next decade: innovation needed ASAP. Drug Discovery Today
CrossRef16
Satoshi Sakamoto, Mamoru Hatakeyama, Takumi Ito, Hiroshi Handa. (2011) Tools and methodologies capable of isolating and identifying a target molecule for a bioactive compound. Bioorganic & Medicinal Chemistry
CrossRef17
Ibrahim Yakoub-Agha, Jean-Yves Mary, Cyrille Hulin, Chantal Doyen, Gérald Marit, Lotfi Benboubker, Laurent Voillat, Philippe Moreau, Christian Berthou, Anne-Marie Stoppa, Frédéric Maloisel, Philippe Rodon, Mamoun Dib, Brigitte Pegourie, Philippe Casassus, Borhane Slama, Ghandi Damaj, Robert Zerbib, Jean-Luc Harousseau, Mohamad Mohty, Thierry Facon, . (2011) Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome. European Journal of Haematologyno-no
CrossRef18
Hirokazu Miki, Shuji Ozaki, Shingen Nakamura, Asuka Oda, Hiroe Amou, Akishige Ikegame, Keiichiro Watanabe, Masahiro Hiasa, Qu Cui, Takeshi Harada, Shiro Fujii, Ayako Nakano, Kumiko Kagawa, Kyoko Takeuchi, Ken-ichiro Yata, Akira Sakai, Masahiro Abe, Toshio Matsumoto. (2011) KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts. British Journal of Haematology 155:3, 328-339
CrossRef19
Asher A. Chanan-Khan, Kasyapa Chitta, Noreen Ersing, Aneel Paulus, Aisha Masood, Taimur Sher, Abhisek Swaika, Paul K. Wallace, Terry L. Mashtare, Greg Wilding, Kelvin Lee, Myron S. Czuczman, Ivan Borrello, Naveen Bangia. (2011) Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. British Journal of Haematology 155:4, 457-467
CrossRef20
Heyang Jin, Melinda Hemingway, Ram B. Gupta, Fei Xia, Yaping Zhao. (2011) Preparation of thalidomide nano-flakes by supercritical antisolvent with enhanced mass transfer. Particuology
CrossRef21
Michel Delforge. (2011) Bortezomib for previously untreated multiple myeloma. Expert Opinion on Pharmacotherapy 12:16, 2553-2564
CrossRef22
Naoki Hosen, Hiroyoshi Ichihara, Atsuko Mugitani, Yasutaka Aoyama, Yuki Fukuda, Satoshi Kishida, Yoshikazu Matsuoka, Hiroko Nakajima, Manabu Kawakami, Tamotsu Yamagami, Shigeo Fuji, Hiroya Tamaki, Takafumi Nakao, Sumiyuki Nishida, Akihiro Tsuboi, Shinsuke Iida, Masayuki Hino, Yoshihiro Oka, Yusuke Oji, Haruo Sugiyama. (2011) CD48 as a novel molecular target for antibody therapy in multiple myeloma. British Journal of Haematologyno-no
CrossRef23
S. Mailankody, R. M. Pfeiffer, S. Y. Kristinsson, N. Korde, M. Bjorkholm, L. R. Goldin, I. Turesson, O. Landgren. (2011) Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood 118:15, 4086-4092
CrossRef24
J. Miller, P.A. Alton. (2011) Myelomatous pleural effusion-A case report. Respiratory Medicine CME
CrossRef25
Stefano Sacchi, Raffaella Marcheselli, Antonio Lazzaro, Fortunato Morabito, Alberto Fragasso, Nicola Di Renzo, Enrico Balleari, Santo Neri, Giovanni Quarta, Raimondo Ferrara, Maria Luigia Vigliotti, Giuseppe Polimeno, Pellegrino Musto, Ugo Consoli, Alessandra Zoboli, Gabriele Buda, Alessandro Pastorini, Luciano Masini. (2011) A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant. Leukemia & Lymphoma 52:10, 1942-1948
CrossRef26
Marek Hus, Norbert Grzasko, Marta Szostek, Andrzej Pluta, Grzegorz Helbig, Dariusz Woszczyk, Maria Adamczyk-Cioch, Dariusz Jawniak, Wojciech Legiec, Marta Morawska, Justyna Kozinska, Piotr Waciński, Anna Dmoszynska. (2011) Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. Annals of Hematology 90:10, 1161-1166
CrossRef27
F L Khanim, B A M E Merrick, H V Giles, M Jankute, J B Jackson, L J Giles, J Birtwistle, C M Bunce, M T Drayson. (2011) Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production. Blood Cancer Journal 1:10, e39
CrossRef28
S. V. Rajkumar, G. Gahrton, P. L. Bergsagel. (2011) Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 118:12, 3205-3211
CrossRef29
M. Q. Lacy, J. B. Allred, M. A. Gertz, S. R. Hayman, K. D. Short, F. Buadi, A. Dispenzieri, S. Kumar, P. R. Greipp, J. A. Lust, S. J. Russell, D. Dingli, S. Zeldenrust, R. Fonseca, P. L. Bergsagel, V. Roy, A. K. Stewart, K. Laumann, S. J. Mandrekar, C. Reeder, S. V. Rajkumar, J. R. Mikhael. (2011) Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 118:11, 2970-2975
CrossRef30
Elena Zamagni, Alessandro Petrucci, Patrizia Tosi, Paola Tacchetti, Giulia Perrone, Annamaria Brioli, Lucia Pantani, Beatrice Zannetti, Carolina Terragna, Michele Baccarani, Michele Cavo. (2011) Long-term results of thalidomide and dexamethasone (thal–dex) as therapy of first relapse in multiple myeloma. Annals of Hematology
CrossRef31
Youssef L. Bennani. (2011) Drug discovery in the next decade: innovation needed ASAP. Drug Discovery Today 16:17-18, 779-792
CrossRef32
Philipp Baumann, Laura Schneider, Sonja Mandl-Weber, Fuat Oduncu, Ralf Schmidmaier. (2011) Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anti-Cancer Drugs1
CrossRef33
, Britta Auel, Hartmut Goldschmidt, Thomas Geer, Thomas M. Moehler, Uwe Platzbecker, Ralph Naumann, Igor Blau, Mathias Hänel, Wolfgang Knauf, Holger Nückel, Hans-Jürgen Salwender, Christof Scheid, Katja Weisel, Marcus Gorschlüter, Axel Glasmacher, Ingo G. H. Schmidt-Wolf. (2011) Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma. Indian Journal of Hematology and Blood Transfusion
CrossRef34
S. Madan, M. Q. Lacy, A. Dispenzieri, M. A. Gertz, F. Buadi, S. R. Hayman, K. Detweiler-Short, D. Dingli, S. Zeldenrust, J. Lust, P. R. Greipp, S. V. Rajkumar, S. Kumar. (2011) Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. Blood 118:7, 1763-1765
CrossRef35
P. M. Fayers, A. Palumbo, C. Hulin, A. Waage, P. Wijermans, M. Beksac, S. Bringhen, J.-Y. Mary, P. Gimsing, F. Termorshuizen, R. Haznedar, T. Caravita, P. Moreau, I. Turesson, P. Musto, L. Benboubker, M. Schaafsma, P. Sonneveld, T. Facon, . (2011) Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 118:5, 1239-1247
CrossRef36
Francesca Patriarca, Hermann Einsele, Francesco Spina, Benedetto Bruno, Miriam Isola, Chiara Nozzoli, Andrea Nozza, Alessandra Sperotto, Fortunato Morabito, Gernot Stuhler, Moreno Festuccia, Alberto Bosi, Renato Fanin, Paolo Corradini. (2011) Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability. Biology of Blood and Marrow Transplantation
CrossRef37
S K Kumar, J H Lee, J J Lahuerta, G Morgan, P G Richardson, J Crowley, J Haessler, J Feather, A Hoering, P Moreau, X LeLeu, C Hulin, S K Klein, P Sonneveld, D Siegel, J Bladé, H Goldschmidt, S Jagannath, J S Miguel, R Orlowski, A Palumbo, O Sezer, S V Rajkumar, B G M Durie, Niels Abildgaard, Rafat Abonour, Ray Alexanian, Melissa Alsina, Kenneth, C Anderson, Michael Attal, Hervé Avet-Loiseau, Ashraf Badros, Dalsu Baris, Bart Barlogie, Régis Bataille, Meral Beksaç, Andrew Belch, Dina Ben-Yehuda, Bill Bensinger, P Leif Bergsagel, Jenny Bird, Joan Bladé, Mario Boccadoro, Michele Cavo, Asher Chanan-Khan, Wen Ming Chen, Tony Child, James Chim, Wee-Joo Chng, Ray Comenzo, John Crowley, William Dalton, Faith Davies, Cármino de Souza, Michel Delforge, Meletios Dimopoulos, Angela Dispenzieri, Johannes Drach, Matthew Drake, Brian G M Durie, Hermann Einsele, Theirry Facon, Dorotea Fantl, Jean-Paul Fermand, Rafael Fonseca, Gösta Gahrton, Ramón García-Sanz, Christina Gasparetto, Morie Gertz, John Gibson, Sergio Giralt, Hartmut Goldschmidt, Philip Greipp, Roman Hajek, Izhar Hardan, Parameswaran Hari, Jean-Luc Harousseau, Hiroyuki Hata, Yutaka Hattori, Tom Heffner, Joy Ho, Vania Hungria, Shinsuke Ida, Peter Jacobs, Sundar Jagannath, Hans Johnsen, Hou Jian, Douglas Joshua, Artur Jurczyszyn, Michio Kawano, Nicolaus Kröger, Shaji Kumar, Robert A Kyle, Martha Lacy, Juan José Lahuerta, Ola Landgren, Jacob Laubach, Jae Hoon Lee, Xavier LeLeu, Suzanne Lentzsch, Henk Lokhorst, Sagar Lonial, Heinz Ludwig, Angelo Maiolino, María Mateos, Jayesh Mehta, Ulf-Henrik Mellqvist, GiamPaolo Merlini, Joseph Mikhael, Angelina Rodríguez Morales, Philippe Moreau, Gareth Morgan, Hareth Nari, Nikhil Munshi, Ruben Niesvizky, Amara Nouel, Yana Novis, Robert Orlowski, Antonio Palumbo, Santiago Pavlovsky, Linda Pilarski, Raymond Powles, Noopur Raje, S Vincent Rajkumar, Donna Reece, Tony Reiman, Paul G Richardson, David Roodman, Laura Rosiñol, Jesús San Miguel, Orhan Sezer, Jatin J Shah, John Shaughnessy, Kazuyuki Shimizu, Chaim Shustik, David Siegel, Seema Singhal, Pieter Sonneveld, Andrew Spencer, Edward Stadtmauer, Keith Stewart, Evangelos Terpos, Patrizia Tosi, Guido Tricot, Ingemar Turesson, Ben Van Camp, Brian Van Ness, Ivan Van Riet, Isabelle Vande Broek, Karin Vanderkerken, Robert Vescio, David Vesole, Anders Waage, Michael Wang, Donna Weber, Jan Westin, Keith Wheatley, Jeffrey Zonder. (2011) Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia
CrossRef38
Sumit Madan, Shaji Kumar. (2011) Current treatment options for elderly patients with multiple myeloma: clinical impact of novel agents. Therapy 8:4, 415-429
CrossRef39
V. J. Haupt, M. Schroeder. (2011) Old friends in new guise: repositioning of known drugs with structural bioinformatics. Briefings in Bioinformatics 12:4, 312-326
CrossRef40
J. T. Dudley, T. Deshpande, A. J. Butte. (2011) Exploiting drug-disease relationships for computational drug repositioning. Briefings in Bioinformatics 12:4, 303-311
CrossRef41
Steven Chuan-Hao Kao, Rozelle Harvie, Florian Paturi, Robyn Taylor, Ross Davey, Rick Abraham, Stephen Clarke, Gavin Marx, Martin Cullen, Zoltan Kerestes, Nick Pavlakis. (2011) The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer
CrossRef42
M. A. Sukhai, P. A. Spagnuolo, S. Weir, J. Kasper, L. Patton, A. D. Schimmer. (2011) New sources of drugs for hematologic malignancies. Blood 117:25, 6747-6755
CrossRef43
M. Victoria Mateos, Jesús San-Miguel. (2011) Treatment of Newly Diagnosed Myeloma in Patients not Eligible for Transplantation. Current Hematologic Malignancy Reports 6:2, 113-119
CrossRef44
Benedetto Bruno, Francesca Gay, Mario Boccadoro, Antonio Palumbo. (2011) Management of Myeloma: An Italian Perspective. Clinical Lymphoma Myeloma and Leukemia 11, S82-S86
CrossRef45
Niels W.C.J. van de Donk, Henk M. Lokhorst, Meletios Dimopoulos, Michele Cavo, Gareth Morgan, Hermann Einsele, Martin Kropff, Steve Schey, Hervé Avet-Loiseau, Heinz Ludwig, Hartmut Goldschmidt, Pieter Sonneveld, Hans E. Johnsen, Joan Bladé, Jesús F. San-Miguel, Antonio Palumbo. (2011) Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treatment Reviews 37:4, 266-283
CrossRef46
Yonghua Li, Zujun Jiang, Yang Xiao, Li Li, Yang Gao. (2011) Metabolism of thalidomide by human liver microsome cytochrome CYP2C19 is required for its antimyeloma and antiangiogenic activities in vitro. Hematological Oncologyn/a-n/a
CrossRef47
Martha Q. Lacy. (2011) New Immunomodulatory Drugs in Myeloma. Current Hematologic Malignancy Reports 6:2, 120-125
CrossRef48
D. KOLEVA, S. CORTELAZZO, C. TOLDO, L. GARATTINI. (2011) Healthcare costs of multiple myeloma: an Italian study. European Journal of Cancer Care 20:3, 330-336
CrossRef49
Haruyuki Fujita, Masakatsu Hishizawa, Soichiro Sakamoto, Tadakazu Kondo, Norimistu Kadowaki, Takayuki Ishikawa, Junji Itoh, Atsushi Fukatsu, Takashi Uchiyama, Akifumi Takaori-Kondo. (2011) Durable hematological response and improvement of nephrotic syndrome on thalidomide therapy in a patient with refractory light chain deposition disease. International Journal of Hematology 93:5, 673-676
CrossRef50
Giulia Benevolo, Alessandra Larocca, Massimo Gentile, Patrizia Pregno, Francesca Gay, Barbara Botto, Chiara Frairia, Andrea Evangelista, Fortunato Morabito, Mario Boccadoro, Umberto Vitolo, Antonio Palumbo. (2011) The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens. Cancer 117:9, 1884-1890
CrossRef51
Takumi Ito, Hideki Ando, Hiroshi Handa. (2011) Teratogenic effects of thalidomide: molecular mechanisms. Cellular and Molecular Life Sciences 68:9, 1569-1579
CrossRef52
J. Jakubikova, S. Adamia, M. Kost-Alimova, S. Klippel, D. Cervi, J. F. Daley, D. Cholujova, S.-Y. Kong, M. Leiba, S. Blotta, M. Ooi, J. Delmore, J. Laubach, P. G. Richardson, J. Sedlak, K. C. Anderson, C. S. Mitsiades. (2011) Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood 117:17, 4409-4419
CrossRef53
S. Vincent Rajkumar. (2011) Treatment of multiple myeloma. Nature Reviews Clinical Oncology 8:8, 479-491
CrossRef54
Bart Barlogie, Vanessa Bolejack, Michael Schell, John Crowley. (2011) Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival. Annals of Hematology 90:4, 423-428
CrossRef55
P Kapoor, S V Rajkumar, A Dispenzieri, M A Gertz, M Q Lacy, D Dingli, J R Mikhael, V Roy, R A Kyle, P R Greipp, S Kumar, S J Mandrekar. (2011) Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia 25:4, 689-696
CrossRef56
Martha Q. Lacy, Ayalew Tefferi. (2011) Pomalidomide therapy for multiple myeloma and myelofibrosis: an update. Leukemia & Lymphoma 52:4, 560-566
CrossRef57
Lun Yang, Ke-Jian Wang, Li-Shan Wang, Anil G. Jegga, Sheng-Ying Qin, Guang He, Jian Chen, Yue Xiao, Lin He. (2011) Chemical-protein interactome and its application in off-target identification. Interdisciplinary Sciences: Computational Life Sciences 3:1, 22-30
CrossRef58
Roch Houot, Holbrook Kohrt, Matthew J. Goldstein, Ronald Levy. (2011) Immunomodulating antibodies and drugs for the treatment of hematological malignancies. Cancer and Metastasis Reviews 30:1, 97-109
CrossRef59
Jacob Laubach, Paul Richardson, Kenneth Anderson. (2011) Multiple Myeloma. Annual Review of Medicine 62:1, 249-264
CrossRef60
Keith Wheatley, Andrew Howman, Cassey Brookes, Rebecca Stowe, Kelly Handley, Benjamin Djulbegovic, Keith Wheatley. 2011. Thalidomide, lenalidomide and their analogues, as therapy for multiple myeloma. .
CrossRef61
Jae-Cheol Jo, Byung Woog Kang, Sun Jin Sym, Sung Sook Lee, Geundoo Jang, Shin Kim, Dae Ho Lee, Sang-We Kim, Jung Shin Lee, Cheolwon Suh. (2011) Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma. Investigational New Drugs 29:1, 175-181
CrossRef62
Douglas W. McMillin, Jake Delmore, Joseph Negri, Leutz Buon, Hannah M. Jacobs, Jacob Laubach, Jana Jakubikova, Melissa Ooi, Patrick Hayden, Robert Schlossman, Nikhil C. Munshi, Christoph Lengauer, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades. (2011) Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. British Journal of Haematology 152:4, 420-432
CrossRef63
Guadalupe Martínez-Jaramillo, Jorge Vela-Ojeda, Patricia Flores-Guzmán, Hector Mayani. (2011) In vitro growth of hematopoietic progenitors and stromal bone marrow cells from patients with multiple myeloma. Leukemia Research 35:2, 250-255
CrossRef64
Somashekar G. Krishna, Weizhi Zhao, Monica L. Grazziutti, Naveen Sanathkumar, Bart Barlogie, Elias J. Anaissie. (2011) Incidence and risk factors for lower alimentary tract mucositis after 1529 courses of chemotherapy in a homogenous population of oncology patients. Cancer 117:3, 648-655
CrossRef65
Hui-Ju Ch’ang, Chiun Hsu, Chien-Hung Chen, Ya-Hui Chang, Jeffrey S. Chang, Li-Tzong Chen. (2011) Phase II Study of Concomitant Thalidomide During Radiotherapy for Hepatocellular Carcinoma. International Journal of Radiation OncologyBiologyPhysics
CrossRef66
Ola Landgren, S. Vincent Rajkumar. (2011) Development of Early Treatment Strategies for High-Risk Myeloma Precursor Disease in the Future. Seminars in Hematology 48:1, 66-72
CrossRef67
Naohiro Sekiguchi, Naoki Takezako, Akihisa Nagata, Miyuki Wagatsuma, Satoshi Noto, Kazuaki Yamada, Akiyoshi Miwa. (2011) Successful Treatment of Immunoglobulin D Myeloma by Bortezomib and Dexamethasone Therapy. Internal Medicine 50:21, 2653-2657
CrossRef68
Christopher P. Venner, Joseph M. Connors, Heather J. Sutherland, John D. Shepherd, Linda Hamata, Yasser Abou Mourad, Michael J. Barnett, Raewyn Broady, Donna L. Forrest, Donna E. Hogge, Stephen H. Nantel, Sujaatha Narayanan, Thomas J. Nevill, Janet Nitta, Maryse M. Power, Cynthia L. Toze, Clayton A. Smith, Kevin W. Song. (2011) Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months). Leukemia & Lymphoma 52:1, 34-41
CrossRef69
S. Vincent Rajkumar. (2011) Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. American Journal of Hematology 86:1, 57-65
CrossRef70
Stefan Knop. (2011) Continuous Treatment in Multiple Myeloma – Ready for Prime Time?. Onkologie 34:8, 461-466
CrossRef71
Meletios A. Dimopoulos, Jesus F. San-Miguel, Kenneth C. Anderson. (2011) Emerging therapies for the treatment of relapsed or refractory multiple myeloma. European Journal of Haematology 86:1, 1-15
CrossRef72
Irina Idler, Nupur Bhattacharya, Hartmut Döhner, Stephan Stilgenbauer, Daniel Mertens. (2011) Immune modulatory agents in hematopoietic malignancies. Cancer Treatment Reviews 37, S2-S7
CrossRef73
Goce Dimeski, Peter Wood. (2011) Sudden significant total protein concentration change: not an analytical problem. Journal of Clinical Laboratory Analysis 25:5, 330-331
CrossRef74
Zeinab A. Issa, Mira S. Zantout, Sami T. Azar. (2011) Multiple Myeloma and Diabetes. ISRN Endocrinology 2011, 1-6
CrossRef75
Hye Jung Chang, Jae Hoon Lee, Young Rok Do, Sung-Hwa Bae, Jung-Lim Lee, Seung Hyun Nam, Sung-Soo Yoon, Soo-Mee Bang. (2011) A Combination of Melphalan, Prednisone, and 50 mg Thalidomide Treatment in Non-Transplant-Candidate Patients with Newly Diagnosed Multiple Myeloma. The Korean Journal of Internal Medicine 26:4, 403
CrossRef76
FE Davies, KC Anderson. 2011. Abnormalities in immunoglobulin synthesizing cells. , 451-469.
CrossRef77
A. J. Waxman, P. J. Mink, S. S. Devesa, W. F. Anderson, B. M. Weiss, S. Y. Kristinsson, K. A. McGlynn, O. Landgren. (2010) Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 116:25, 5501-5506
CrossRef78
Jean-Luc Harousseau. (2010) Ten Years of Improvement in the Management of Multiple Myeloma: 2000-2010. Clinical Lymphoma, Myeloma & Leukemia 10:6, 424-442
CrossRef79
S. Lonial. (2010) Relapsed Multiple Myeloma. Hematology 2010:1, 303-309
CrossRef80
Enrique M. Ocio, Jesús F. San Miguel. (2010) The DAC system and associations with multiple myeloma. Investigational New Drugs 28:S1, 28-35
CrossRef81
S. Y. Kristinsson. (2010) Thrombosis in Multiple Myeloma. Hematology 2010:1, 437-444
CrossRef82
Michel Delforge, Joan Bladé, Meletios A Dimopoulos, Thierry Facon, Martin Kropff, Heinz Ludwig, Antonio Palumbo, Philip Van Damme, Jesús F San-Miguel, Pieter Sonneveld. (2010) Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. The Lancet Oncology 11:11, 1086-1095
CrossRef83
Anuj Mahindra, Teru Hideshima, Kenneth C. Anderson. (2010) Multiple myeloma: biology of the disease. Blood Reviews 24, S5-S11
CrossRef84
Kristen Detweiler-Short, Suzanne Hayman, Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri, Shaji Kumar, Steven R. Zeldenrust, Stephen J. Russell, John A. Lust, Robert A. Kyle, Philip R. Greipp, Thomas E. Witzig, S. Vincent Rajkumar. (2010) Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. American Journal of Hematology 85:10, 737-740
CrossRef85
Massimo Offidani, Pietro Leoni, Laura Corvatta, Claudia Polloni, Silvia Gentili, Anna Marina Liberati, Stefano Pulini, Alessandro Gozzetti, Stelvio Ballanti, Chiara Nozzoli, Antonio Palumbo. (2010) Outcome and Toxicity in the Modern Era of New Drugs for Multiple Myeloma: A Reappraisal for Comparison With Future Investigational Trials. Clinical Lymphoma, Myeloma & Leukemia 10:5, 353-360
CrossRef86
Anna Dmoszynska, Adam Walter-Croneck, Iwona Hus, Norbert Grzasko, Joanna Manko, Wieslaw Wiktor Jedrzejczak, Grzegorz Charlinski, Lidia Usnarska-Zubkiewicz, Aleksander Skotnicki, Teresa Wolska-Smolen, Jaroslaw Piszcz, Janusz Kloczko. (2010) The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma—A report by the Polish Myeloma Study Group. Leukemia Research 34:10, 1330-1335
CrossRef87
J. Mehta, M. Cavo, S. Singhal. (2010) How I treat elderly patients with myeloma. Blood 116:13, 2215-2223
CrossRef88
D P Cronin-Fenton, F Søndergaard, L A Pedersen, J P Fryzek, K Cetin, J Acquavella, J A Baron, H T Sørensen. (2010) Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006. British Journal of Cancer 103:7, 947-953
CrossRef89
Christoph Ufer, Chi Chiu Wang, Astrid Borchert, Dagmar Heydeck, Hartmut Kuhn. (2010) Redox Control in Mammalian Embryo Development. Antioxidants & Redox Signaling 13:6, 833-875
CrossRef90
A. Waage, P. Gimsing, P. Fayers, N. Abildgaard, L. Ahlberg, B. Bjorkstrand, K. Carlson, I. M. Dahl, K. Forsberg, N. Gulbrandsen, E. Haukas, O. Hjertner, M. Hjorth, T. Karlsson, L. M. Knudsen, J. L. Nielsen, O. Linder, U.-H. Mellqvist, I. Nesthus, J. Rolke, M. Strandberg, J. H. Sorbo, F. Wisloff, G. Juliusson, I. Turesson, . (2010) Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 116:9, 1405-1412
CrossRef91
Mehnaz A. Shafi, Robert S. Bresalier. (2010) The Gastrointestinal Complications of Oncologic Therapy. Gastroenterology Clinics of North America 39:3, 629-647
CrossRef92
, Sung Sook Lee, Cheolwon Suh, Bong-Seog Kim, Jooseop Chung, Young-Don Joo, Hun-Mo Ryoo, Young Rok Do, Jong-Youl Jin, Hye Jin Kang, Gyeong-Won Lee, Moon Hee Lee, Hyeok Shim, Kihyun Kim, Sung-Soo Yoon, Soo Mee Bang, Ho Young Kim, Je-Jung Lee, Jinny Park, Dong Soon Lee, Jae-Hoon Lee. (2010) Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety. Annals of Hematology 89:9, 905-912
CrossRef93
F. van Rhee, J. Szymonifka, E. Anaissie, B. Nair, S. Waheed, Y. Alsayed, N. Petty, J. D. Shaughnessy, A. Hoering, J. Crowley, B. Barlogie. (2010) Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood 116:8, 1220-1227
CrossRef94
Adam J. Waxman, Michael Kuehl, Arun Balakumaran, Brendan Weiss, Ola Landgren. (2010) Smoldering (Asymptomatic) Multiple Myeloma: Revisiting the Clinical Dilemma and Looking Into the Future. Clinical Lymphoma, Myeloma & Leukemia 10:4, 248-257
CrossRef95
Edwin P. Alyea, Daniel J. DeAngelo, Jeffrey Moldrem, John M. Pagel, Donna Przepiorka, Michel Sadelin, James W. Young, Sergio Giralt, Michael Bishop, Stan Riddell. (2010) NCI First International Workshop on the Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: Report from the Committee on Prevention of Relapse Following Allogeneic Cell Transplantation for Hematologic Malignancies. Biology of Blood and Marrow Transplantation 16:8, 1037-1069
CrossRef96
Chanchal Rana, Seema Sharma, Vinita Agrawal, Uttam Singh. (2010) Bone marrow angiogenesis in multiple myeloma and its correlation with clinicopathological factors. Annals of Hematology 89:8, 789-794
CrossRef97
Stephen A. Schey, Gareth J. Morgan, Karthik Ramasamy, Beth Hazel, Dariusz Ladon, Sophie Corderoy, Matthew Jenner, Karen Phekoo, Kevin Boyd, Faith E. Davies. (2010) The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. British Journal of Haematology 150:3, 326-333
CrossRef98
A. Palumbo, F. Davies, M. Kropff, J. Bladé, M. Delforge, F. Costa, R. Garcia Sanz, S. Schey, T. Facon, G. Morgan, P. Moreau. (2010) Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma. Annals of Hematology 89:8, 803-811
CrossRef99
Monika Engelhardt, Martina Kleber, Josefina Udi, Ralph Wäsch, Andrew Spencer, Francesca Patriarca, StefAn Knop, Benedetto Bruno, Martin Gramatzki, Fortunato Morabito, Martin Kropff, Antonino Neri, Orhan Sezer, Rom Hajek, Donald Bunjes, Mario Boccadoro, Christian Straka, Michele Cavo, Aaron Polliack, Hermann Einsele, Antonio Palumbo. (2010) Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leukemia & Lymphoma 51:8, 1424-1443
CrossRef100
S. Y. Kristinsson, R. M. Pfeiffer, M. Bjorkholm, L. R. Goldin, S. Schulman, C. Blimark, U.-H. Mellqvist, A. Wahlin, I. Turesson, O. Landgren. (2010) Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood 115:24, 4991-4998
CrossRef101
Tiffany Richards, Donna Weber. (2010) Advances in treatment for relapses and refractory multiple myeloma. Medical Oncology 27:S1, 25-42
CrossRef102
P. Moreau, C. Hulin. (2010) Les nouveaux médicaments du myélome. Oncologie 12:5-6, 353-361
CrossRef103
Steve Schey, Irene Higginson. (2010) Cost–effectiveness of lenalidomide in multiple myeloma. Expert Review of Pharmacoeconomics & Outcomes Research 10:3, 229-238
CrossRef104
Jacob P. Laubach, Paul G. Richardson, Kenneth C. Anderson. (2010) The evolution and impact of therapy in multiple myeloma. Medical Oncology 27:S1, 1-6
CrossRef105
Thomas Reske, Mariateresa Fulciniti, Nikhil C. Munshi. (2010) Mechanism of action of immunomodulatory agents in multiple myeloma. Medical Oncology 27:S1, 7-13
CrossRef106
David Dingli, S. Vincent Rajkumar. (2010) How best to use new therapies in multiple myeloma. Blood Reviews 24:3, 91-100
CrossRef107
A Palumbo, A Larocca, P Falco, G Sanpaolo, A P Falcone, V Federico, L Canepa, M Crugnola, M Genuardi, V Magarotto, M T Petrucci, M Boccadoro. (2010) Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. Leukemia 24:5, 1037-1042
CrossRef108
Brian G.M. Durie. (2010) Role of new treatment approaches in defining treatment goals in multiple myeloma – the ultimate goal is extended survival. Cancer Treatment Reviews 36, S18-S23
CrossRef109
María-Victoria Mateos. (2010) Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treatment Reviews 36, S24-S32
CrossRef110
Liliana Guedez, William G. Stetler-Stevenson. (2010) The prognostic value of TIMP-1 in multiple myeloma. Leukemia Research 34:5, 576-577
CrossRef111
Hyeon-Seok Eom, Yeo-Kyeoung Kim, Joo-Seop Chung, Kihyun Kim, Hyo Jung Kim, Ho Young Kim, Jong-Youl Jin, Young-Rok Do, Suk-Joong Oh, Cheolwon Suh, Chu-Myong Seong, Chul Soo Kim, Dong Soon Lee, Jae Hoon Lee. (2010) Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP). Annals of Hematology 89:5, 489-497
CrossRef112
Keren Osman, Brian Elliott, John Mandeli, Eileen Scigliano, Adriana Malone, Luis Isola, Celia Grosskreutz. (2010) Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma. American Journal of Hematology 85:4, 249-254
CrossRef113
D. J. Tsakiris, V. S. Stel, P. Finne, E. Fraser, J. Heaf, J. de Meester, S. Schmaldienst, F. Dekker, E. Verrina, K. J. Jager. (2010) Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study. Nephrology Dialysis Transplantation 25:4, 1200-1206
CrossRef114
E.J. Shannon, F. Sandoval. (2010) Thalidomide inhibited the synthesis of IgM and IgG whereas Thalidomide+Dexamethasone and Dexamethasone alone acted as co-stimulants with pokeweed and enhanced their synthesis. International Immunopharmacology 10:4, 487-492
CrossRef115
T. Ito, H. Ando, T. Suzuki, T. Ogura, K. Hotta, Y. Imamura, Y. Yamaguchi, H. Handa. (2010) Identification of a Primary Target of Thalidomide Teratogenicity. Science 327:5971, 1345-1350
CrossRef116
S. Rutsch, V. T. Neppalli, D.-M. Shin, W. DuBois, H. C. Morse, H. Goldschmidt, S. Janz. (2010) IL-6 and MYC collaborate in plasma cell tumor formation in mice. Blood 115:9, 1746-1754
CrossRef117
Toshiya Suzuki, Masahito Tanaka, Motoo Shiro, Norio Shibata, Tetsuya Osaka, Toru Asahi. (2010) Evaluation of stability difference between asymmetric homochiral dimer in (S)-thalidomide crystal and symmetric heterochiral dimer in (RS)-thalidomide crystal. Phase Transitions 83:3, 223-234
CrossRef118
M. Kropff, W.E. Berdel. (2010) Therapieoptionen im Rezidiv des multiplen Myeloms. Der Onkologe 16:3, 282-288
CrossRef119
Thean Hsiang TAN, Ganesalingam PRANAVAN, Hodo Z HAXHIMOLLA, Desmond YIP. (2010) New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies. Asia-Pacific Journal of Clinical Oncology 6:1, 5-18
CrossRef120
Anuj Mahindra, Diana Cirstea, Noopur Raje. (2010) Novel therapeutic targets for multiple myeloma. Future Oncology 6:3, 407-418
CrossRef121
Martha Q. Lacy, S. Vincent Rajkumar. (2010) Pomalidomide: A new IMiD with remarkable activity in both multiple myeloma and myelofibrosis. American Journal of Hematology 85:2, 95-96
CrossRef122
M. Varettoni, A. Corso, G. Pica, S. Mangiacavalli, C. Pascutto, M. Lazzarino. (2010) Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Annals of Oncology 21:2, 325-330
CrossRef123
, Youngil Koh, Soo-Mee Bang, Jae Hoon Lee, Hwi-Joong Yoon, Young-Rok Do, Hun-Mo Ryoo, Nari Lee, Seok Jin Kim, Kihyun Kim, Sung-Soo Yoon, Jong-Ho Won, Yeung-Chul Mun, Moon-Hee Lee, Ki-Hyun Rhee, Hyo-Jung Kim, HyeonSeok Eom, Min Kyoung Kim, Hyun Chun Shin. (2010) Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. Annals of Hematology 89:2, 201-206
CrossRef124
Don M. Benson, Kathryn Panzner, Mehdi Hamadani, Craig C. Hofmeister, Courtney E. Bakan, Megan K. Smith, Pat Elder, David Krugh, Lynn O'Donnell, Steven M. Devine. (2010) Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma. Leukemia & Lymphoma 51:2, 243-251
CrossRef125
Michael Medinger, Natalie Fischer, Alexandar Tzankov. (2010) Vascular Endothelial Growth Factor-Related Pathways in Hemato-Lymphoid Malignancies. Journal of Oncology 2010, 1-13
CrossRef126
Isabelle Azaïs, Rachel Brault, Françoise Debiais. (2010) New treatments for myeloma. Joint Bone Spine 77:1, 20-26
CrossRef127
S Vincent Rajkumar, Susanna Jacobus, Natalie S Callander, Rafael Fonseca, David H Vesole, Michael E Williams, Rafat Abonour, David S Siegel, Michael Katz, Philip R Greipp. (2010) Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. The Lancet Oncology 11:1, 29-37
CrossRef128
Nobuhiro Ooba, Tsugumichi Sato, Hikaru Watanabe, Kiyoshi Kubota. (2010) Resolving a Double Standard for Risk Management of Thalidomide. Drug Safety 33:1, 35-45
CrossRef129
S V Rajkumar, N M-B Killmann. (2009) Spotlight review series on multiple myeloma. Leukemia 23:1r, R1-R2
CrossRef130
Weiyan Zheng, Guoqing Wei, Xiujin Ye, Jingsong He, Li Li, Wenjun Wu, Jimin Shi, Jie Zhang, Weijia Huang, Wanzhuo Xie, Yi Luo, Xingkui Xue, Maofang Lin, He Huang, Zhen Cai. (2009) Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: A Chinese experience. Leukemia Research 33:12, 1615-1618
CrossRef131
Joseph M. Negri, Douglas W. McMillin, Jake Delmore, Nicholas Mitsiades, Patrick Hayden, Steffen Klippel, Teru Hideshima, Dharminder Chauhan, Nikhil C. Munshi, Carolyn A. Buser, John Pollard, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades. (2009) In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. British Journal of Haematology 147:5, 672-676
CrossRef132
Thoralf Christoffersen, Tormod K. Guren, Karen-Lise Garm Spindler, Olav Dahl, Per Eystein Lønning, Bjørn Tore Gjertsen. (2009) Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. European Journal of Pharmacology 625:1-3, 6-22
CrossRef133
J P Laubach, A Mahindra, C S Mitsiades, R L Schlossman, N C Munshi, I M Ghobrial, N Carreau, T Hideshima, K C Anderson, P G Richardson. (2009) The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia 23:12, 2222-2232
CrossRef134
S Ueno, H Tatetsu, H Hata, T Iino, H Niiro, K Akashi, D G Tenen, H Mitsuya, Y Okuno. (2009) PU.1 induces apoptosis in myeloma cells through direct transactivation of TRAIL. Oncogene 28:46, 4116-4125
CrossRef135
Shihui Li, Fang Xue, Zhiyong Cheng, Xiaoyang Yang, Suyun Wang, Fengyong Geng, Ling Pan. (2009) Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFκB p65. International Journal of Hematology 90:4, 513-521
CrossRef136
Jesus San-Miguel, M Victoria Mateos, Norma C. Gutierrez. (2009) Risk Stratification in the Era of Novel Therapies. The Cancer Journal 15:6, 457-464
CrossRef137
Diana Cirstea, Sonia Vallet, Noopur Raje. (2009) Future Novel Single Agent and Combination Therapies. The Cancer Journal 15:6, 511-518
CrossRef138
A P Chiang, A J Butte. (2009) Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses. Clinical Pharmacology & Therapeutics 86:5, 507-510
CrossRef139
Bhawna Sirohi, Ray Powles. (2009) Lenalidomide in multiple myeloma. Expert Review of Anticancer Therapy 9:11, 1559-1570
CrossRef140
Sherif S. Farag, Shuhong Zhang, Buffy S. Jansak, Xiaojing Wang, Eric Kraut, Kenneth Chan, Janet E. Dancey, Michael R. Grever. (2009) Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leukemia Research 33:11, 1475-1480
CrossRef141
Jacob P. Laubach, Paul G. Richardson, Kenneth C. Anderson. (2009) Hematology: Thalidomide maintenance in multiple myeloma. Nature Reviews Clinical Oncology 6:10, 565-566
CrossRef142
K Giannopoulos, A Dmoszynska, M Kowal, E Wąsik-Szczepanek, A Bojarska-Junak, J Rolinski, H Döhner, S Stilgenbauer, L Bullinger. (2009) Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia. Leukemia 23:10, 1771-1778
CrossRef143
Robert J. Greenstein, Liya Su, Sheldon T. Brown. (2009) On the effect of thalidomide on Mycobacterium avium subspecies paratuberculosis in culture. International Journal of Infectious Diseases 13:5, e254-e263
CrossRef144
Enrico Balleari, Andrea Bruzzone. (2009) Unusual myeloma relapse after thalidomide therapy: The dark side of the moon?. Leukemia Research 33:9, 1164-1165
CrossRef145
Alessandro Corso, Patrizia Zappasodi, Luciana Barbarano, Maria Teresa Petrucci, Antonio Palumbo, Tommaso Caravita, Silvia Mangiacavalli, Anna Maria Cafro, Marzia Varettoni, Francesca Gay, Enrica Morra, Mario Lazzarino. (2009) Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects. Leukemia Research 33:9, e145-e149
CrossRef146
S. M. Lee, P. J. Woll, R. Rudd, D. Ferry, M. O'Brien, G. Middleton, S. Spiro, L. James, K. Ali, M. Jitlal, A. Hackshaw. (2009) Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial. JNCI Journal of the National Cancer Institute 101:15, 1049-1057
CrossRef147
Christine Chen, Donna E. Reece, David Siegel, Ruben Niesvizky, Ralph V. Boccia, Edward A. Stadtmauer, Rafat Abonour, Paul Richardson, Jeffrey Matous, Shaji Kumar, Nizar J. Bahlis, Melissa Alsina, Robert Vescio, Steven E. Coutre, Dennis Pietronigro, Robert D. Knight, Jerome B. Zeldis, Vincent Rajkumar. (2009) Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. British Journal of Haematology 146:2, 164-170
CrossRef148
Marc S Raab, Klaus Podar, Iris Breitkreutz, Paul G Richardson, Kenneth C Anderson. (2009) Multiple myeloma. The Lancet 374:9686, 324-339
CrossRef149
C B Reeder, D E Reece, V Kukreti, C Chen, S Trudel, J Hentz, B Noble, N A Pirooz, J E Spong, J G Piza, V H J Zepeda, J R Mikhael, J F Leis, P L Bergsagel, R Fonseca, A K Stewart. (2009) Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 23:7, 1337-1341
CrossRef150
Uday Popat, Rima Saliba, Rupinderjit Thandi, Chitra Hosing, Muzaffar Qazilbash, Paolo Anderlini, Elizabeth Shpall, John McMannis, Martin Körbling, Amin Alousi, Borje Andersson, Yago Nieto, Partow Kebriaei, Issa Khouri, Marcos de Lima, Donna Weber, Sheeba Thomas, Michael Wang, Roy Jones, Richard Champlin, Sergio Giralt. (2009) Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation 15:6, 718-723
CrossRef151
Gautam Sethi, Vinay Tergaonkar. (2009) Potential pharmacological control of the NF-κB pathway. Trends in Pharmacological Sciences 30:6, 313-321
CrossRef152
E Kastritis, K Zervas, A Symeonidis, E Terpos, S Delimbassi, N Anagnostopoulos, E Michali, A Zomas, E Katodritou, D Gika, A Pouli, D Christoulas, M Roussou, Z Kartasis, T Economopoulos, M A Dimopoulos. (2009) Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). Leukemia 23:6, 1152-1157
CrossRef153
Hirokazu Murakami, Kazuyuki Shimizu, Morio Sawamura, Kenshi Suzuki, Isamu Sugiura, Hiroshi Kosugi, Chihiro Shimazaki, Masafumi Taniwaki, Masahiro Abe, Toshiyuki Takagi. (2009) Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed/refractory multiple myeloma. International Journal of Hematology 89:5, 636-641
CrossRef154
Angela Pennisi, Xin Li, Wen Ling, Sharmin Khan, Dana Gaddy, Larry J. Suva, Bart Barlogie, John D. Shaughnessy, Nazneen Aziz, Shmuel Yaccoby. (2009) Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease. British Journal of Haematology 145:6, 775-787
CrossRef155
Edward A. Stadtmauer, Donna M. Weber, Ruben Niesvizky, Andrew Belch, Miles H. Prince, Jesús F. San Miguel, Thierry Facon, Marta Olesnyckyj, Zhinuan Yu, Jerome B. Zeldis, Robert D. Knight, Meletios A. Dimopoulos. (2009) Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. European Journal of Haematology 82:6, 426-432
CrossRef156
Yoshihiro Inamoto, Shingo Kurahashi, Nobuhiko Imahashi, Nobuaki Fukushima, Tatsuya Adachi, Tomohiro Kinoshita, Keitaro Tsushita, Koichi Miyamura, Tomoki Naoe, Isamu Sugiura. (2009) Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation. American Journal of Hematology 84:5, 283-286
CrossRef157
N Raje, T Hideshima, S Mukherjee, M Raab, S Vallet, S Chhetri, D Cirstea, S Pozzi, C Mitsiades, M Rooney, T Kiziltepe, K Podar, Y Okawa, H Ikeda, R Carrasco, P G Richardson, D Chauhan, N C Munshi, S Sharma, H Parikh, B Chabner, D Scadden, K C Anderson. (2009) Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia 23:5, 961-970
CrossRef158
G L Uy, S D Goyal, N M Fisher, A Y Oza, M H Tomasson, K Stockerl-Goldstein, J F DiPersio, R Vij. (2009) Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study. Bone Marrow Transplantation 43:10, 793-800
CrossRef159
J.-L. Harousseau, M. Dreyling, . (2009) Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 20:Supplement 4, iv97-iv99
CrossRef160
Ellen Meijer, Pieter Sonneveld. (2009) Hematology: Lenalidomide plus dexamethasone is effective in multiple myeloma. Nature Reviews Clinical Oncology 6:5, 247-248
CrossRef161
S. Knop, C. Gerecke, P. Liebisch, M. S. Topp, U. Platzbecker, O. Sezer, C. Vollmuth, K. Falk, A. Glasmacher, U. Maeder, H. Einsele, R. C. Bargou. (2009) Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 113:18, 4137-4143
CrossRef162
E. M. Ocio, P. Maiso, X. Chen, M. Garayoa, S. Alvarez-Fernandez, L. San-Segundo, D. Vilanova, L. Lopez-Corral, J. C. Montero, T. Hernandez-Iglesias, E. de Alava, C. Galmarini, P. Aviles, C. Cuevas, J. F. San-Miguel, A. Pandiella. (2009) Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood 113:16, 3781-3791
CrossRef163
H. Ludwig, R. Hajek, E. Tothova, J. Drach, Z. Adam, B. Labar, M. Egyed, I. Spicka, H. Gisslinger, R. Greil, I. Kuhn, N. Zojer, A. Hinke. (2009) Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 113:15, 3435-3442
CrossRef164
Jonathan Kaufman, Charise Gleason, Sagar Lonial. (2009) Treatment of relapsed and refractory myeloma. Current Hematologic Malignancy Reports 4:2, 99-107
CrossRef165
Peter H. Wiernik. (2009) Treatment of Hematologic Neoplasms with New Immunomodulatory Drugs (IMiDs). Current Treatment Options in Oncology 10:1-2, 1-15
CrossRef166
Efstathios Kastritis, Antonio Palumbo, Meletios A. Dimopoulos. (2009) Treatment of Relapsed/Refractory Multiple Myeloma. Seminars in Hematology 46:2, 143-157
CrossRef167
F. DAVIES, C. MORRIS, J. BIRD, G. COOK, C. WILLIAMS, J. TIGHE, J. CAVENAGH, J. BEHRENS, S. SCHEY, G. MORGAN, . (2009) United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma. International Journal of Laboratory Hematology 31:2, 119-131
CrossRef168
S. Vincent Rajkumar, Pieter Sonneveld. (2009) Front-Line Treatment in Younger Patients With Multiple Myeloma. Seminars in Hematology 46:2, 118-126
CrossRef169
Wesley Hsu, Thomas A. Kosztowski, Hasan A. Zaidi, Michael Dorsi, Ziya L. Gokaslan, Jean-Paul Wolinsky. (2009) Multidisciplinary Management of Primary Tumors of the Vertebral Column. Current Treatment Options in Oncology 10:1-2, 107-125
CrossRef170
Thierry Facon, Jesus San Miguel, Maria Victoria Mateos, Cyrille Hulin. (2009) Frontline Treatment in Elderly Patients With Multiple Myeloma. Seminars in Hematology 46:2, 133-142
CrossRef171
Ingrid I van Gameren, Edo Vellenga, Bouke PC Hazenberg. (2009) Novel treatments for systemic amyloidosis. International Journal of Clinical Rheumatology 4:2, 171-188
CrossRef172
Efstathios Kastritis, Andreas Charidimou, Andreas Varkaris, Meletios A. Dimopoulos. (2009) Targeted therapies in multiple myeloma. Targeted Oncology 4:1, 23-36
CrossRef173
Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster, Edward A. Stadtmauer, Thierry Facon, Jean-Luc Harousseau, Dina Ben-Yehuda, Sagar Lonial, Hartmut Goldschmidt, Donna Reece, Joan Bladé, Mario Boccadoro, Jamie D. Cavenagh, Anthony L. Boral, Dixie-Lee Esseltine, Patrick Y. Wen, Anthony A. Amato, Kenneth C. Anderson, Jesus San Miguel. (2009) Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. British Journal of Haematology 144:6, 895-903
CrossRef174
Vincent Peigne, Kateřina Rusinová, Lionel Karlin, Michael Darmon, Jean-Paul Fermand, Benoît Schlemmer, Élie Azoulay. (2009) Continued survival gains in recent years among critically ill myeloma patients. Intensive Care Medicine 35:3, 512-518
CrossRef175
Philipp Baumann, Karin Müller, Sonja Mandl-Weber, Johann Leban, Robert Doblhofer, Astrid Ammendola, Roland Baumgartner, Fuat Oduncu, Ralf Schmidmaier. (2009) The peptide-semicarbazone S-2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells. British Journal of Haematology 144:6, 875-886
CrossRef176
Vrushali Dabak, Philip Kuriakose. (2009) Thalidomide-induced severe hepatotoxicity. Cancer Chemotherapy and Pharmacology 63:4, 583-585
CrossRef177
Khaled M. Musallam, Fadi S. Dahdaleh, Ali I. Shamseddine, Ali T. Taher. (2009) Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy. Thrombosis Research 123:5, 679-686
CrossRef178
Philipp Baumann, Sonja Mandl-Weber, Fuat Oduncu, Ralf Schmidmaier. (2009) The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Experimental Cell Research 315:3, 485-497
CrossRef179
Sabine Tricot, Céline Berthon, Marie-Dominique Venon, Julie Gay, Remy Dulery, Aldo M Roccaro, Teru Hideshima, Irene M Ghobrial, Thierry Facon, Xavier Leleu. (2009) Thalidomide in multiple myeloma in the elderly. Aging Health 5:1, 7-18
CrossRef180
Tomer Mark, Ruben Niesvizky, Morton Coleman. (2009) Novel agents in myeloma: An exciting saga. Cancer 115:2, 236-242
CrossRef181
Tomonori Nakazato, Kazuhito Suzuki, Ai Mihara, Yukinari Sanada, Tsunayuki Kakimoto. (2009) Refractory Plasmablastic Type Myeloma with Multiple Extramedullary Plasmacytomas and Massive Myelomatous Effusion: Remarkable Response with a Combination of Thalidomide and Dexamethasone. Internal Medicine 48:20, 1827-1832
CrossRef182
K Podar, D Chauhan, K C Anderson. (2009) Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 23:1, 10-24
CrossRef183
S. Vincent Rajkumar. (2009) Multiple Myeloma. Current Problems in Cancer 33:1, 7-64
CrossRef184
D. M.-Y. Sze, G. C.-F. Chan. (2009) Supplements for immune enhancement in hematologic malignancies. Hematology 2009:1, 313-319
CrossRef185
William W. Li, Michelle Hutnik, Gerald Gehr. (2008) Antiangiogenesis in haematological malignancies. British Journal of Haematology 143:5, 622-631
CrossRef186
Marta Davila, Robert S Bresalier. (2008) Gastrointestinal complications of oncologic therapy. Nature Clinical Practice Gastroenterology & Hepatology 5:12, 682-696
CrossRef187
Diane R. Bielenberg, Patricia A. D'Amore. (2008) Judah Folkman's Contribution to the Inhibition of Angiogenesis. Lymphatic Research and Biology 6:3-4, 203-207
CrossRef188
Meletios A Dimopoulos, Efstathios Kastritis. (2008) Thalidomide plus dexamethasone as primary therapy for newly diagnosed patients with multiple myeloma. Nature Clinical Practice Oncology 5:12, 690-691
CrossRef189
Francesca Magalini, Adriano Stella, Paolo Sansoni. (2008) Completely reversible agranulocytosis in a multiple myeloma patient treated with thalidomide–dexamethasone. Internal and Emergency Medicine 3:4, 383-385
CrossRef190
Magdy A.-H. Zahran, Tarek A.-R. Salem, Rehab M. Samaka, Hussein S. Agwa, Ayman R. Awad. (2008) Design, synthesis and antitumor evaluation of novel thalidomide dithiocarbamate and dithioate analogs against Ehrlich ascites carcinoma-induced solid tumor in Swiss albino mice. Bioorganic & Medicinal Chemistry 16:22, 9708-9718
CrossRef191
T. C. M. Morris, P. J. Kettle, M. Drake, F. C. G. Jones, D. R. Hull, K. Boyd, A. Morrison, P. Clarke, P. O’Reilly, J. Quinn. (2008) Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma. British Journal of Haematology 143:3, 349-354
CrossRef192
Daniel Man-Yuen Sze, Jian Hou, Lily Zhou. (2008) Newly developed effective anti-cancer drugs targeting multiple myeloma. Drug Development Research 69:7, 451-459
CrossRef193
B. Barlogie, F. van Rhee, J. D. Shaughnessy, J. Epstein, S. Yaccoby, M. Pineda-Roman, K. Hollmig, Y. Alsayed, A. Hoering, J. Szymonifka, E. Anaissie, N. Petty, N. S. Kumar, G. Srivastava, B. Jenkins, J. Crowley, J. B. Zeldis. (2008) Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 112:8, 3122-3125
CrossRef194
A. Palumbo, S. Bringhen, A. M. Liberati, T. Caravita, A. Falcone, V. Callea, M. Montanaro, R. Ria, A. Capaldi, R. Zambello, G. Benevolo, D. Derudas, F. Dore, F. Cavallo, F. Gay, P. Falco, G. Ciccone, P. Musto, M. Cavo, M. Boccadoro. (2008) Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 112:8, 3107-3114
CrossRef195
Wolfram Pönisch, Marta Rozanski, Hartmut Goldschmidt, Franz Albert Hoffmann, Thomas Boldt, Andreas Schwarzer, Ute Ritter, Robert Rohrberg, Elke Schwalbe, Jens Uhlig, Thomas Zehrfeld, Veronika Schirmer, Antje Haas, Ute Kreibich, Dietger Niederwieser, . (2008) Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. British Journal of Haematology 143:2, 191-200
CrossRef196
Abu Shadat M. Noman, Naoki Koide, Imtiaz I.-E. Khuda, Jargalsaikhan Dagvadorj, Gantsetseg Tumurkhuu, Yoshikazu Naiki, Takayuki Komatsu, Tomoaki Yoshida, Takashi Yokochi. (2008) Thalidomide inhibits epidermal growth factor-induced cell growth in mouse and human monocytic leukemia cells via Ras inactivation. Biochemical and Biophysical Research Communications 374:4, 683-687
CrossRef197
S. V. Rajkumar. (2008) Treatment of Myeloma: Cure vs Control. Mayo Clinic Proceedings 83:10, 1142-1145
CrossRef198
Jo Caers, Isabelle Vande broek, Hendrik De Raeve, Lucienne Michaux, Fabienne Trullemans, Rik Schots, Ben Van Camp, Karin Vanderkerken. (2008) Multiple myeloma - an update on diagnosis and treatment. European Journal of Haematology
CrossRef199
James R Berenson, Ori Yellin. (2008) New drugs in multiple myeloma. Current Opinion in Supportive and Palliative Care 2:3, 204-210
CrossRef200
Giuseppe Saccomanni, Veronica Turini, Clementina Manera, Giorgio Placanica, Emanuela Omodeo Salè, Costantino Jemos, Mario Giorgi, Marco Macchia. (2008) High performance liquid chromatographic determination of thalidomide in patients affected by hepatocellular carcinoma. Journal of Pharmaceutical and Biomedical Analysis 48:2, 447-451
CrossRef201
Elisabetta Abruzzese, Francesco Iuliano, Malgorzata Monika Trawinska, Massimo Di Maio. (2008) 153 Sm: its use in multiple myeloma and report of a clinical experience. Expert Opinion on Investigational Drugs 17:9, 1379-1387
CrossRef202
J. Kay Noel, Sheila Crean, Janet E. Claflin, Gayatri Ranganathan, Heather Linz, Michael Lahn. (2008) Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer. Medical Oncology 25:3, 323-330
CrossRef203
Aaron P. Brown, Deborah E. Citrin, Kevin A. Camphausen. (2008) Clinical biomarkers of angiogenesis inhibition. Cancer and Metastasis Reviews 27:3, 415-434
CrossRef204
Matthew Brown, Jonah Cohen, Pattatheyil Arun, Zhong Chen, Carter Van Waes. (2008) NF-κB in carcinoma therapy and prevention. Expert Opinion on Therapeutic Targets 12:9, 1109-1122
CrossRef205
J Mehta, S Singhal. (2008) Current status of autologous hematopoietic stem cell transplantation in myeloma. Bone Marrow Transplantation 42, S28-S34
CrossRef206
Lisa K. Hicks, Adam E. Haynes, Donna E. Reece, Irwin R. Walker, Jordan A. Herst, Ralph M. Meyer, Kevin Imrie. (2008) A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treatment Reviews 34:5, 442-452
CrossRef207
A. Corso, S. Mangiacavalli, L. Barbarano, L. Montalbetti, A. Mazzone, S. Fava, M. Varettoni, P. Zappasodi, E. Morra, M. Lazzarino. (2008) Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy. Leukemia Research 32:7, 1085-1090
CrossRef208
Om Prakash, Bikash Medhi, Uma Nahar Saikia, Promila Pandhi. (2008) Effect of Different Doses of Thalidomide in Experimentally Induced Inflammatory Bowel Disease in Rats. Basic & Clinical Pharmacology & Toxicology 103:1, 9-16
CrossRef209
M A Dimopoulos, E Kastritis, S V Rajkumar. (2008) Treatment of plasma cell dyscrasias with lenalidomide. Leukemia 22:7, 1343-1353
CrossRef210
M Pineda-Roman, M Zangari, F van Rhee, E Anaissie, J Szymonifka, A Hoering, N Petty, J Crowley, J Shaughnessy, J Epstein, B Barlogie. (2008) VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 22:7, 1419-1427
CrossRef211
Madhav V Dhodapkar, Dennis L Cooper. (2008) Does lenalidomide plus dexamethasone improve outcome in patients with relapsed multiple myeloma?. Nature Clinical Practice Oncology 5:7, 372-373
CrossRef212
Iris Breitkreutz, Kenneth C Anderson. (2008) Thalidomide in multiple myeloma – clinical trials and aspects of drug metabolism and toxicity. Expert Opinion on Drug Metabolism & Toxicology 4:7, 973-985
CrossRef213
Jens Hillengass, Christian M. Zechmann, Andreas Nadler, Dirk Hose, Friedrich W. Cremer, Anna Jauch, Christiane Heiss, Axel Benner, Anthony D. Ho, Claus R. Bartram, Hans-Ulrich Kauczor, Stefan Delorme, Hartmut Goldschmidt, Thomas M. Moehler. (2008) Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma. International Journal of Cancer 122:12, 2871-2875
CrossRef214
C. Lafaras, E. Mandala, E. Verrou, D. Platogiannis, N. Barbetakis, T. Bischiniotis, K. Zervas. (2008) Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: A pilot study. Annals of Oncology 19:10, 1765-1769
CrossRef215
Stefania Ciolli, Franco Leoni, Cinzia Casini, Carla Breschi, Valeria Santini, Alberto Bosi. (2008) The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma. British Journal of Haematology 141:6, 814-819
CrossRef216
Yutaka Hattori, Shin-ichiro Okamoto, Naoki Shimada, Tsunayuki Kakimoto, Kunihiko Morita, Yusuke Tanigawara, Yasuo Ikeda. (2008) Single-institute phase 2 study of thalidomide treatment for refractory or relapsed multiple myeloma: Prognostic factors and unique toxicity profile. Cancer Science 99:6, 1243-1250
CrossRef217
Wen-Juei Jeng, Ming-Chung Kuo, Lee-Yung Shih, Pao-Hsien Chu. (2008) Pulmonary embolism in a patient with multiple myeloma receiving thalidomide–dexamethasone therapy. International Journal of Hematology 87:5, 542-544
CrossRef218
S.-I. FUCHIDA, C. SHIMAZAKI, H. HIRAI, S. AKAMATSU, N. YAMADA, R. UCHIDA, A. OKANO, M. OKAMOTO, T. INABA, M. TANIWAKI. (2008) The effects of thalidomide on chemotactic migration of multiple myeloma cell lines. International Journal of Laboratory Hematology 30:3, 220-229
CrossRef219
Katharine D. Grugan, Chunguang Ma, Seema Singhal, Nancy L. Krett, Steven T. Rosen. (2008) Dual regulation of glucocorticoid-induced leucine zipper (GILZ) by the glucocorticoid receptor and the PI3-kinase/AKT pathways in multiple myeloma. The Journal of Steroid Biochemistry and Molecular Biology 110:3-5, 244-254
CrossRef220
H de Lavallade, J El-Cheikh, C Faucher, S Fürst, A-M Stoppa, D Coso, R Bouabdallah, C Chabannon, J-A Gastaut, D Blaise, M Mohty. (2008) Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplantation 41:11, 953-960
CrossRef221
Ron H.N. van Schaik. (2008) CYP450 pharmacogenetics for personalizing cancer therapy. Drug Resistance Updates 11:3, 77-98
CrossRef222
Patrizia Falco, Federica Cavallo, Alessandra Larocca, Anna Marina Liberati, Pellegrino Musto, Mario Boccadoro, Antonio Palumbo. (2008) Lenalidomide and its role in the management of multiple myeloma. Expert Review of Anticancer Therapy 8:6, 865-874
CrossRef223
F. van Rhee, M. Dhodapkar, J. D. Shaughnessy, E. Anaissie, D. Siegel, A. Hoering, J. Zeldis, B. Jenkins, S. Singhal, J. Mehta, J. Crowley, S. Jagannath, B. Barlogie. (2008) First thalidomide clinical trial in multiple myeloma: a decade. Blood 112:4, 1035-1038
CrossRef224
Maurizio Zangari, Frits van Rhee, Elias Anaissie, Mauricio Pineda-Roman, Jeff Haessler, John Crowley, Bart Barlogie. (2008) Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. British Journal of Haematology 141:4, 433-444
CrossRef225
A Munguia, T Ota, T Miest, S J Russell. (2008) Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Therapy 15:10, 797-806
CrossRef226
Emilio García Quetglas, José Ramón Azanza Perea, Ramón Lecumberri Villamediana. (2008) Nuevas estrategias terapéuticas en el tratamiento del mieloma múltiple. Análisis de su eficacia y coste-efectividad. Medicina Clínica 130:16, 626-635
CrossRef227
Shaji Kumar. (2008) Role of allogeneic stem cell transplantation in multiple myeloma. Current Hematologic Malignancy Reports 3:2, 99-106
CrossRef228
Jair Bar, Amir Onn. (2008) Combined anti-proliferative and anti-angiogenic strategies for cancer. Expert Opinion on Pharmacotherapy 9:5, 701-715
CrossRef229
Matthew J. Streetly, Kylie Gyertson, Yvonne Daniel, Jerome B. Zeldis, Majid Kazmi, Stephen A. Schey. (2008) Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. British Journal of Haematology 141:1, 41-51
CrossRef230
Ahmed Awais, Constantine S. Tam, Dimitrios Kontoyiannis, Alessandra Ferrajoli, Madeleine Duvic, Jorge Cortes, Michael J. Keating. (2008) Rapid Resolution of Mycobacterium marinum Chronic Skin Infection during Lenalidomide Therapy for Chronic Lymphocytic Leukemia. Clinical Infectious Diseases 46:7, e69-e71
CrossRef231
P. S. Haas, U. Denz, G. Ihorst, M. Engelhardt. (2008) Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses. European Journal of Haematology 80:4, 303-309
CrossRef232
Haruhito Azuma, Naruya Tomita, Takeshi Sakamoto, Satoshi Kiyama, Teruo Inamoto, Kiyoshi Takahara, Yatsugu Kotake, Naoki Segawa, Ryuichi Morishita, Shiro Takahara, Hana Hayasaki, Yoshinori Otsuki, Shigeo Horie, Nobuhiko Tanigawa, Yoji Katsuoka. (2008) Marked regression of liver metastasis by combined therapy of ultrasound-mediated NFkB-decoy transfer and transportal injection of paclitaxel, in mouse. International Journal of Cancer 122:7, 1645-1656
CrossRef233
L Haddad, H El Hajj, R Abou-Merhi, Y Kfoury, R Mahieux, M El-Sabban, A Bazarbachi. (2008) KSHV-transformed primary effusion lymphoma cells induce a VEGF-dependent angiogenesis and establish functional gap junctions with endothelial cells. Leukemia 22:4, 826-834
CrossRef234
Martin H Fenner, Gernot Beutel, Viktor Grünwald. (2008) Targeted therapies for patients with germ cell tumors. Expert Opinion on Investigational Drugs 17:4, 511-522
CrossRef235
R. A. Kyle, S. V. Rajkumar. (2008) Multiple myeloma. Blood 111:6, 2962-2972
CrossRef236
Siow Ming Lee, Lindsay James, Tomas Buchler, Mike Snee, Paul Ellis, Allan Hackshaw. (2008) Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer. Lung Cancer 59:3, 364-368
CrossRef237
S. K. Kumar, S. V. Rajkumar, A. Dispenzieri, M. Q. Lacy, S. R. Hayman, F. K. Buadi, S. R. Zeldenrust, D. Dingli, S. J. Russell, J. A. Lust, P. R. Greipp, R. A. Kyle, M. A. Gertz. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:5, 2516-2520
CrossRef238
D. Ribatti, A. Vacca. (2008) Angiogenesis and anti-angiogenesis in haematological diseases. memo - Magazine of European Medical Oncology 1:1, 31-33
CrossRef239
Henry G Watson, Yen Lin Chee. (2008) Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism. Blood Reviews 22:2, 107-116
CrossRef240
M. Teresa Cibeira, María Rozman, Marta Segarra, Esther Lozano, Laura Rosiñol, Maria C. Cid, Xavier Filella, Joan Bladé. (2008) Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. Cytokine 41:3, 244-253
CrossRef241
H. Brenner, A. Gondos, D. Pulte. (2008) Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111:5, 2521-2526
CrossRef242
Jayesh Mehta. (2008) Treatment for elderly patients with multiple myeloma. The Lancet 371:9617, 983
CrossRef243
Kristen N. Ganjoo, Annette M. Moore, Attilio Orazi, Joy A. Sen, Cynthia S. Johnson, Caroline S. An. (2008) The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. Journal of Cancer Research and Clinical Oncology 134:3, 381-387
CrossRef244
A. Abdelkefi, S. Ladeb, L. Torjman, T. B. Othman, A. Lakhal, N. B. Romdhane, H. E. Omri, M. Elloumi, H. Belaaj, R. Jeddi, L. Aissaoui, H. Ksouri, A. B. Hassen, F. Msadek, A. Saad, M. Hsairi, K. Boukef, A. Amouri, H. Louzir, K. Dellagi, A. B. Abdeladhim, . (2008) Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood 111:4, 1805-1810
CrossRef245
Alessandro Corso, Silvia Mangiacavalli. (2008) The place of thalidomide in the treatment of multiple myeloma. Oncology Reviews 1:4, 205-214
CrossRef246
K C Anderson, R A Kyle, S V Rajkumar, A K Stewart, D Weber, P Richardson. (2008) Clinically relevant end points and new drug approvals for myeloma. Leukemia 22:2, 231-239
CrossRef247
S Yaccoby, A Pennisi, X Li, S R Dillon, F Zhan, B Barlogie, J D Shaughnessy. (2008) Atacicept (TACI-Ig) inhibits growth of TACIhigh primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia 22:2, 406-413
CrossRef248
Jae K. Ryu, James G. McLarnon. (2008) Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-α in an animal model of inflamed Alzheimer’s disease brain. Neurobiology of Disease 29:2, 254-266
CrossRef249
A. Palumbo, T. Facon, P. Sonneveld, J. Blade, M. Offidani, F. Gay, P. Moreau, A. Waage, A. Spencer, H. Ludwig, M. Boccadoro, J.-L. Harousseau. (2008) Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111:8, 3968-3977
CrossRef250
Donna E. Reece, Heather A. Leitch, Harold Atkins, Michael Voralia, Leah A. Canning, Richard LeBlanc, Andrew R. Belch, Darrell White, Michael J. Kovacs. (2008) Treatment of relapsed and refractory myeloma. Leukemia & Lymphoma 49:8, 1470-1485
CrossRef251
Manzoor H. Mangi, Adrian C. Newland. (2008) ANGIOGENESIS and ANGIOGENIC MEDIATORS IN HAEMATOLOGICAL MALIGNANCIES. British Journal of Haematology 111:1, 43
CrossRef252
Mustaqeem Siddiqui, Morie Gertz. (2008) The role of high-dose chemotherapy followed by peripheral blood stem cell transplantation for the treatment of multiple myeloma. Leukemia & Lymphoma 49:8, 1436-1451
CrossRef253
Konstantinos Anargyrou, Meletios-Athanassios Dimopoulos, Orhan Sezer, Evangelos Terpos. (2008) Novel anti-myeloma agents and angiogenesis. Leukemia & Lymphoma 49:4, 677-689
CrossRef254
Lisa A. Hammond-Thelin. (2008) Cutaneous Reactions Related to Systemic Immunomodulators and Targeted Therapeutics. Dermatologic Clinics 26:1, 121-159
CrossRef255
Orhan Sezer, Christian Jakob, Jan Eucker, Kathrin Niemöller, Frauke Gatz, Klaus-Dieter Wernecke, Kurt Possinger. (2008) Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. European Journal of Haematology 66:2, 83
CrossRef256
C. W. Tiplady, G. P. Summerfield. (2008) Continuous low-dose dexamethasone in relapsed or refractory multiple myeloma. British Journal of Haematology 111:1, 381
CrossRef257
Ghada Kchour, Mahdi Tarhini, Nourieh Sharifi, Reza Farid, Ali Reza Khooei, Abbas Shirdel, Jalil Tavakkol Afshari, Ali Sadeghian, Zaher Otrock, Olivier Hermine, Marwan El-Sabban, Ali Bazarbachi. (2008) Increased microvessel density in involved organs from patients with HTLV-I associated adult T cell leukemia lymphoma. Leukemia & Lymphoma 49:2, 265-270
CrossRef258
Taraneh Paravar, Delphine J. Lee. (2008) Thalidomide: Mechanisms of Action. International Reviews of Immunology 27:3, 111-135
CrossRef259
Sonia Vallet, Antonio Palumbo, Noopur Raje, Mario Boccadoro, Kenneth C. Anderson. (2008) Thalidomide and lenalidomide: Mechanism-based potential drug combinations. Leukemia & Lymphoma 49:7, 1238-1245
CrossRef260
Yukiyoshi FUJITA, Koujirou YAMAMOTO, Tohru AOMORI, Hirokazu MURAKAMI, Ryuya HORIUCHI. (2008) Comparison of Dissolution Profile and Plasma Concentration-time Profile of the Thalidomide Formulations Made by Japanese, Mexican and British Companies. YAKUGAKU ZASSHI 128:10, 1449-1457
CrossRef261
Robert A. Kyle. (2008) Multiple myeloma: an odyssey of discovery. British Journal of Haematology 111:4, 1035
CrossRef262
Paul W. Sanders. 2008. Myeloma and Secondary Involvement of the Kidney in Dysproteinemias. , 461-468.
CrossRef263
Patrick J. Hayden, Constantine S. Mitsiades, Kenneth C. Anderson, Paul G. Richardson. (2008) From the bench to the bedside: emerging new treatments in multiple myeloma. Targeted Oncology 3:1, 19-29
CrossRef264
Muralikrishnan Srikanth, Faith E Davies, Gareth J Morgan. (2008) An update on drug combinations for treatment of myeloma. Expert Opinion on Investigational Drugs 17:1, 1-12
CrossRef265
Efstathios Kastritis, Constantine S. Mitsiades, Meletios A. Dimopoulos, Paul G. Richardson. (2007) Management of Relapsed and Relapsed Refractory Myeloma. Hematology/Oncology Clinics of North America 21:6, 1175-1215
CrossRef266
B Sirohi, R Powles. (2007) Future challenges. Bone Marrow Transplantation 40:12, 1157-1164
CrossRef267
Thierry Facon, Stéphane Darre. (2007) Frontline treatment in multiple myeloma patients not eligible for stem-cell transplantation. Best Practice & Research Clinical Haematology 20:4, 737-746
CrossRef268
M S Raab, I Breitkreutz, K C Anderson. (2007) Targeted treatments to improve stem cell outcome: old and new drugs. Bone Marrow Transplantation 40:12, 1129-1137
CrossRef269
Constantine S. Mitsiades, Douglas W. McMillin, Steffen Klippel, Teru Hideshima, Dharminder Chauhan, Paul G. Richardson, Nikhil C. Munshi, Kenneth C. Anderson. (2007) The Role of the Bone Marrow Microenvironment in the Pathophysiology of Myeloma and Its Significance in the Development of More Effective Therapies. Hematology/Oncology Clinics of North America 21:6, 1007-1034
CrossRef270
Sheeba K. Thomas, Tiffany A. Richards, Donna M. Weber. (2007) Lenalidomide in multiple myeloma. Best Practice & Research Clinical Haematology 20:4, 717-735
CrossRef271
Efstathios Kastritis, Meletios A. Dimopoulos. (2007) Thalidomide in the treatment of multiple myeloma. Best Practice & Research Clinical Haematology 20:4, 681-699
CrossRef272
J Mehta, S Singhal. (2007) High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years. Bone Marrow Transplantation 40:12, 1101-1114
CrossRef273
Klaus Podar, Paul G. Richardson, Teru Hideshima, Dharminder Chauhan, Kenneth C. Anderson. (2007) The malignant clone and the bone-marrow environment. Best Practice & Research Clinical Haematology 20:4, 597-612
CrossRef274
Constantine S. Mitsiades, Patrick J. Hayden, Kenneth C. Anderson, Paul G. Richardson. (2007) From the bench to the bedside: emerging new treatments in multiple myeloma. Best Practice & Research Clinical Haematology 20:4, 797-816
CrossRef275
Angela Dispenzieri. (2007) Complications of Myeloma Therapy. Hematology/Oncology Clinics of North America 21:6, 1247-1273
CrossRef276
Bart Barlogie, Elias Anaissie, Frits van Rhee, Mauricio Pineda-Roman, Maurizio Zangari, John Shaughnessy, Joshua Epstein, John Crowley. (2007) The Arkansas approach to therapy of patients with multiple myeloma. Best Practice & Research Clinical Haematology 20:4, 761-781
CrossRef277
S. Vincent Rajkumar, Antonio Palumbo. (2007) Management of Newly Diagnosed Myeloma. Hematology/Oncology Clinics of North America 21:6, 1141-1156
CrossRef278
Weber, Donna M., Chen, Christine, Niesvizky, Ruben, Wang, Michael, Belch, Andrew, Stadtmauer, Edward A., Siegel, David, Borrello, Ivan, Rajkumar, S. Vincent, Chanan-Khan, Asher Alban, Lonial, Sagar, Yu, Zhinuan, Patin, John, Olesnyckyj, Marta, Zeldis, Jerome B., Knight, Robert D., . (2007) Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America. New England Journal of Medicine 357:21, 2133-2142
Full Text279
Dimopoulos, Meletios, Spencer, Andrew, Attal, Michael, Prince, H. Miles, Harousseau, Jean-Luc, Dmoszynska, Anna, Miguel, Jesus San, Hellmann, Andrzej, Facon, Thierry, Foà, Robin, Corso, Alessandro, Masliak, Zvenyslava, Olesnyckyj, Marta, Yu, Zhinuan, Patin, John, Zeldis, Jerome B., Knight, Robert D., . (2007) Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine 357:21, 2123-2132
Full Text280
Laura F. Hutchins, James Moon, Joseph I. Clark, John A. Thompson, Marianne K. Lange, Lawrence E. Flaherty, Vernon K. Sondak. (2007) Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. Cancer 110:10, 2269-2275
CrossRef281
Ulka N. Vaishampayan, Lance K. Heilbrun, Cynthia Marsack, Daryn W. Smith, Lawrence E. Flaherty. (2007) Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma. Anti-Cancer Drugs 18:10, 1221-1226
CrossRef282
Patrick J Hayden, Constantine S Mitsiades, Kenneth C Anderson, Paul G Richardson. (2007) Novel therapies in myeloma. Current Opinion in Hematology 14:6, 609-615
CrossRef283
Angela Dispenzieri. (2007) POEMS syndrome. Blood Reviews 21:6, 285-299
CrossRef284
W. Aerbajinai, J. Zhu, Z. Gao, K. Chin, G. P. Rodgers. (2007) Thalidomide induces -globin gene expression through increased reactive oxygen species mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood 110:8, 2864-2871
CrossRef285
Gergely P. Vasvari, Gerhard Dyckhoff, Farzaneh Kashfi, Britt Lemke, Jennifer Lohr, Burkhard M. Helmke, Volker Schirrmacher, Peter K. Plinkert, Philipp Beckhove, Christel C. Herold-Mende. (2007) Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activityin vitro andin vivo. International Journal of Cancer 121:8, 1697-1704
CrossRef286
Seema Singhal, Jayesh Mehta. (2007) Lenalidomide in Myeloma. Current Treatment Options in Oncology 8:2, 154-163
CrossRef287
Thierry Facon, Jean Yves Mary, Cyrille Hulin, Lotfi Benboubker, Michel Attal, Brigitte Pegourie, Marc Renaud, Jean Luc Harousseau, Gaëlle Guillerm, Carine Chaleteix, Mamoun Dib, Laurent Voillat, Hervé Maisonneuve, Jacques Troncy, Véronique Dorvaux, Mathieu Monconduit, Claude Martin, Philippe Casassus, Jérôme Jaubert, Henry Jardel, Chantal Doyen, Brigitte Kolb, Bruno Anglaret, Bernard Grosbois, Ibrahim Yakoub-Agha, Claire Mathiot, Hervé Avet-Loiseau. (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. The Lancet 370:9594, 1209-1218
CrossRef288
Sheeba Thomas, Tiffany Richards, Donna M. Weber. 2007. Novel Agents for Previously Untreated Multiple Myeloma. , 141-168.
CrossRef289
Giovanni Tonon. 2007. Novel Therapeutic Targets in Multiple Myeloma. , 75-94.
CrossRef290
Teru Hideshima, Noopur Raje. 2007. The Role of the Bone Marrow Microenvironment in the Pathogenesis of Multiple Myeloma. , 23-44.
CrossRef291
Melissa Alsina, Paul Richardson. 2007. Novel Therapeutic Options for the Treatment of Relapsed and Relapsed, Refractory Myeloma. , 169-196.
CrossRef292
Adam D. Cohen, Ping Zhou, Joanne Chou, Julie Teruya-Feldstein, Lilian Reich, Hani Hassoun, Beth Levine, Daniel A. Filippa, Elyn Riedel, Tarun Kewalramani, Michael D. Stubblefield, Martin Fleisher, Stephen Nimer, Raymond L. Comenzo. (2007) Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone
thalidomide for systemic light-chain amyloidosis: results of a phase II trial. British Journal of Haematology 139:2, 224-233
CrossRef293
Jean-Luc Harousseau. 2007. High-Dose Therapy in Multiple Myeloma. , 197-210.
CrossRef294
C. Hulin. (2007) Les nouveaux médicaments du myélome. La Revue de Médecine Interne 28:10, 682-688
CrossRef295
Vladimír Maisnar, Jakub Radocha, Tomáš Büchler, Václav Bláha, Jaroslav Malý, Roman Hájek. (2007) Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment. European Journal of Haematology 79:4, 305-309
CrossRef296
Hirokazu Murakami, Hiroshi Handa, Masahiro Abe, Sinsuke Iida, Akihiro Ishii, Takayuki Ishikawa, Tadao Ishida, Masatsugu Oota, Shuji Ozaki, Masaaki Kosaka, Akira Sakai, Morio Sawamura, Chihiro Shimazaki, Kazuyuki Shimizu, Toshiyuki Takagi, Hiroyuki Hata, Takashi Fukuhara, Hiroshi Fujii, Akira Miyata, Toshio Wakayama, Kiyoshi Takatsuki. (2007) Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. European Journal of Haematology 79:3, 234-239
CrossRef297
Guy Pratt, Oliver Goodyear, Paul Moss. (2007) Immunodeficiency and immunotherapy in multiple myeloma. British Journal of Haematology 138:5, 563-579
CrossRef298
F. Merchionne, F. Perosa, F. Dammacco. (2007) New therapies in multiple myeloma. Clinical and Experimental Medicine 7:3, 83-97
CrossRef299
D. Scott McMeekin, Michael W. Sill, Kathleen M. Darcy, Deborah J. Stearns-Kurosawa, Kenneth Webster, Steven Waggoner, Doris Benbrook. (2007) A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: A gynecologic oncology group study. Gynecologic Oncology 106:3, 596-603
CrossRef300
Rafael Fonseca, Suzanne Hayman. (2007) Waldenström macroglobulinaemia. British Journal of Haematology 138:6, 700-720
CrossRef301
Pellegrino Musto, Fiorella D'Auria. (2007) Melphalan: old and new uses of a still master drug for multiple myeloma. Expert Opinion on Investigational Drugs 16:9, 1467-1487
CrossRef302
Joseph D. Tariman. (2007) Lenalidomide: A New Agent for Patients With Relapsed or Refractory Multiple Myeloma. Clinical Journal of Oncology Nursing 11:4, 569-574
CrossRef303
Edmundo A. Rodriguez-Frias, William M. Lee. (2007) Cancer Chemotherapy I: Hepatocellular Injury. Clinics in Liver Disease 11:3, 641-662
CrossRef304
Teru Hideshima, Constantine Mitsiades, Giovanni Tonon, Paul G. Richardson, Kenneth C. Anderson. (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nature Reviews Cancer 7:8, 585-598
CrossRef305
H. Miles Prince, Michael Adena, Dell Kingsford Smith, Judy Hertel. (2007) Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison. European Journal of Haematology 79:2, 93-99
CrossRef306
Constantine S. Mitsiades, Nicholas S. Mitsiades, Paul G. Richardson, Nikhil C. Munshi, Kenneth C. Anderson. (2007) Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. Journal of Cellular Biochemistry 101:4, 950-968
CrossRef307
Magda Melchert, Alan List. (2007) The thalidomide saga. The International Journal of Biochemistry & Cell Biology 39:7-8, 1489-1499
CrossRef308
Junru LIU, Juan LI, Chang SU, Beihui HUANG, Shaokai LUO. (2007) Soluble Fms-like Tyrosine Kinase-1 Expression Inhibits the Growth of Multiple Myeloma in Nude Mice. Acta Biochimica et Biophysica Sinica 39:7, 499-506
CrossRef309
Bart Barlogie, Elias Anaissie, Frits van Rhee, Jeffrey Haessler, Klaus Hollmig, Mauricio Pineda-Roman, Michele Cottler-Fox, Abid Mohiuddin, Yazan Alsayed, Guido Tricot, Vanessa Bolejack, Maurizio Zangari, Joshua Epstein, Nathan Petty, Douglas Steward, Bonnie Jenkins, Jennifer Gurley, Ellen Sullivan, John Crowley, John D. Shaughnessy. (2007) Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. British Journal of Haematology 138:2, 176-185
CrossRef310
Kenneth B. Ain, Charles Lee, Kevin D. Williams. (2007) Phase II Trial of Thalidomide for Therapy of Radioiodine-Unresponsive and Rapidly Progressive Thyroid Carcinomas. Thyroid 17:7, 663-670
CrossRef311
Fernando J. Barata, Ana Filipa Costa. (2007) Carcinoma do pulmão de pequenas células – Estado da arte e perspectivas futuras. Revista Portuguesa de Pneumologia (English Edition) 13:4, 587-604
CrossRef312
I Breitkreutz, H M Lokhorst, M S Raab, B van der Holt, F W Cremer, D Herrmann, A Glasmacher, I G H Schmidt-Wolf, I W Blau, H Martin, H Salwender, A Haenel, P Sonneveld, H Goldschmidt. (2007) Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 21:6, 1294-1299
CrossRef313
R Mihelic, J L Kaufman, S Lonial. (2007) Maintenance therapy in multiple myeloma. Leukemia 21:6, 1150-1157
CrossRef314
Antonius A. Miller, Doug Case, Michele Harmon, Paul Savage, Glenn Lesser, David Hurd, Susan A. Melin. (2007) Phase I Study of Lenalidomide in Solid Tumors. Journal of Thoracic Oncology 2:5, 445-449
CrossRef315
D. Scott McMeekin, Michael W. Sill, Doris Benbrook, Kathleen M. Darcy, Deborah J. Stearns-Kurosawa, Lynne Eaton, S. Diane Yamada. (2007) A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study. Gynecologic Oncology 105:2, 508-516
CrossRef316
Kenneth C. Anderson. (2007) Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Experimental Hematology 35:4, 155-162
CrossRef317
Klaus Podar, Paul G Richardson, Dharminder Chauhan, Kenneth C Anderson. (2007) Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. Expert Review of Anticancer Therapy 7:4, 551-566
CrossRef318
Massimo Offidani, Sara Bringhen, Laura Corvatta, Patrizia Falco, Monica Marconi, Ilaria Avonto, Maria-Novella Piersantelli, Claudia Polloni, Mario Boccadoro, Pietro Leoni, Antonio Palumbo. (2007) Thalidomide?dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide?dexamethasone: a case-matched study in advanced multiple myeloma. European Journal of Haematology 78:4, 297-302
CrossRef319
Joseph D. Tariman. (2007) Current Therapies for Multiple Myeloma. Journal of Infusion Nursing 30:2, 113-118
CrossRef320
Maurizio Zangari, Francesca Elice, Louis Fink, Guido Tricot. (2007) Thrombosis in multiple myeloma. Expert Review of Anticancer Therapy 7:3, 307-315
CrossRef321
Soo Hyun Jin, Tae Il Kim, Kyoung Min Yang, Won Ho Kim. (2007) Thalidomide destabilizes cyclooxygenase-2 mRNA by inhibiting p38 mitogen-activated protein kinase and cytoplasmic shuttling of HuR. European Journal of Pharmacology 558:1-3, 14-20
CrossRef322
Efstathios Kastritis, Meletios A Dimopoulos. (2007) The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opinion on Pharmacotherapy 8:4, 497-509
CrossRef323
Irene M Ghobrial, Xavier Leleu, Evdoxia Hatjiharissi, Teru Hideshima, Constantine Mitsiades, Robert Schlossman, Kenneth C Anderson, Paul Richardson. (2007) Emerging drugs in multiple myeloma. Expert Opinion on Emerging Drugs 12:1, 155-163
CrossRef324
H Yasui, T Hideshima, H Ikeda, E M Ocio, T Kiziltepe, S Vallet, Y Okawa, P Neri, K Sukhdeo, K Podar, D Chauhan, P G Richardson, N Raje, D R Carrasco, K C Anderson. (2007) Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of β-catenin/TCF pathway. Leukemia 21:3, 535-540
CrossRef325
Heike E. Daldrup-Link, Tobias Henning, Thomas M. Link. (2007) MR imaging of therapy-induced changes of bone marrow. European Radiology 17:3, 743-761
CrossRef326
Bernardo J. González González, Luis Hernández Nieto. (2007) Tratamiento del mieloma múltiple con talidomida y dexametasona: avanzando lentamente. Medicina Clínica 128:4, 133-134
CrossRef327
Parham Khosravi Shahi, Víctor Manuel Díaz Muñoz de la Espada, Pilar Sabin Domínguez, Sara Encinas García, José Ángel Arranz Arija, José Rafael Carrión Galindo, Gumersindo Pérez Manga. (2007) Efectividad de la talidomida y la dexametasona en el tratamiento del mieloma múltiple resistente al tratamiento: estudio retrospectivo de 36 casos consecutivos. Medicina Clínica 128:4, 121-124
CrossRef328
Francesco A. Piazza, Carmela Gurrieri, Livio Trentin, Gianpietro Semenzato. (2007) Towards a new age in the treatment of multiple myeloma. Annals of Hematology 86:3, 159-172
CrossRef329
Maria Roussou, Athanasios Anagnostopoulos, Efstathios Kastritis, Charis Matsouka, Despina Barmparousi, Vasiliki Koutsoukou, Meletios A. Dimopoulos. (2007) Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: Long term follow up and disease control after subsequent treatments. Leukemia & Lymphoma 48:4, 754-758
CrossRef330
Massimo Martino, Giuseppe Console, Vincenzo Callea, Caterina Stelitano, Elisabetta Massara, Giuseppe Irrera, Giuseppe Messina, Fortunato Morabito, Pasquale Iacopino. (2007) Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients. European Journal of Haematology 78:1, 35-40
CrossRef331
Sachin R Shah, Thu M Tran. (2007) Lenalidomide in Myelodysplastic Syndrome and Multiple Myeloma. Drugs 67:13, 1869-1881
CrossRef332
Federica Cavallo, Maria Teresa Ambrosini, Cecilia Rus, Mario Boccadoro, Antonio Palumbo. (2007) The treatment of the elderly multiple myeloma patients. Leukemia & Lymphoma 48:3, 469-480
CrossRef333
Paul Barr, Pingfu Fu, Hillard Lazarus, Donna Kane, Howard Meyerson, Paul Hartman, Rania Reyes, Richard Creger, Karen Stear, Mary Laughlin, William Tse, Brenda Cooper. (2007) Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia. Leukemia & Lymphoma 48:10, 1940-1949
CrossRef334
William H. Krüger, Thomas Kiefer, Frank Schüler, Christian Lotze, Christoph Busemann, Gottfried Dölken. (2007) Complete Remission and Early Relapse of Refractory Plasma Cell Leukemia after Bortezomib Induction and Consolidation by HLA-Mismatched Unrelated Allogeneic Stem Cell Transplantation. Onkologie 30:4, 193-195
CrossRef335
Hang Quach, H Miles Prince, Linda Mileshkin. (2007) Treatment Strategies in Elderly Patients with Multiple Myeloma. Drugs & Aging 24:10, 829-850
CrossRef336
Maria Teresa Petrucci, Vincenza Martini, Anna Levi, Cristiano Gallucci, Giovanna Palumbo, Patrizia Del Bianco, Concetta Torromeo, Robin Foà. (2007) Thalidomide does not modify the prognosis of plasma cell leukemia patients: Experience of a single center. Leukemia & Lymphoma 48:1, 180-182
CrossRef337
H. Miles Prince, Brad Schenkel, Linda Mileshkin. (2007) An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. Leukemia & Lymphoma 48:1, 46-55
CrossRef338
Stefano Molica. (2007) Immunomodulatory drugs in chronic lymphocytic leukemia: A new treatment paradigm. Leukemia & Lymphoma 48:5, 866-869
CrossRef339
Amitabha Mazumder, Sundar Jagannath. (2006) Thalidomide and lenalidomide in multiple myeloma. Best Practice & Research Clinical Haematology 19:4, 769-780
CrossRef340
John K. Chan, Michael R. Manuel, Giuseppe Ciaravino, Michael K. Cheung, Amreen Husain, Nelson N.H. Teng. (2006) Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma. Gynecologic Oncology 103:3, 919-923
CrossRef341
M. Teresa Cibeira, Laura Rosiñol, Laia Ramiro, Jordi Esteve, Montserrat Torrebadell, Joan Bladé. (2006) Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. European Journal of Haematology 77:6, 486-492
CrossRef342
M. Kenealy, H. M. Prince. (2006) Current status of new drugs for the treatment of patients with multiple myeloma. Internal Medicine Journal 36:12, 781-789
CrossRef343
Matthew M Cooney, Willem van Heeckeren, Shyam Bhakta, Jose Ortiz, Scot C Remick. (2006) Drug Insight: vascular disrupting agents and angiogenesis—novel approaches for drug delivery. Nature Clinical Practice Oncology 3:12, 682-692
CrossRef344
Sara Bringhen, Ilaria Avonto, Valeria Magarotto, Mario Boccadoro, Antonio Palumbo. (2006) Investigational treatments for multiple myeloma. Expert Opinion on Investigational Drugs 15:12, 1565-1582
CrossRef345
Richard F. Riedel, Jeffrey Crawford, Frank Dunphy, James E. Herndon II, Jennifer Garst, Michael J. Kelley. (2006) Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer. Lung Cancer 54:3, 431-432
CrossRef346
Wei Wang, Masaaki Adachi, Rina Kawamura, Hiroki Sakamoto, Toshiaki Hayashi, Tadao Ishida, Kohzoh Imai, Yasuhisa Shinomura. (2006) Parthenolide-induced apoptosis in multiple myeloma cells involves reactive oxygen species generation and cell sensitivity depends on catalase activity. Apoptosis 11:12, 2225-2235
CrossRef347
R García-Sanz, JM Hernández, A Sureda, J García-Laraña, F Prósper, A Alegre, A Bárez, MV Mateos, JF San Miguel. (2006) Pegylated liposomal doxorubicin, melphalan and prednisone therapy for elderly patients with multiple myeloma. Hematological Oncology 24:4, 205-211
CrossRef348
Monica M. Mita, Eric K. Rowinsky, Leonardo Forero, S. Gail Eckhart, Elzbieta Izbicka, Geoffrey R. Weiss, Muralidhar Beeram, Alain C. Mita, Johann S. Bono, Anthony W. Tolcher, Lisa A. Hammond, Paul Simmons, Kristin Berg, Chris Takimoto, Amita Patnaik. (2006) A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. Cancer Chemotherapy and Pharmacology 59:2, 165-174
CrossRef349
Miguel Villalona-Calero, Larry Schaaf, Gary Phillips, Gregory Otterson, Kevin Panico, Wenrui Duan, Barbara Kleiber, Manisha Shah, Donn Young, Wan-Hong Wu, John Kuhn. (2006) Thalidomide and celecoxib as potential modulators of irinotecan’s activity in cancer patients. Cancer Chemotherapy and Pharmacology 59:1, 23-33
CrossRef350
Her-Shyong Shiah, Yee Chao, Li-Tzong Chen, Tzy-Jyun Yao, Jin-Ding Huang, Jang-Yang Chang, Pei-Jer Chen, Tsai-Rong Chuang, Yung-Hsin Chin, Jacqueline Whang-Peng, Tsang-Wu Liu. (2006) Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology 58:5, 654-664
CrossRef351
Paul G Richardson, Constantine S Mitsiades, Nikhil C Munshi, Kenneth C Anderson. (2006) Can thalidomide improve outcome in patients with multiple myeloma?. Nature Clinical Practice Oncology 3:11, 590-591
CrossRef352
Giacomo Allegrini, Antonello Paolo, Elisa Cerri, Samanta Cupini, Federica Amatori, Gianluca Masi, Romano Danesi, Lorenzo Marcucci, Guido Bocci, Mario Tacca, Alfredo Falcone. (2006) Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. Cancer Chemotherapy and Pharmacology 58:5, 585-593
CrossRef353
Susan E. Krown, Donna Niedzwiecki, Wen-Jen Hwu, Lydia Hodgson, Alan N. Houghton, Frank G. Haluska, . (2006) Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain. Cancer 107:8, 1883-1890
CrossRef354
Bart Barlogie, Guido J. Tricot, Frits van Rhee, Edguardo Angtuaco, Ron Walker, Joshua Epstein, John D. Shaughnessy, Sundar Jagannath, Vanessa Bolejack, Jennifer Gurley, Antje Hoering, David Vesole, Raman Desikan, David Siegel, Jayesh Mehta, Seema Singhal, Nikhil C. Munshi, Madhav Dhodapkar, Bonnie Jenkins, Michel Attal, Jean-Luc Harousseau, John Crowley. (2006) Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. British Journal of Haematology 135:2, 158-164
CrossRef355
N. Raje, S. Kumar, T. Hideshima, K. Ishitsuka, H. Yasui, S. Chhetri, S. Vallet, E. Vonescu, N. Shiraishi, T. Kiziltepe, H.L. Elford, N.C. Munshi, K.C. Anderson. (2006) Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells. British Journal of Haematology 135:1, 52-61
CrossRef356
Benjamin D Hedley, Alison L Allan, Ann F Chambers. (2006) Tumor dormancy and the role of metastasis suppressor genes in regulating ectopic growth. Future Oncology 2:5, 627-641
CrossRef357
Jean-Luc Harousseau. (2006) Thalidomide in multiple myeloma: past, present and future. Future Oncology 2:5, 577-589
CrossRef358
Edgardo S Santos, Mohamed A Kharfan-Dabaja. (2006) New horizons in multiple myeloma therapy. Expert Review of Anticancer Therapy 6:10, 1483-1501
CrossRef359
M L Grazziutti, L Dong, M H Miceli, S G Krishna, E Kiwan, N Syed, A Fassas, F van Rhee, H Klaus, B Barlogie, E J Anaissie. (2006) Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplantation 38:7, 501-506
CrossRef360
Henryk Stępień, Hanna Ławnicka, Sławomir Mucha, Małgorzata Wągrowska-Danilewicz, Bartłomiej Stępień, Agnieszka Siejka, Jan Komorowski. (2006) Inhibitory effect of thalidomide on the growth, secretory function and angiogenesis of estrogen-induced prolactinoma in Fischer 344 rats. Life Sciences 79:18, 1741-1748
CrossRef361
Noopur Raje, Teru Hideshima, Kenneth C Anderson. (2006) Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma. Expert Review of Anticancer Therapy 6:9, 1239-1247
CrossRef362
Paul G Richardson, Constantine Mitsiades, Teru Hideshima, Kenneth C Anderson. (2006) Lenalidomide in multiple myeloma. Expert Review of Anticancer Therapy 6:8, 1165-1173
CrossRef363
Ana R. Quesada, Ramón Muñoz-Chápuli, Miguel A. Medina. (2006) Anti-angiogenic drugs: from bench to clinical trials. Medicinal Research Reviews 26:4, 483-530
CrossRef364
Lakshmi Balasubramanian, Andrew M Evens. (2006) Targeting angiogenesis for the treatment of sarcoma. Current Opinion in Oncology 18:4, 354-359
CrossRef365
A. James Hanje, Jennifer L Shamp, Fred B Thomas, Greg M Meis. (2006) Thalidomide-Induced Severe Hepatotoxicity. Pharmacotherapy 26:7, 1018-1022
CrossRef366
Vanessa Almendro, Pere Gascón. (2006) Inhibitors of angiogenesis. Clinical and Translational Oncology 8:7, 475-481
CrossRef367
M. A. Hussein, R. Baz, G. Srkalovic, N. Agrawal, R. Suppiah, E. Hsi, S. Andresen, M. A. Karam, J. Reed, B. Faiman, M. Kelly, E. Walker. (2006) Phase 2 Study of Pegylated Liposomal Doxorubicin, Vincristine, Decreased-Frequency Dexamethasone, and Thalidomide in Newly Diagnosed and Relapsed-Refractory Multiple Myeloma. Mayo Clinic Proceedings 81:7, 889-895
CrossRef368
M. Q. Lacy. (2006) Multiple Myeloma: New Options, New Challenges. Mayo Clinic Proceedings 81:7, 877-879
CrossRef369
Eiji Kusumi, Tomoko Matsumura, Koichiro Yuji, Yuji Tanaka, Masahiro Kami. (2006) Thalidomide in elderly patients with multiple myeloma. The Lancet 367:9527, 1977
CrossRef370
Andrea Nozza, Licia Siracusano, Santoro Armando. (2006) Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function. Clinical Therapeutics 28:6, 953-959
CrossRef371
S Saraf, Y-H Chen, L C Dobogai, N Mahmud, D Peace, Y Saunthararajah, R Hoffman, S Chunduri, D Rondelli. (2006) Prolonged responses after autologous stem cell transplantation in African-American patients with multiple myeloma. Bone Marrow Transplantation 37:12, 1099-1102
CrossRef372
Brett T. Brinker, Edmund K. Waller, Traci Leong, Leonard T. Heffner, Jr., Istvan Redei, Amelia A. Langston, Sagar Lonial. (2006) Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer 106:10, 2171-2180
CrossRef373
Deborah A. Thomas, Francis J. Giles, Maher Albitar, Jorge E. Cortes, Srdan Verstovsek, Stefan Faderl, Susan M. O'Brien, Guillermo Garcia-Manero, Michael J. Keating, Sherry Pierce, Jerome Zeldis, Hagop M. Kantarjian. (2006) Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 106:9, 1974-1984
CrossRef374
Joan Bladé, Laura Rosiñol. (2006) Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance. Current Treatment Options in Oncology 7:3, 237-245
CrossRef375
Rosinol Laura, Ma Teresa Cibeira, Carla Uriburu, Sebastian Yantorno, Olga Salamero, Joan Blade, Emili Montserrat. (2006) Bortezomib: an effective agent in extramedullary disease in multiple myeloma. European Journal of Haematology 76:5, 405-408
CrossRef376
Rajni Sinha, Sagar Lonial. (2006) Novel treatment approaches for patients with relapsed and refractory multiple myeloma. Current Treatment Options in Oncology 7:3, 246-257
CrossRef377
F Sahebi, R Spielberger, N M Kogut, H Fung, P M Falk, P Parker, A Krishnan, R Rodriguez, R Nakamura, A Nademanee, L Popplewell, P Frankel, C Ruel, R Tin, P Ilieva, S J Forman, G Somlo. (2006) Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma. Bone Marrow Transplantation 37:9, 825-829
CrossRef378
Mohamad A Hussein. (2006) Pharmacotherapy of multiple myeloma. Expert Opinion on Pharmacotherapy 7:6, 767-781
CrossRef379
Gareth J Morgan, Biju Krishnan, Matthew Jenner, Faith E Davies. (2006) Advances in oral therapy for multiple myeloma. The Lancet Oncology 7:4, 316-325
CrossRef380
Roberta WC Pang, Ronnie TP Poon. (2006) Clinical implications of angiogenesis in cancers. Vascular Health and Risk Management 2:2, 97-108
CrossRef381
John De Vos, Dirk Hose, Thierry Reme, Karin Tarte, Jerome Moreaux, Karene Mahtouk, Michel Jourdan, Hartmut Goldschmidt, Jean-Francois Rossi, Friedrich W. Cremer, Bernard Klein. (2006) Microarray-based understanding of normal and malignant plasma cells. Immunological Reviews 210:1, 86-104
CrossRef382
Anna Dmoszynska, Monika Podhorecka, Piotr Klimek, Norbert Grzasko. (2006) Lovastatin and thalidomide have a combined effect on the rate of multiple myeloma cell apoptosis in short term cell cultures. European Journal of Clinical Pharmacology 62:4, 325-329
CrossRef383
Antonio Palumbo, Ilaria Avonto, Benedetto Bruno, Maria Teresa Ambrosini, Sara Bringhen, Federica Cavallo, Patrizia Falco, Mario Boccadoro. (2006) Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. European Journal of Haematology 76:4, 273-277
CrossRef384
Pier Paolo Piccaluga, Giovanni Martinelli, Michele Baccarani. (2006) Advances in the treatment for haematological malignancies. Expert Opinion on Pharmacotherapy 7:6, 721-732
CrossRef385
Barlogie, Bart, Tricot, Guido, Anaissie, Elias, Shaughnessy, John, Rasmussen, Erik, van Rhee, Frits, Fassas, Athanasios, Zangari, Maurizio, Hollmig, Klaus, Pineda-Roman, Mauricio, Lee, Choon, Talamo, Giampaolo, Thertulien, Raymond, Kiwan, Elias, Krishna, Somashekar, Fox, Michele, Crowley, John, . (2006) Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine 354:10, 1021-1030
Full Text386
Antonio Palumbo, Sara Bringhen, Tommaso Caravita, Emanuela Merla, Vincenzo Capparella, Vincenzo Callea, Clotilde Cangialosi, Mariella Grasso, Fausto Rossini, Monica Galli, Lucio Catalano, Elena Zamagni, Maria Teresa Petrucci, Valerio De Stefano, Manuela Ceccarelli, Maria Teresa Ambrosini, Ilaria Avonto, Patrizia Falco, Giovannino Ciccone, Anna Marina Liberati, Pellegrino Musto, Mario Boccadoro. (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. The Lancet 367:9513, 825-831
CrossRef387
Axel Glasmacher, Corinna Hahn, Florian Hoffmann, Ralph Naumann, Hartmut Goldschmidt, Marie Lilienfeld-Toal, Katjana Orlopp, Ingo Schmidt-Wolf, Marcus Gorschluter. (2006) A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. British Journal of Haematology 132:5, 584-593
CrossRef388
S. El Mahou, B. Jamard, A. Constantin, A. Cantagrel, B. Maziéres, M. Laroche, M. Attal, C. Arnaud. (2006) Do new therapeutic approaches (autotransplants, thalidomide, dexamethasone) improve the survival of patients with multiple myeloma followed in a rheumatology department?. Clinical Rheumatology 25:2, 175-182
CrossRef389
Shaji Kumar. (2006) Progress in the treatment of multiple myeloma. The Lancet 367:9513, 791-792
CrossRef390
Shaji Kumar, Noopur Raje, Teru Hideshima, Kenji Ishitsuka, Klaus Podar, Steven Le Gouille, Dharminder Chauhan, Paul Richardson, Nikhil C. Munshi, Kenneth Anderson. (2006) FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. British Journal of Haematology 132:6, 698-704
CrossRef391
Robert L Vessella, Theresa A Guise, Edward S Susman, Larry J Suva, Gregory A Clines, Scott L Kominsky, Kristy L Weber, John M Chirgwin, Laurie K McCauley, Wende Kozlow. (2006) Meeting report from skeletal complications of malignancy IV. BoneKEy-Osteovision 3:3, 15-42
CrossRef392
Ramón García-Sanz. (2006) Thalidomide in multiple myeloma. Expert Opinion on Pharmacotherapy 7:2, 195-213
CrossRef393
A Vacca, D Ribatti. (2006) Bone marrow angiogenesis in multiple myeloma. Leukemia 20:2, 193-199
CrossRef394
Alastair Smith, Finn Wisloff, Diana Samson, . (2006) Guidelines on the diagnosis and management of multiple myeloma 2005. British Journal of Haematology 132:4, 410-451
CrossRef395
Teru Hideshima, Paul G Richardson, Kenneth C Anderson. (2006) Current therapeutic uses of lenalidomide in multiple myeloma. Expert Opinion on Investigational Drugs 15:2, 171-179
CrossRef396
Fuat Erdem, Mehmet Gundogdu, Ilhami Kiki, ILYAS Çapoĝlu. (2006) Autoimmune thyroiditis during thalidomide treatment. American Journal of Hematology 81:2, 152-152
CrossRef397
Emerson Peter da S. Falcão, Sebastião J. de Melo, Rajendra M. Srivastava, Maria Tereza Jansen de A. Catanho, Silene Carneiro Do Nascimento. (2006) Synthesis and antiinflammatory activity of 4-amino-2-aryl-5-cyano-6-{3- and 4-(N-phthalimidophenyl)} pyrimidines11Taken in part from the Ph.D. thesis (2003) of Emerson Peter da S. Falcão. European Journal of Medicinal Chemistry 41:2, 276-282
CrossRef398
Satoki Nakamura, Miki Kobayashi, Kiyoshi Shibata, Naohi Sahara, Kazuyuki Shigeno, Kaori Shinjo, Kensuke Naito, Hideharu Hayashi, Kazunori Ohnishi. (2006) Etodolac induces apoptosis and inhibits cell adhesion to bone marrow stromal cells in human myeloma cells. Leukemia Research 30:2, 123-135
CrossRef399
Dong Hyun Kim, Yearn Seong Choe, Kyoung-Ho Jung, Kyung-Han Lee, Yong Choi, Byung-Tae Kim. (2006) Synthesis and evaluation of 4-[18F]fluorothalidomide for the in vivo studies of angiogenesis. Nuclear Medicine and Biology 33:2, 255-262
CrossRef400
John Kuruvilla, Kevin Song, Peter Mollee, Tony Panzarella, Jan McCrae, Tracy Nagy, Michael Crump, Armand Keating. (2006) A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. Hematology 11:1, 25-29
CrossRef401
A David McCollum, Bingyan Wu, Jeffrey W. Clark, Matthew H. Kulke, Peter C. Enzinger, David P. Ryan, Craig C. Earle, Ann Michelini, Charles S. Fuchs. (2006) The Combination of Capecitabine and Thalidomide in Previously Treated, Refractory Metastatic Colorectal Cancer. American Journal of Clinical Oncology 29:1, 40-44
CrossRef402
Yonghua Li, Jian Hou, Dongxing Wang, Weijun Fu, Zhengang Yuan, Yubao Chen, Zhongfei Tao. (2006) Prognostic factors for the efficacy of thalidomide in the treatment of multiple myeloma: A clinical study of 110 patients in China. Leukemia & Lymphoma 47:12, 2593-2600
CrossRef403
Robert J Amato, Jaroslaw Jac. (2006) Targeted Anti-Cancer Therapies for Renal Cancer. Drugs 66:17, 2161-2171
CrossRef404
Meletios A. Dimopoulos, Efstathios Kastritis. (2006) Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy?. Leukemia & Lymphoma 47:11, 2271-2272
CrossRef405
Seong-Hoon Jeong, Je-Jung Lee, Sang-Kyun Sohn, Ho-Jin Shin, Deok-Hwan Yang, Yeo-Kyeoung Kim, Sang-Ki Kim, Jin-Ho Baek, Dong-Hwan Kim, Jong-Gwang Kim, Joo-Sep Chung, Goon-Jae Cho, Hyeoung-Joon Kim. (2006) Clinical Efficacy of Thalidomide Containing Regimens as a Primary Therapy in Patients with Multiple Myeloma. The Korean Journal of Hematology 41:2, 83
CrossRef406
Klaus Podar, Teru Hideshima, Yu-Tzu Tai, Paul G Richardson, Dharminder Chauhan, Kenneth C Anderson. (2006) Emerging Therapies for Multiple Myeloma. American Journal of Cancer 5:3, 141-153
CrossRef407
Dirk Hönemann, H. Miles Prince. (2006) Myeloma, thalidomide and thrombosis. Leukemia & Lymphoma 47:11, 2273-2275
CrossRef408
G. Cherian, D. W. Thomas, S. A. J. Rule. (2006) The efficacy of low dose thalidomide in refractory/relapsed myeloma—a retrospective audit. Leukemia & Lymphoma 47:11, 2409-2411
CrossRef409
Kristen N. Ganjoo, Caroline S. An, Michael J. Robertson, Leo I. Gordon, Joy A. Sen, Jill Weisenbach, Shuli Li, Edie A. Weller, Attilio Orazi, Sandra J. Horning. (2006) Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis. Leukemia & Lymphoma 47:6, 998-1005
CrossRef410
Paul G Richardson, Robert Schlossman, Nikhil Munshi, Kenneth Anderson. (2006) Management Strategies for Relapsed Multiple Myeloma. American Journal of Cancer 5:6, 393-409
CrossRef411
Kena C. Miller, Swaminathan Padmanabhan, Laurie Dimicelli, Dawn Depaolo, Beverly Landrigan, Jihnhee Yu, Virginia Doran, Patricia Marshal, Asher Chanan-Khan. (2006) Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leukemia & Lymphoma 47:11, 2339-2343
CrossRef412
S. Ciolli, F. Leoni, F. Gigli, L. Rigacci, A. Bosi. (2006) Low dose velcade, thalidomide and dexamethasone (LD-VTD): An effective regimen for relapsed and refractory multiple myeloma patients. Leukemia & Lymphoma 47:1, 171-173
CrossRef413
Sharon E. Jacob, Sari Fien, Francisco A. Kerdel. (2006) Scleromyxedema, a Positive Effect with Thalidomide. Dermatology 213:2, 150-152
CrossRef414
Michele Bertolotto, Gabriele Pozzato, Lory Saveria Croc??, Fabiana Nascimben, Cristiana Gasparini, Maria Assunta Cova, Claudio Tiribelli. (2006) Blood Flow Changes in Hepatocellular Carcinoma After the Administration of Thalidomide Assessed by Reperfusion Kinetics During Microbubble Infusion. Investigative Radiology 41:1, 15-21
CrossRef415
Tufia C. Haddad, Edward W. Greeno. (2006) Chemotherapy-induced thrombosis. Thrombosis Research 118:5, 555-568
CrossRef416
Robert A. Kyle, S. Vincent Rajkumar. (2006) Treatment of multiple myeloma: An emphasis on new developments. Annals of Medicine 38:2, 111-115
CrossRef417
Philipp Schütt, Dieter Brandhorst, Werner Stellberg, Miriam Poser, Peter Ebeling, Siemke Müller, Ulrike Buttkereit, Bertram Opalka, Monika Lindemann, Hans Grosse-Wilde, Siegfried Seeber, Thomas Moritz, Mohammad R. Nowrousian. (2006) Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. Leukemia & Lymphoma 47:8, 1570-1582
CrossRef418
Ping Wu, Faith E. Davies, Clive Horton, Matthew W. Jenner, Biju Krishnan, Caroline L. Alvares, Radovan Saso, Rita Mccormack, Sharon Dines, Jennifer G. Treleaven, Michael N. Potter, Mark E. Ethell, Gareth J Morgan. (2006) The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide – vincristine – doxorubicin – methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. Leukemia & Lymphoma 47:11, 2335-2338
CrossRef419
Sang Hoon Han, Se Hoon Park, Jung Ho Kim, Jong Jun Lee, So Young Kwon, Oh Sang Kwon, Sun Suk Kim, Ju Hyun Kim, Keon Kug Kim, Yeon Ho Park, Jeong Nam Lee, Eunmi Nam, Soo-Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee. (2006) Thalidomide for Treating Metastatic Hepatocellular Carcinoma: A Pilot Study. The Korean Journal of Internal Medicine 21:4, 225
CrossRef420
James R. Berenson. (2005) Myeloma bone disease. Best Practice & Research Clinical Haematology 18:4, 653-672
CrossRef421
Satoru Takada, Kimio Morita, Kunihiko Hayashi, Takahumi Matsushima, Morio Sawamura, Hirokazu Murakami, Yoshihisa Nojima. (2005) Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with multiple myeloma. European Journal of Haematology 75:6, 505-510
CrossRef422
Teru Hideshima, Klaus Podar, Dharminder Chauhan, Kenneth C. Anderson. (2005) Cytokines and signal transduction. Best Practice & Research Clinical Haematology 18:4, 509-524
CrossRef423
S. Vincent Rajkumar, Robert A. Kyle. (2005) Conventional therapy and approach to management. Best Practice & Research Clinical Haematology 18:4, 585-601
CrossRef424
Paul G. Richardson, Constantine S. Mitsiades, Teru Hideshima, Kenneth C. Anderson. (2005) Novel biological therapies for the treatment of multiple myeloma. Best Practice & Research Clinical Haematology 18:4, 619-634
CrossRef425
Maria-Theresa Krauth, Alexander Bankier, Peter Valent, Peter Kalhs, Johannes Drach. (2005) Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib. Leukemia Research 29:12, 1473-1477
CrossRef426
S. V. Rajkumar. (2005) Thalidomide Therapy and Deep Venous Thrombosis in Multiple Myeloma. Mayo Clinic Proceedings 80:12, 1549-1551
CrossRef427
Y. Trieu, S. Trudel, G. R. Pond, J. Mikhael, W. Jaksic, D. E. Reece, C. I. Chen, A. K. Stewart. (2005) Weekly Cyclophosphamide and Alternate-Day Prednisone: An Effective, Convenient, and Well-Tolerated Oral Treatment for Relapsed Multiple Myeloma After Autologous Stem Cell Transplantation. Mayo Clinic Proceedings 80:12, 1578-1582
CrossRef428
Hiroshi Yasui, Teru Hideshima, Paul G. Richardson, Kenneth C. Anderson. (2005) Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. British Journal of Haematology 0:0, 051220022257014
CrossRef429
E Terpos, D Mihou, R Szydlo, K Tsimirika, C Karkantaris, M Politou, E Voskaridou, A Rahemtulla, M A Dimopoulos, K Zervas. (2005) The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 19:11, 1969-1976
CrossRef430
Heinz Ludwig, Ivan Spicka, Pavel Klener, Richard Greil, Zdenek Adam, Heinz Gisslinger, Gabor Tarkovacs, Werner Linkesch, Alice Maniatis, Rudolf Morant, Johannes Drach, Ingrid Kuhn, Judith Schuster, Axel Hinke. (2005) Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma. British Journal of Haematology 131:3, 329-337
CrossRef431
Evangelos Terpos, Katayoun Rezvani, Supratik Basu, Alison E. Milne, Peter E. Rose, Geoffrey L. Scott, Amin Rahemtulla, Diana Samson, Jane F. Apperley. (2005) Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. European Journal of Haematology 75:5, 376-383
CrossRef432
Giampietro Gasparini, Raffaele Longo, Masakazu Toi, Napoleone Ferrara. (2005) Angiogenic inhibitors: a new therapeutic strategy in oncology. Nature Clinical Practice Oncology 2:11, 562-577
CrossRef433
Antonio Palumbo, Patrizia Falco, Maria Teresa Ambrosini, Maria Teresa Petrucci, Pellegrino Musto, Tommaso Caravita, Patrizia Pregno, Alessandra Bertola, Federica Cavallo, Giovannino Ciccone, Mario Boccadoro. (2005) Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant. European Journal of Haematology 75:5, 391-395
CrossRef434
Maurizio Zangari, Francesca Elice, Guido Tricot. (2005) Immunomodulatory drugs in multiple myeloma. Expert Opinion on Investigational Drugs 14:11, 1411-1418
CrossRef435
P Hari, M C Pasquini, D H Vesole. (2005) Cure of multiple myeloma – more hype, less reality. Bone Marrow Transplantation
CrossRef436
Kenneth C. Anderson. (2005) Lenalidomide and Thalidomide: Mechanisms of Action—Similarities and Differences. Seminars in Hematology 42, S3-S8
CrossRef437
Paul Richardson. (2005) Management of the Relapsed/Refractory Myeloma Patient: Strategies Incorporating Lenalidomide. Seminars in Hematology 42, S9-S15
CrossRef438
B Bruno, L Giaccone, M Rotta, K Anderson, M Boccadoro. (2005) Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside. Leukemia 19:10, 1729-1738
CrossRef439
Shaji Kumar, S Vincent Rajkumar. (2005) Thalidomide and dexamethasone: therapy for multiple myeloma. Expert Review of Anticancer Therapy 5:5, 759-766
CrossRef440
Naoya Ochiai, Noriko Yamada, Ryo Uchida, Shin-ichi Fuchida, Akira Okano, Mayumi Hatsuse, Masashi Okamoto, Eishi Ashihara, Chihiro Shimazaki. (2005) Combination Therapy with Thalidomide, Incadronate, and Dexamethasone for Relapsed or Refractory Multiple Myeloma. International Journal of Hematology 82:3, 243-247
CrossRef441
Mohamad A. Hussein. (2005) Lenalidomide: Patient Management Strategies. Seminars in Hematology 42, S22-S25
CrossRef442
S. V. Rajkumar, R. A. Kyle. (2005) Multiple Myeloma: Diagnosis and Treatment. Mayo Clinic Proceedings 80:10, 1371-1382
CrossRef443
M. Cem Ar, Teoman Soysal, Gulen Hatemi, Ayse Salihoglu, Hasan Yazici, Birsen Ulku. (2005) Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma. Annals of Hematology 84:9, 609-613
CrossRef444
D Ribatti, A Vacca. (2005) Therapeutic renaissance of thalidomide in the treatment of haematological malignancies. Leukemia 19:9, 1525-1531
CrossRef445
Philipp Schütt, Peter Ebeling, Ulrike Buttkereit, Dieter Brandhorst, Bertram Opalka, Miriam Poser, Siemke Müller, Michael Flasshove, Thomas Moritz, Siegfried Seeber, Mohammad Resa Nowrousian. (2005) Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival. Annals of Hematology 84:9, 594-600
CrossRef446
Sandy Srinivas, Alice E. Guardino. (2005) A lower dose of thalidomide is better than a high dose in metastatic renal cell carcinoma. BJU International 96:4, 536-539
CrossRef447
C. Strupp, R. Fenk, A. Kündgen, N. Gattermann, R. Haas, U. Germing. (2005) Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide. Leukemia Research 29:8, 967-969
CrossRef448
M Hus, A Dmoszyñska, J Kocki, I Hus, D Jawniak, M Adamczyk-Cioch, N Grzasko. (2005) Long-term thalidomide therapy resulted in lack of mdr1 gene expression in a patient with primary resistant multiple myeloma. Leukemia 19:8, 1497-1499
CrossRef449
Robert Knight. (2005) IMiDs: A Novel Class of Immunomodulators. Seminars in Oncology 32, 24-30
CrossRef450
L.-T. CHEN, T.-W. LIU, Y. CHAO, H.-S. SHIAH, J.-Y. CHANG, S.-H. JUANG, S.-C. CHEN, T.-R. CHUANG, Y.-H. CHIN, J. WHANG-PENG. (2005) alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics 22:3, 217-226
CrossRef451
A Abdelkefi, L Torjman, N Ben Romdhane, S Ladeb, H El Omri, T Ben Othman, M Elloumi, H Bellaj, A Lakhal, R Jeddi, L Aissaouï, A Saad, M Hsaïri, K Boukef, K Dellagi, A Ben Abdeladhim. (2005) First-line thalidomide–dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma. Bone Marrow Transplantation 36:3, 193-198
CrossRef452
Levi S. Downs, Lisa M. Rogers, Yumi Yokoyama, Sundaram Ramakrishnan. (2005) Thalidomide and angiostatin inhibit tumor growth in a murine xenograft model of human cervical cancer. Gynecologic Oncology 98:2, 203-210
CrossRef453
Jurstine Daruwalla, Mehrdad Nikfarjam, Cathy Malcontenti-Wilson, Vijayaragavan Muralidharan, Chris Christophi. (2005) Effect of thalidomide on colorectal cancer liver metastases in CBA mice. Journal of Surgical Oncology 91:2, 134-140
CrossRef454
S. J. Harrison, G. Cook. (2005) Immunotherapy in multiple myeloma - possibility or probability?. British Journal of Haematology 130:3, 344-362
CrossRef455
Jay Rhee, Paulo M Hoff. (2005) Angiogenesis inhibitors in the treatment of cancer. Expert Opinion on Pharmacotherapy 6:10, 1701-1711
CrossRef456
Sílvia Nosàs-Garcia, Thomas Moehler, Klaus Wasser, Fabian Kiessling, Reiner Bartl, Ivan Zuna, Jens Hillengass, Hartmut Goldschmidt, Hans-Ulrich Kauczor, Stefan Delorme. (2005) Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: A comparative study with histology and clinical markers. Journal of Magnetic Resonance Imaging 22:1, 154-162
CrossRef457
B Sirohi, R Powles, J Mehta, C Rudin, S Kulkarni, C Horton, R Saso, S Singhal, J Treleaven. (2005) An elective single autograft with high-dose melphalan: single-center study of 451 patients. Bone Marrow Transplantation 36:1, 19-24
CrossRef458
S Kumar, N Raje, T Hideshima, K Ishitsuka, A Roccaro, N Shiraishi, M Hamasaki, H Yasui, N C Munshi, P Richardson, W D Figg, K C Anderson. (2005) Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs. Leukemia 19:7, 1253-1261
CrossRef459
Michael Wang, Donna M. Weber, Kay Delasalle, Raymond Alexanian. (2005) Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. American Journal of Hematology 79:3, 194-197
CrossRef460
Dispenzieri, Angela, . (2005) Bortezomib for Myeloma — Much Ado about Something. New England Journal of Medicine 352:24, 2546-2548
Full Text461
Charalampia Kyriakou, Kirsty Thomson, Shirley D'Sa, Angela Flory, Judith Hanslip, Anthony H. Goldstone, Kwee L. Yong. (2005) Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. British Journal of Haematology 129:6, 763-770
CrossRef462
Evangelos Terpos, Amin Rahemtulla, Meletios-Athanassios Dimopoulos. (2005) Current treatment options for myeloma. Expert Opinion on Pharmacotherapy 6:7, 1127-1142
CrossRef463
Johannes Drach, Sonja Seidl, Hannes Kaufmann. (2005) Treatment of mantle cell lymphoma: targeting the microenvironment. Expert Review of Anticancer Therapy 5:3, 477-485
CrossRef464
Heather E. Oakervee, Rakesh Popat, Nicola Curry, Pat Smith, Curly Morris, Mary Drake, Samir Agrawal, Jim Stec, David Schenkein, Dixie-Lee Esseltine, Jamie D. Cavenagh. (2005) PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. British Journal of Haematology 129:6, 755-762
CrossRef465
Kirsty J Thomson, Karl S Peggs. (2005) Role of allogeneic stem cell transplantation in multiple myeloma. Expert Review of Anticancer Therapy 5:3, 455-464
CrossRef466
Caroline L. Alvares, Faith E. Davies, Clive Horton, Gita Patel, Ray Powles, Bhawna Sirohi, Roslin Zuha, Alex Gatt, Radovan Saso, Jennifer G. Treleaven, Claire E. Dearden, Michael N. Potter, Mark E. Ethell, Gareth J. Morgan. (2005) Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments. British Journal of Haematology 129:5, 607-614
CrossRef467
R A Kyle. (2005) Five decades of therapy for multiple myeloma: a paradigm for therapeutic models. Leukemia 19:6, 910-912
CrossRef468
Rosangela Invernizzi, Erica Travaglino, Mara De Amici, Silvia Brugnatelli, Isabella Ramajoli, Bianca Rovati, Chiara Benatti, Edoardo Ascari. (2005) Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes. Leukemia Research 29:6, 641-647
CrossRef469
Angela Dispenzieri, Morie A Gertz. (2005) Treatment options for POEMS syndrome. Expert Opinion on Pharmacotherapy 6:6, 945-953
CrossRef470
Nicole McNeil, Joong Su Kim, Thomas Ried, Siegfried Janz. (2005) Extraosseous IL-6 transgenic mouse plasmacytoma sometimes lacksMyc-activating chromosomal translocation. Genes, Chromosomes and Cancer 43:2, 137-146
CrossRef471
Sjoerd Hovenga, Simon M. G. J. Daenen, Joost T. M. Wolf, Gustaaf W. Imhoff, Hanneke C. Kluin-Nelemans, Wim J. Sluiter, Edo Vellenga. (2005) Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study. Annals of Hematology 84:5, 311-316
CrossRef472
Paul Baas, Willem Boogerd, Otilia Dalesio, Annebeth Haringhuizen, Frank Custers, Nico van Zandwijk. (2005) Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 48:2, 291-296
CrossRef473
Henk MW Verheul, Herbert M Pinedo. (2005) Inhibition of angiogenesis in cancer patients. Expert Opinion on Emerging Drugs 10:2, 403-412
CrossRef474
Alessandro Morabito, Guido Carillio, Raffaele Longo, Giampietro Gasparini. (2005) Thalidomide Is Inactive in Heavily Pretreated Patients with Metastatic Breast Cancer. The Cancer Journal 11:3, 248-251
CrossRef475
Shaji Kumar, Kenneth C Anderson. (2005) Drug Insight: thalidomide as a treatment for multiple myeloma. Nature Clinical Practice Oncology 2:5, 262-270
CrossRef476
A Dogan, L S P Ngu, S H Ng, P L Cervi. (2005) Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide. Leukemia 19:5, 873-875
CrossRef477
P. J. Hayden, A. O’Driscoll, N. Gardiner, R. Swords, J. Sargent, F. Ainle, A. Fortune, P. T. Murphy, M. Leahy, F. Jackson, M. Ryan, B. Hennessy, M. Cahill, G. M. Crotty, H. Enright, E. Conneally, E. Vandenberghe, S. R. McCann, P. V. Browne. (2005) Autologous stem cell transplantation in myeloma: the St James’s Hospital experience, 1997–2003. Irish Journal of Medical Science 174:2, 26-32
CrossRef478
Mohamed A Hussein. (2005) Multiple myeloma: an update of developments in targeted therapy. Expert Review of Anticancer Therapy 5:2, 379-389
CrossRef479
Klaus Podar, Teru Hideshima, Dharminder Chauhan, Kenneth C Anderson. (2005) Targeting signalling pathways for the treatment of multiple myeloma. Expert Opinion on Therapeutic Targets 9:2, 359-381
CrossRef480
Johnny Hyde, D. Scott McMeekin. (2005) Targeted therapies for gynecologic malignancies. Current Treatment Options in Oncology 6:2, 121-132
CrossRef481
S. Ladoire, F. Ghiringhelli, P. Manckoundia, R.O. Casasnovas, E. Solary, J.F. Besancenot, P. Pfitzenmeyer. (2005) Prise en charge des cancers solides et des hémopathies malignes du sujet âgé : l'oncogériatrie, une discipline en devenir. Seconde partie : traitement des cancers solides (partie 2) et des hémopathies malignes du sujet âgé. La Revue de Médecine Interne 26:4, 304-314
CrossRef482
Steven K. Teo. (2005) Properties of thalidomide and its analogues: Implications for anticancer therapy. The AAPS Journal 7:1, E14-E19
CrossRef483
Patrizia Tosi, Elena Zamagni, Claudia Cellini, Rosaria Plasmati, Delia Cangini, Paola Tacchetti, Giulia Perrone, Francesca Pastorelli, Sante Tura, Michele Baccarani, Michele Cavo. (2005) Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. European Journal of Haematology 74:3, 212-216
CrossRef484
Yehuda Z. Patt, Manal M. Hassan, Richard D. Lozano, Ajay K. Nooka, Isaac I. Schnirer, Jerome B. Zeldis, James L. Abbruzzese, Thomas D. Brown. (2005) Thalidomide in the treatment of patients with hepatocellular carcinoma. Cancer 103:4, 749-755
CrossRef485
X. Leleu, J.B. Micol, R. Guieze, C. Berthon, F. Kuhnovsky, L. Terriou, A.S. Moreau, I. Yakoub-Agha, F. Bauters, T. Facon. (2005) Thalidomide : mécanismes d'action et indications en hématologie. La Revue de Médecine Interne 26:2, 119-127
CrossRef486
E. Mauro, C. Fraulini, G. M. Rigolin, R. Galeotti, R. Spanedda, G. Castoldi. (2005) A case of disseminated Langerhans' cell histiocytosis treated with thalidomide. European Journal of Haematology 74:2, 172-174
CrossRef487
Domenico Ribatti, Mirco Ponzoni. (2005) Antiangiogenic strategies in neuroblastoma. Cancer Treatment Reviews 31:1, 27-34
CrossRef488
Auro del Giglio, Patricia Weinschenker, Ana Rita de Araújo Burgos Manhani, Ana Lucia Ippolito Carbonell, Cristina A.T.S. Mitteldorf. (2005) Hepatic Plasmacytosis as a Manifestation of Relapse in Multiple Myeloma Treated With Thalidomide. Southern Medical Journal 98:2, 238-240
CrossRef489
G. Damaj, R. Bouabdallah, N. Vey, K. Bilger, M. Mohty, J. A. Gastaut. (2005) Single-agent thalidomide induces response in T-cell lymphoma. European Journal of Haematology 74:2, 169-171
CrossRef490
G J Morgan, F E Davies. (2005) Evolving treatment strategies for myeloma. British Journal of Cancer
CrossRef491
Asher Chanan-Khan, Kena C Miller. (2005) Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma. Leukemia & Lymphoma 46:7, 1103-1104
CrossRef492
Young Jin Yuh, Hyun Su Kim, Young Jung Park, Heung Sik Um, Sang Bong Choi, Ban Suck Lee, Sung Rok Kim, Tae Hee Han. (2005) A Case of Extramedullary Progression Despite of Serologic Improvement in a Patient Treated with Thalidomide for Multiple Myeloma. The Korean Journal of Hematology 40:3, 188
CrossRef493
P. Schutt, P. Ebeling, U. Buttkereit, D. Brandhorst, B. Opalka, M. Hoiczyk, M. Flasshove, J. Hense, P. Bojko, K. Metz, T. Moritz, S. Seeber, M. R. Nowrousian. (2005) Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. European Journal of Haematology 74:1, 40-46
CrossRef494
Keun-Wook Lee, Tak Yun, Eun Kee Song, Im il Na, Hyunchoon Shin, Soo-Mee Bang, Jae Hoon Lee, Seung Tae Lee, Jee Hyun Kim, Sung-Soo Yoon, Jong Seok Lee, Seonyang Park, Byoung Kook Kim, Noe Kyeong Kim. (2005) A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma. Journal of Korean Medical Science 20:4, 598
CrossRef495
Min Zhang, Yasunobu Abe, Takamitsu Matsushima, Junji Nishimura, Hajime Nawata, Koichiro Muta. (2005) Selective cyclooxygenase 2 inhibitor NS-398 induces apoptosis in myeloma cells via a Bcl-2 independent pathway. Leukemia & Lymphoma 46:3, 425-433
CrossRef496
C Strupp, U Germing, M Aivado, A Kündgen, R Fenk, A Hünerlitürkoglu, G Kobbe, R Haas, N Gattermann. (2005) The ratio between CD4 + and CD8 + cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide. Leukemia & Lymphoma 46:7, 999-1006
CrossRef497
Mathias Kees, Markus Raderer, Sylvia Metz-Schimmerl, Andreas Chott, Heinz Gisslinger. (2005) Very good partial response in a patient with MALT-lymphoma of the lung after treatment with low-dose thalidomide. Leukemia & Lymphoma 46:9, 1379-1382
CrossRef498
Linda Mileshkin, H Miles Prince. (2005) The adverse prognostic impact of advanced age in multiple myeloma. Leukemia & Lymphoma 46:7, 951-966
CrossRef499
Bryan T. Hennessy, Deborah A. Thomas, Francis J. Giles, Hagop Kantarjian, Srdan Verstovsek. (2005) New approaches in the treatment of myelofibrosis. Cancer 103:1, 32-43
CrossRef500
Serena Mazzotta, Alessandro Gozzetti, Maria Teresa Pirrotta, Monica Bocchia, Simona Sammassimo, Alessandro Bucalossi, Francesco Lauria. (2005) Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis. Leukemia & Lymphoma 46:12, 1837-1838
CrossRef501
Keith Dredge, Rebecca Horsfall, Simon P. Robinson, Ling-Hua Zhang, Ling Lu, Yang Tang, Michael A. Shirley, George Muller, Peter Schafer, David Stirling, Angus G. Dalgleish, J. Blake Bartlett. (2005) Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvascular Research 69:1-2, 56-63
CrossRef502
S. Chiruka, C.S. Chapman. (2005) Severe tremors associated with use of thalidomide. American Journal of Hematology 78:1, 81-82
CrossRef503
Axel Glasmacher, Marie von Lilienfeld-Toal. (2005) The Current Status of Thalidomide in the Management of Multiple Myeloma. Acta Haematologica 114:1, 3-7
CrossRef504
Mohamad A Hussein. (2005) Thalidomide: present and future in multiple myeloma. Expert Review of Anticancer Therapy 5:1, 25-31
CrossRef505
Aristotle Bamias, Meletios A Dimopoulos. (2005) Thalidomide and immunomodulatory drugs in the treatment of cancer. Expert Opinion on Investigational Drugs 14:1, 45-55
CrossRef506
Albert Y. Lin, Nathalie Brophy, George A. Fisher, Sam So, Christopher Biggs, Torunn I. Yock, Lee Levitt. (2005) Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 103:1, 119-125
CrossRef507
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Ebeling, Sally H.Ellender, Stacey M.Peters, Christine C., Richardson, Paul G., Kassarjian, Ara, Jing, Wen, . (2004) Case 38-2004. New England Journal of Medicine 351:25, 2637-2645
Full Text508
Mohamad A. Hussein, Kenneth C. Anderson. (2004) Role of liposomal anthracyclines in the treatment of multiple myeloma. Seminars in Oncology 31, 147-160
CrossRef509
G. Damaj, M. Mohty, N. Vey, E. Dincan, R. Bouabdallah, C. Faucher, A. M. Stoppa, J. A. Gastaut. (2004) Features of extramedullary and extraosseous multiple myeloma: a report of 19 patients from a single center. European Journal of Haematology 73:6, 402-406
CrossRef510
Franklin Joseph, Navid Younis, Geoffery Haydon, David H Adams, Siann Wynne, Martin B Gillet, Yasmine M Maurice, Mark E Lipton, David Berstock, Ian R Jones. (2004) Peliosis of the spleen with massive recurrent haemorrhagic ascites, despite splenectomy, and associated with elevated levels of vascular endothelial growth factor. European Journal of Gastroenterology & Hepatology 16:12, 1401-1406
CrossRef511
E. Hatjiharissi, E. Terpos, M. Papaioannou, C. Hatjileontis, V. Kaloutsi, G. Galaktidou, G. Gerotziafas, J. Christakis, K. Zervas. (2004) The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma. Hematological Oncology 22:4, 159-168
CrossRef512
Christine Galustian, Marie-Christine Labarthe, J Blake Bartlett, Angus G Dalgleish. (2004) Thalidomide-derived immunomodulatory drugs as therapeutic agents. Expert Opinion on Biological Therapy 4:12, 1963-1970
CrossRef513
I Hus, A Dmoszynska, J Manko, M Hus, D Jawniak, M Soroka-Wojtaszko, A Hellmann, H Ciepluch, A Skotnicki, T Wolska-Smolen, K Sulek, T Robak, L Konopka, J Kloczko. (2004) An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma. British Journal of Cancer 91:11, 1873-1879
CrossRef514
Constantine S. Mitsiades, Nicholas Mitsiades, Nikhil C. Munshi, Kenneth C. Anderson. (2004) Focus on multiple myeloma. Cancer Cell 6:5, 439-444
CrossRef515
Gösta Gahrton. (2004) New therapeutic targets in multiple myeloma. The Lancet 364:9446, 1648-1649
CrossRef516
Joan E. Smallshaw, Elaine Coleman, Camelia Spiridon, Ellen S. Vitetta. (2004) The Generation and Anti-Myeloma Activity of a Chimeric Anti-CD54 Antibody, cUV3. Journal of Immunotherapy 27:6, 419-424
CrossRef517
C. Rus, M. Bazzan, A. Palumbo, S. Bringhen, M. Boccadoro. (2004) Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis. Journal of Thrombosis and Haemostasis 2:11, 2063-2065
CrossRef518
Kyle, Robert A., Rajkumar, S. Vincent, . (2004) Multiple Myeloma. New England Journal of Medicine 351:18, 1860-1873
Full Text519
Domenico Ribatti, Claudio Scavelli, Aldo M. Roccaro, Enrico Crivellato, Beatrice Nico, Angelo Vacca. (2004) Hematopoietic Cancer and Angiogenesis. Stem Cells and Development 13:5, 484-495
CrossRef520
Benjamin Purow, Howard A. Fine. (2004) Antiangiogenic therapy for primary and metastatic brain tumors. Hematology/Oncology Clinics of North America 18:5, 1161-1181
CrossRef521
J. M. Hernández, R. García-Sanz, E. Golvano, J. Bladé, J. Fernandez-Calvo, J. Trujillo, J. A. Soler, S. Gardella, F. Carbonell, G. Mateo, J. F. San Miguel. (2004) Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. British Journal of Haematology 127:2, 159-164
CrossRef522
S. Jagannath, B. Barlogie, J. Berenson, D. Siegel, D. Irwin, P. G. Richardson, R. Niesvizky, R. Alexanian, S. A. Limentani, M. Alsina, J. Adams, M. Kauffman, D.-L. Esseltine, D. P. Schenkein, K. C. Anderson. (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. British Journal of Haematology 127:2, 165-172
CrossRef523
Mohamad A. Hussein. (2004) New treatment strategies for multiple myeloma. Seminars in Hematology 41, 2-8
CrossRef524
Karl A Thiel. (2004) Goodbye Columbus! New NRDOs forego discovery. Nature Biotechnology 22:9, 1087-1092
CrossRef525
Yutaka Hattori, Toyotaka Iguchi. (2004) Thalidomide for the treatment of multiple myeloma. Congenital Anomalies 44:3, 125-136
CrossRef526
Maurizio Zangari, Bart Barlogie, Elias Anaissie, Fariba Saghafifar, Paul Eddlemon, Joth Jacobson, Choon-Kee Lee, Raymond Thertulien, Giampaolo Talamo, Teri Thomas, Frits Van Rhee, Athanasios Fassas, Louis Fink, Guido Tricot. (2004) Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. British Journal of Haematology 126:5, 715-721
CrossRef527
Patrizia Tosi, Elena Zamagni, Claudia Cellini, Delia Cangini, Paola Tacchetti, Sante Tura, Michele Baccarani, Michele Cavo. (2004) Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. European Journal of Haematology 73:2, 98-103
CrossRef528
JUDAH FOLKMAN. (2004) Endogenous angiogenesis inhibitors. APMIS 112:7-8, 496-507
CrossRef529
R. A. Mesa, M. A. Elliott, G. Schroeder, A. Tefferi. (2004) Durable Responses to Thalidomide-Based Drug Therapy for Myelofibrosis With Myeloid Metaplasia. Mayo Clinic Proceedings 79:7, 883-889
CrossRef530
P. Richardson, R. Schlossman, S. Jagannath, M. Alsina, R. Desikan, E. Blood, E. Weller, C. Mitsiades, T. Hideshima, F. Davies, D. Doss, A. Freeman, J. Bosch, J. Patin, R. Knight, J. Zeldis, W. Dalton, K. Anderson. (2004) Thalidomide for Patients With Relapsed Multiple Myeloma After High-Dose Chemotherapy and Stem Cell Transplantation: Results of an Open-Label Multicenter Phase 2 Study of Efficacy, Toxicity, and Biological Activity. Mayo Clinic Proceedings 79:7, 875-882
CrossRef531
S. V. Rajkumar. (2004) Thalidomide: Tragic Past and Promising Future. Mayo Clinic Proceedings 79:7, 899-903
CrossRef532
Michel Vulfovich, Nabil Saba. (2004) Molecular biological design of novel antineoplastic therapies. Expert Opinion on Investigational Drugs 13:6, 577-607
CrossRef533
Paul Richardson, Teru Hideshima, Kenneth C. Anderson. (2004) An update of novel therapeutic approaches for multiple myeloma. Current Treatment Options in Oncology 5:3, 227-238
CrossRef534
K. Panteli, N. Zagorianakou, M. Bai, A. Katsaraki, N. J. Agnantis, K. Bourantas. (2004) Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression. European Journal of Haematology 72:6, 410-415
CrossRef535
Massimo Offidani, Laura Corvatta, Monica Marconi, Lara Malerba, Anna Mele, Attilio Olivieri, Marino Brunori, Massimo Catarini, Marco Candela, Debora Capelli, Mauro Montanari, Serena Rupoli, Pietro Leoni. (2004) Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. European Journal of Haematology 72:6, 403-409
CrossRef536
Yoshiko Okikawa, Akira Sakai, Yasuo Takimoto, Masaaki Noda, Jun Imagawa, Yuta Katayama, Yoshiaki Kuroda, Hajime Okita, Kingo Fujimura, Akiro Kimura. (2004) Progressive Myeloma after Thalidomide Therapy in a Patient with Immature Phenotype of Myeloma (Plasma) Cells. International Journal of Hematology 79:4, 364-368
CrossRef537
Michael E Franks, Gordon R Macpherson, William D Figg. (2004) Thalidomide. The Lancet 363:9423, 1802-1811
CrossRef538
Noopur Raje, Teru Hideshima, Faith E. Davies, Dharminder Chauhan, Steven P. Treon, Gloria Young, Yu-Tzu Tai, David Avigan, Jianlin Gong, Robert L. Schlossman, Paul Richardson, Donald W. Kufe, Kenneth C. Anderson. (2004) Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. British Journal of Haematology 125:3, 343-352
CrossRef539
Wenlin Du, Yutaka Hattori, Akinori Hashiguchi, Kensuke Kondoh, Nobumichi Hozumi, Yasuo Ikeda, Michiie Sakamoto, Jun-ichi Hata, Taketo Yamada. (2004) Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment. Pathology International 54:5, 285-294
CrossRef540
Mohamad A. Hussein, Mansoor Saleh, Farhad Ravandi, James Mason, Robert M. Rifkin, Ralph Ellison. (2004) Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma. British Journal of Haematology 125:4, 470-476
CrossRef541
James P. Farese, Leslie E. Fox, Carol J. Detrisac, James M. Van Gilder, Sara L. Roberts, Jamie M Baldwin. (2004) Effect of thalidomide on growth and metastasis of canine osteosarcoma cells after xenotransplantation in athymic mice. American Journal of Veterinary Research 65:5, 659-664
CrossRef542
Fadi Fakhouri, Houda Guerraoui, Claire Presne, Julie Peltier, Richard Delarue, Patrice Muret, Bertrand Knebelmann. (2004) Thalidomide in patients with multiple myeloma and renal failure. British Journal of Haematology 125:1, 96-97
CrossRef543
Jonathan Kaufman, Sagar Lonial. (2004) Multiple myeloma: The role of transplant and novel treatment strategies. Seminars in Oncology 31, 99-105
CrossRef544
Yutaka Hattori, Tsunayuki Kakimoto, Shinichiro Okamoto, Norihide Sato, Yasuo Ikeda. (2004) Thalidomide-Induced Severe Neutropenia during Treatment of Multiple Myeloma. International Journal of Hematology 79:3, 283-288
CrossRef545
Anders Waage, Peter Gimsing, Gunnar Juliusson, Ingemar Turesson, Nina Gulbrandsen, Tommy Eriksson, Martin Hjorth, Johan Lanng Nielsen, Stig Lenhoff, Jan Westin, Finn Wisloff, . (2004) Early response predicts thalidomide efficiency in patients with advanced multiple myeloma*. British Journal of Haematology 125:2, 149-155
CrossRef546
Nikhil C Munshi. (2004) Recent advances in the management of multiple myeloma. Seminars in Hematology 41, 21-26
CrossRef547
Christoph P. Jung, Bertold Emmerich, Frank-D. Goebel, Johannes R. Bogner. (2004) Successful treatment of a patient with HIV-associated multicentric Castleman disease (MCD) with thalidomide. American Journal of Hematology 75:3, 176-177
CrossRef548
Izhar Hardan, Rachel Rothman, Alain Gelibter, Ninette Cohen, Avichai Shimoni, Maya Sokolovsky, Malka Reichart, Galina Ishoev, Ninette Amariglio, Gideon Rechavi, Arnon Nagler, Luba Trakhtenbrot. (2004) Determination of chromosome 13 status in bone marrow cells of patients with multiple myeloma using combined morphologic and fluorescence in situ hybridization analysis. Experimental Hematology 32:3, 254-260
CrossRef549
Bhawna Sirohi, Ray Powles. (2004) Multiple myeloma. The Lancet 363:9412, 875-887
CrossRef550
V. Kaushal, G. P. Kaushal, S. N. Melkaveri, P. Mehta. (2004) Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. Journal of Thrombosis and Haemostasis 2:2, 327-334
CrossRef551
Frederick A Luzzio, William D Figg. (2004) Thalidomide analogues: derivatives of an orphan drug with diverse biological activity. Expert Opinion on Therapeutic Patents 14:2, 215-229
CrossRef552
Alessandro Morabito, Roberta Sarmiento, Paola Bonginelli, Giampietro Gasparini. (2004) Antiangiogenic strategies, compounds, and early clinical results in breast cancer. Critical Reviews in Oncology/Hematology 49:2, 91-107
CrossRef553
Steve K. Teo, Kevin H. Denny, David I. Stirling, Steve D. Thomas, Sandra L. Morseth, Alan M. Hoberman. (2004) Effects of thalidomide on reproductive function and early embryonic development in male and female New Zealand white rabbits. Birth Defects Research Part B: Developmental and Reproductive Toxicology 71:1, 1-16
CrossRef554
G. Molostvov, A. Morris, P. Rose, S. Basu, G. Muller. (2004) The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures. British Journal of Haematology 124:3, 366-375
CrossRef555
William Rastetter, Arturo Molina, Christine A. White. (2004) Rituximab: Expanding Role in Therapy for Lymphomas and Autoimmune Diseases. Annual Review of Medicine 55:1, 477-503
CrossRef556
Robert P Baughman, Elyse E Lower. (2004) Newer Therapies for Cutaneous Sarcoidosis. American Journal of Clinical Dermatology 5:6, 385-394
CrossRef557
Emmanuel Laffitte, Jean Revuz. (2004) Thalidomide: an old drug with new clinical applications. Expert Opinion on Drug Safety 3:1, 47-56
CrossRef558
Kari Koskela, Tarja-Terttu Pelliniemi, Kari Pulkki, Kari Remes. (2004) Treatment of Multiple Myeloma with All-Trans Retinoic Acid Alone and in Combination with Chemotherapy: a Phase I/II Trial. Leukemia & Lymphoma 45:4, 749-754
CrossRef559
Athanasios Anagnostopoulos, Dimitra Gika, George Hamilos, Konstantinos Zervas, Athanasios Zomas, Anastasia Pouli, Markela Zorzou, Efstathios Kastritis, Nikolaos Anagnostopoulos, Anna Tassidou, Dimitra Anagnostou, Meletios-Athanasios Dimopoulos. (2004) Treatment of Relapsed/Refractory Multiple Myeloma with Thalidomide-based Regimens: Identification of Prognostic Factors. Leukemia & Lymphoma 45:11, 2275-2279
CrossRef560
Brijesh Arora, Ruben Mesa, Ayalew Tefferi. (2004) Angiogenesis and Anti-angiogenic Therapy in Myelofibrosis with Myeloid Metaplasia. Leukemia & Lymphoma 45:12, 2373-2386
CrossRef561
ATHANASIOS B-T FASSAS, SUSAN WARD, FIRAS MUWALLA, RUDY VAN HEMERT, KEITH SCHLUTERMAN, SAMI HARIK, GUIDO TRICOT. (2004) Myeloma of the Central Nervous System: Strong Association with Unfavorable Chromosomal Abnormalities and Other High-risk Disease Features. Leukemia & Lymphoma 45:2, 291-300
CrossRef562
Steve K Teo, Wayne A Colburn, William G Tracewell, Karin A Kook, David I Stirling, Markian S Jaworsky, Michael A Scheffler, Steve D Thomas, Oscar L Laskin. (2004) Clinical Pharmacokinetics of Thalidomide. Clinical Pharmacokinetics 43:5, 311-327
CrossRef563
P Joy Ho, John Gibson, Douglas E Joshua. (2004) Treatment of Multiple Myeloma. American Journal of Cancer 3:1, 47-66
CrossRef564
Dina M. Elaraj, Donald E. White, Seth M. Steinberg, Leah Haworth, Steven A. Rosenberg, James C. Yang. (2004) A Pilot Study of Antiangiogenic Therapy with Bevacizumab and Thalidomide in Patients with Metastatic Renal Cell Carcinoma. Journal of Immunotherapy 27:4, 259-264
CrossRef565
Enrico Balleari, Riccardo Ghio, Antonietta Falcone, Pellegrino Musto. (2004) Possible Multiple Myeloma Dedifferentiation Following Thalidomide Therapy: A Report of Four Cases. Leukemia & Lymphoma 45:4, 735-738
CrossRef566
ATHANASIOS ANAGNOSTOPOULOS, GEORGE HAMILOS, MARKELA P ZORZOU, VASILIKI GRIGORAKI, DIMITRA ANAGNOSTOU, MELETIOS ATHANASIOS DIMOPOULOS. (2004) Discordant Response or Progression in Patients with Myeloma Treated with Thalidomide-based Regimens. Leukemia & Lymphoma 45:1, 113-116
CrossRef567
Hirofumi NAGANUMA, Satoshi SAKATSUME, Masao SUGITA, Eiji SATOH, Takayuki ASAHARA, Hideaki NUKUI. (2004) Solitary Plasmacytoma of the Skull: Immunohistochemical Study of Angiogenic Factors and Syndecan-1-Two Case Reports-. Neurologia medico-chirurgica 44:4, 195-200
CrossRef568
C. Strupp, U. Germing, A. Scherer, A. Kundgen, U. Modder, N. Gattermann, R. Haas. (2004) Thalidomide for the treatment of idiopathic myelofibrosis. European Journal of Haematology 72:1, 52-57
CrossRef569
Stadtmauer, Edward A., . (2003) Multiple Myeloma, 2004 — One or Two Transplants?. New England Journal of Medicine 349:26, 2551-2553
Full Text570
Attal, Michel, Harousseau, Jean-Luc, Facon, Thierry, Guilhot, François, Doyen, Chantal, Fuzibet, Jean-Gabriel, Monconduit, Mathieu, Hulin, Cyrille, Caillot, Denis, Bouabdallah, Reda, Voillat, Laurent, Sotto, Jean-Jacques, Grosbois, Bernard, Bataille, Regis, . (2003) Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine 349:26, 2495-2502
Full Text571
Bronwen E. Shaw, Karl Peggs, Jennifer M. Bird, Jamie Cavenagh, A. Hunter, J. Alejandro Madrigal, Nigel H. Russell, Bhawna Sirohi, Keiren Towlson, Catherine D. Williams, David I. Marks. (2003) The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma. British Journal of Haematology 123:5, 886-895
CrossRef572
Liang Deng, Wanhong Ding, Richard D. Granstein. (2003) Thalidomide Inhibits Tumor Necrosis Factor-alpha Production and Antigen Presentation by Langerhans Cells. Journal of Investigative Dermatology 121:5, 1060-1065
CrossRef573
Deborah A. Thomas, Elihu Estey, Francis J. Giles, Stefan Faderl, Jorge Cortes, Michael Keating, Susan O'Brien, Maher Albitar, Hagop Kantarjian. (2003) Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. British Journal of Haematology 123:3, 436-441
CrossRef574
James C. Barton. (2003) Thalidomide and dexamethasone therapy of myeloma in a patient with previously untreated B-chronic lymphocytic leukemia. American Journal of Hematology 74:3, 205-207
CrossRef575
S.Vincent Rajkumar. (2003) Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease. Seminars in Hematology 40, 17-22
CrossRef576
Michael A. Thompson, Thomas E. Witzig, Shaji Kumar, Michael M. Timm, Jessica Haug, Rafael Fonseca, Philip R. Greipp, John A. Lust, S. Vincent Rajkumar. (2003) Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. British Journal of Haematology 123:2, 305-308
CrossRef577
Hon-Wah Man, Laura G Corral, David I Stirling, George W Muller. (2003) α-Fluoro-substituted thalidomide analogues. Bioorganic & Medicinal Chemistry Letters 13:20, 3415-3417
CrossRef578
Bart Barlogie. (2003) Introduction: thalidomide and the IMiDs in multiple myeloma. Seminars in Hematology 40, 1-2
CrossRef579
S.A. Schey, J. Cavenagh, R. Johnson, J.A. Child, H. Oakervee, R.W. Jones. (2003) An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leukemia Research 27:10, 909-914
CrossRef580
Bart Barlogie. (2003) Thalidomide and CC-5013 in multiple myeloma: the University of Arkansas experience. Seminars in Hematology 40, 33-38
CrossRef581
Raymond Alexanian, Donna Weber, Athanasios Anagnostopoulos, Kay Delasalle, Michael Wang, Kim Rankin. (2003) Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Seminars in Hematology 40, 3-7
CrossRef582
Meletios A Dimopoulos, Athanasios Anagnostopoulos. (2003) Thalidomide in relapsed/refractory multiple myeloma: pivotal trials conducted outside the United States. Seminars in Hematology 40, 8-16
CrossRef583
S. Yamamoto, D. K. C. Cooper. (2003) An investigation of the effect of thalidomide on anti-gal antibody production in baboons. Xenotransplantation 10:5, 470-474
CrossRef584
Martin H. Kropff, Nicola Lang, Guido Bisping, Nicole Domine, Georg Innig, Markus Hentrich, Manfred Mitterer, Thomas Sudhoff, Roland Fenk, Christian Straka, Achim Heinecke, Olaf M. Koch, Helmut Ostermann, Wolfgang E. Berdel, Joachim Kienast. (2003) Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. British Journal of Haematology 122:4, 607-616
CrossRef585
Peng Liu, Yi Wang, Yan-Han Li, Chen Yang, Yu-Ling Zhou, Bin Li, Shi-Hong Lu, Ren-Chi Yang, Ying-Lin Cai, Gerard Tobelem, Jacques Caen, Zhong Chao Han. (2003) Adenovirus-mediated gene therapy with an antiangiogenic fragment of thrombospondin-1 inhibits human leukemia xenograft growth in nude mice. Leukemia Research 27:8, 701-708
CrossRef586
Diely Pichardo, Seema Singhal, Jayesh Mehta, Steven Rosen. (2003) Recent Developments and Future Directions in the Treatment of Multiple Myeloma. Cancer Biotherapy & Radiopharmaceuticals 18:4, 497-511
CrossRef587
Teru Hideshima, Paul Richardson, Kenneth C. Anderson. (2003) Novel therapeutic approaches for multiple myeloma. Immunological Reviews 194:1, 164-176
CrossRef588
Heinz Gisslinger, Mathias Kees. (2003) Therapy strategies for multiple myeloma: current status. Wiener Klinische Wochenschrift 115:13-14, 451-461
CrossRef589
E. Harris, J. Behrens, D. Samson, A. Rahemtulla, N. H. Russell, J. L. Byrne. (2003) Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. British Journal of Haematology 122:1, 160-161
CrossRef590
Massimo Fanelli, Roberta Sarmiento, Domenico Gattuso, Guido Carillio, Barbara Capaccetti, Angelo Vacca, Aldo Maria Roccaro, Giampietro Gasparini. (2003) Thalidomide: a new anticancer drug?. Expert Opinion on Investigational Drugs 12:7, 1211-1225
CrossRef591
Ronnie Tung-Ping Poon, Sheung-Tat Fan, John Wong. (2003) Clinical Significance of Angiogenesis in Gastrointestinal Cancers. Annals of Surgery 238:1, 9-28
CrossRef592
Richardson, Paul G., Barlogie, Bart, Berenson, James, Singhal, Seema, Jagannath, Sundar, Irwin, David, Rajkumar, S. Vincent, Srkalovic, Gordan, Alsina, Melissa, Alexanian, Raymond, Siegel, David, Orlowski, Robert Z., Kuter, David, Limentani, Steven A., Lee, Stephanie, Hideshima, Teru, Esseltine, Dixie-Lee, Kauffman, Michael, Adams, Julian, Schenkein, David P., Anderson, Kenneth C., . (2003) A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. New England Journal of Medicine 348:26, 2609-2617
Full Text593
Sandeep R. Pandit, David H. Vesole. (2003) Management of renal dysfunction in multiple myeloma. Current Treatment Options in Oncology 4:3, 239-246
CrossRef594
Didier Clerc, Jean-Paul Fermand, Xavier Mariette. (2003) Treatment of multiple myeloma. Joint Bone Spine 70:3, 175-186
CrossRef595
Keith Dredge, Angus G. Dalgleish, J. Blake Marriott. (2003) Thalidomide analogs as emerging anti-cancer drugs. Anti-Cancer Drugs 14:5, 331-335
CrossRef596
Athanasios Anagnostopoulos, Donna Weber, Kim Rankin, Kay Delasalle, Raymond Alexanian. (2003) Thalidomide and dexamethasone for resistant multiple myeloma. British Journal of Haematology 121:5, 768-777
CrossRef597
Seema Singhal, Jayesh Mehta. (2003) Treatment of relapsed and refractory multiple myeloma. Current Treatment Options in Oncology 4:3, 229-237
CrossRef598
Kazunori Imada. (2003) Immunodeficient Mouse Models of Lymphoid Tumors. International Journal of Hematology 77:4, 336-341
CrossRef599
Apostolia-Maria Tsimberidou, Tracey Waddelow, Hagop M Kantarjian, Maher Albitar, Francis J Giles. (2003) Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNFα levels during treatment. Leukemia Research 27:5, 375-380
CrossRef600
Stuart M. Lichtman, J.Andrew Skirvin, Sunitha Vemulapalli. (2003) Pharmacology of antineoplastic agents in older cancer patients. Critical Reviews in Oncology/Hematology 46:2, 101-114
CrossRef601
S.Vincent Rajkumar, Suzanne Hayman, Philip R. Greipp. (2003) Angiogenesis in Waldenstrom's macroglobulinemia. Seminars in Oncology 30:2, 262-264
CrossRef602
Mark C. Okafor. (2003) Thalidomide for Erythema Nodosum Leprosum and Other Applications. Pharmacotherapy 23:4, 481-493
CrossRef603
M.A. Dimopoulos, C. Tsatalas, A. Zomas, G. Hamilos, P. Panayiotidis, D. Margaritis, C. Matsouka, T. Economopoulos, N. Anagnostopoulos. (2003) Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Seminars in Oncology 30:2, 265-269
CrossRef604
Morton Coleman, John Leonard, Larry Lyons, Hubert Szelenyi, Ruben Niesvizky. (2003) Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone. Seminars in Oncology 30:2, 270-274
CrossRef605
Seema Singhal, Jayesh Mehta. (2003) Novel Therapies in Multiple Myeloma. International Journal of Hematology 77:3, 226-231
CrossRef606
Jorge Cortes, Hagop Kantarjian, Maher Albitar, Deborah Thomas, Stefan Faderl, Charles Koller, Guillermo Garcia-Manero, Francis Giles, Michael Andreeff, Susan O'Brien, Michael Keating, Elihu Estey. (2003) A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer 97:5, 1234-1241
CrossRef607
T.M Moehler, A.D Ho, H Goldschmidt, B Barlogie. (2003) Angiogenesis in hematologic malignancies. Critical Reviews in Oncology/Hematology 45:3, 227-244
CrossRef608
T. Barbui, A. Falanga. (2003) Thalidomide and thrombosis in multiple myeloma. Journal of Thrombosis and Haemostasis 1:3, 421-422
CrossRef609
M. C. Minnema, R. Fijnheer, P. G. De Groot, H. M. Lokhorst. (2003) Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. Journal of Thrombosis and Haemostasis 1:3, 445-449
CrossRef610
Perla Vicari, Christian Ribas, Manuella Sampaio, Adriano M Arantes, Mihoko Yamamoto, Joao B Reis Filho, Roberto A Segreto, Jose Orlando Bordin, Gisele W B Colleoni. (2003) Can thalidomide be effective to treat plasma cell leptomeningeal infiltration?. European Journal of Haematology 70:3, 198-199
CrossRef611
McDonald K. Horne, William D. Figg, Phil Arlen, James Gulley, Catherine Parker, Nehal Lakhani, Howard Parnes, William L. Dahut. (2003) Increased Frequency of Venous Thromboembolism with the Combination of Docetaxel and Thalidomide in Patients with Metastatic Androgen-Independent Prostate Cancer. Pharmacotherapy 23:3, 315-318
CrossRef612
David P Steensma, Ayalew Tefferi. (2003) The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leukemia Research 27:2, 95-120
CrossRef613
Jingyi Li, Markian S Jaworsky, David I Stirling. (2003) The determination of a potential impurity in Thalidomide drug substance and product by HPLC with indirect UV detection. Journal of Pharmaceutical and Biomedical Analysis 31:1, 19-27
CrossRef614
Shima Uneda, Hiroyuki Hata, Fumihiko Matsuno, Akitoshi Nagasaki, Naoko Harada, Yumi Mitsuya, Hiromitsu Matsuzaki, Hiroaki Mitsuya. (2003) A nitric oxide synthase inhibitor, NG-nitro-l-arginine-methyl-ester, exerts potent antiangiogenic effects on plasmacytoma in a newly established multiple myeloma severe combined immunodeficient mouse model. British Journal of Haematology 120:3, 396-404
CrossRef615
Ulrika Norén-Nyström, Maria Eriksson, Björn Eriksson, Göran Roos, Anders Bergh, Dan Holmberg. (2003) Antitumor activity of the angiogenesis inhibitor TNP-470 on murine lymphoma/leukemia cells in vivo and in vitro. Experimental Hematology 31:2, 143-149
CrossRef616
Scott R Plotkin, Patrick Y Wen. (2003) Neurologic complications of cancer therapy. Neurologic Clinics 21:1, 279-318
CrossRef617
S.James Matthews, Christopher McCoy. (2003) Thalidomide: A review of approved and investigational uses. Clinical Therapeutics 25:2, 342-395
CrossRef618
Domenico Ribatti, Angelo Vacca, Franco Dammacco, Denis English. (2003) Angiogenesis and Anti-Angiogenesis in Hematological Malignancies. Journal of Hematotherapy <html_ent glyph="@amp;" ascii="&"/> Stem Cell Research 12:1, 11-22
CrossRef619
Kenneth C. Anderson. (2003) Moving disease biology from the lab to the clinic. Cancer 97:S3, 796-801
CrossRef620
M. Kees, G. Dimou, C. Sillaber, J. Drach, J. Ackermann, K. Lechner, H. Gisslinger. (2003) Low Dose Thalidomide in Patients with Relapsed or Refractory Multiple Myeloma. Leukemia & Lymphoma 44:11, 1943-1946
CrossRef621
Tsuyoshi Iwasaki, Hajime Sano. (2003) Predicting Treatment Responses and Disease Progression in Myeloma using Serum Vascular Endothelial Growth Factor and Hepatocyte Growth Factor Levels. Leukemia & Lymphoma 44:8, 1275-1279
CrossRef622
A.D. Wechalekar, C.I. Chen, D. Sutton, D. Reece, M. Voralia, A.K. Stewart. (2003) Intermediate Dose Thalidomide (200 mg Daily) has Comparable Efficacy and Less Toxicity than Higher Doses in Relapsed Multiple Myeloma. Leukemia & Lymphoma 44:7, 1147-1149
CrossRef623
Veena John, Sandeep Mashru, Stuart M Lichtman. (2003) Pharmacological Factors Influencing Anticancer Drug Selection in the Elderly. Drugs & Aging 20:10, 737-759
CrossRef624
(2003) Novel therapies for multiple myeloma. British Journal of Haematology 120:1, 10-17
CrossRef625
Mitchell N. Rashid, Francisco Fuentes, Robert C. Touchon, Paulette S. Wehner. (2003) Obesity and the Risk for Cardiovascular Disease. Preventive Cardiology 6:1, 42-47
CrossRef626
Saad Habib Abdalla, Sarah Mahmoud. (2003) Thalidomide in Relapsed or Refractory Multiple Myeloma: How Much and for How Long?. Leukemia & Lymphoma 44:6, 989-991
CrossRef627
John Shaughnessy, Erming Tian, Jeffrey Sawyer, Jason McCoy, Guido Tricot, Joth Jacobson, Elias Anaissie, Maurizio Zangari, Athanasios Fassas, Firas Muwalla, Christopher Morris, Bart Barlogie. (2003) Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. British Journal of Haematology 120:1, 44-52
CrossRef628
Robert P Baughman, Michael Iannuzzi. (2003) Tumour Necrosis Factor in Sarcoidosis and its Potential for Targeted Therapy. BioDrugs 17:6, 425-431
CrossRef629
V. Eleutherakis-Papaiakovou, M. Karali, I. Kokkonouzis, I. Tiliakos, M.A. Dimopoulos. (2003) Bone Marrow Angiogenesis and Progression in Multiple Myeloma: Clinical Significance and Therapeutic Approach. Leukemia & Lymphoma 44:6, 937-948
CrossRef630
Christian Ribas, Gisele W.B. Colleoni. (2003) Advances in the Treatment of Multiple Myeloma: The Role of Thalidomide. Leukemia & Lymphoma 44:2, 291-298
CrossRef631
Alvaro Aguayo, Francis Giles, Maher Albitar. (2003) Vascularity, Angiogenesis and Angiogenic Factors in Leukemias and Myelodysplastic Syndromes. Leukemia & Lymphoma 44:2, 213-222
CrossRef632
(2003) Thalidomide in multiple myeloma: current status and future prospects. British Journal of Haematology 120:1, 18-26
CrossRef633
Angela Dispenzieri, Martha Q. Lacy, S. Vincent Rajkumar, Susan M. Geyer, Thomas E. Witzig, Rafael Fonseca, John A. Lust, Philip R. Greipp, Robert A. Kyle, Morie A. Gertz. (2003) Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 10:4, 257-261
CrossRef634
Leonard T Heffner, Sagar Lonial. (2003) Breakthroughs in the Management of Multiple Myeloma. Drugs 63:16, 1621-1636
CrossRef635
Tsuyoshi Iwasaki, Hajime Sano. (2003) Predicting Treatment Responses and Disease Progression in Myeloma using Serum Vascular Endothelial Growth Factor and Hepatocyte Growth Factor Levels. Leukemia & Lymphoma 44:8, 1347-1351
CrossRef636
S. Kumar, M. A. Gertz, A. Dispenzieri, M. Q. Lacy, S. M. Geyer, N. L. Iturria, R. Fonseca, S. R. Hayman, J. A. Lust, R. A. Kyle, P. R. Greipp, T. E. Witzig, S. V. Rajkumar. (2003) Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple Myeloma. Mayo Clinic Proceedings 78:1, 34-39
CrossRef637
K. C. Anderson. (2003) Multiple Myeloma: How Far Have We Come?. Mayo Clinic Proceedings 78:1, 15-17
CrossRef638
Kathrin Strasser, Heinz Ludwig. (2002) Thalidomide treatment in multiple myeloma. Blood Reviews 16:4, 207-215
CrossRef639
Keith Dredge, Angus G Dalgleish, J Blake Marriott. (2002) Recent developments in antiangiogenic therapy. Expert Opinion on Biological Therapy 2:8, 953-966
CrossRef640
Shaji Kumar, Rafael Fonseca, Angela Dispenzieri, Martha Q. Lacy, John A. Lust, Thomas E. Witzig, Morie A. Gertz, Robert A. Kyle, Philip R. Greipp, S. Vincent Rajkumar. (2002) Bone marrow angiogenesis in multiple myeloma: effect of therapy. British Journal of Haematology 119:3, 665-671
CrossRef641
T Hoang. (2002) Novel therapies for lung cancer. Surgical Oncology 11:4, 229-241
CrossRef642
Sylvie Bastuji-Garin, Sophie Ochonisky, Pierre Bouche, Romain K Gherardi, Corinne Duguet, Zaya Djerradine, Florence Poli, Jean Revuz, . (2002) Incidence and Risk Factors for Thalidomide Neuropathy: a Prospective Study of 135 Dermatologic Patients. Journal of Investigative Dermatology 119:5, 1020-1026
CrossRef643
Noopur Raje, Kenneth C. Anderson. (2002) Thalidomide and immunomodulatory drugs as cancer therapy. Current Opinion in Oncology 14:6, 635-640
CrossRef644
Apurva A. Desai, Nicholas J. Vogelzang, Brian I. Rini, Rafat Ansari, Stuart Krauss, Walter M. Stadler. (2002) A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 95:8, 1629-1636
CrossRef645
J. B. MARRIOTT, I. A. CLARKE, K. DREDGE, G. MULLER, D. STIRLING, A. G. DALGLEISH. (2002) Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4+ and CD8+ T cells. Clinical and Experimental Immunology 130:1, 75-84
CrossRef646
Edward A. Wilson, Shialesh Jobanputra, Robert Jackson, Anne N. Parker, I. Grant McQuaker. (2002) Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report. British Journal of Haematology 119:1, 128-130
CrossRef647
Robert Kerbel, Judah Folkman. (2002) Clinical translation of angiogenesis inhibitors. Nature Reviews Cancer 2:10, 727-739
CrossRef648
Joan J Ryoo, Craig Emmitt Cole, Kenneth C Anderson. (2002) Novel therapies for multiple myeloma. Blood Reviews 16:3, 167-174
CrossRef649
Deepak Gupta, Teru Hideshima, Kenneth C. Anderson. (2002) NOVEL BIOLOGICALLY BASED THERAPEUTIC STRATEGIES IN MYELOMA. Reviews in Clinical and Experimental Hematology 6:3, 301-324
CrossRef650
Martin A. Pule, Christian Gullmann, Deirdre Dennis, Corrina McMahon, Michael Jeffers, Owen P. Smith. (2002) Increased angiogenesis in bone marrow of children with acute lymphoblastic leukaemia has no prognostic significance. British Journal of Haematology 118:4, 991-998
CrossRef651
Goldschmidt H., Cremer F. W., Möhler Th., Krämer A., Görner M., Egerer G., Ho A. D.. (2002) Therapy of multiple myeloma. The Chinese-German Journal of Clinical Oncology 1:3, 141-144
CrossRef652
S.R Porter, J Jorge Jr. (2002) Thalidomide: a role in oral oncology?. Oral Oncology 38:6, 527-531
CrossRef653
Giancarlo Pruneri, Maurilio Ponzoni, Andrés J. M. Ferreri, Nicola Decarli, Moreno Tresoldi, Francesca Raggi, Chiara Baldessari, Massimo Freschi, Luca Baldini, Maria Goldaniga, Antonino Neri, Nadia Carboni, Francesco Bertolini, Giuseppe Viale. (2002) Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. British Journal of Haematology 118:3, 817-820
CrossRef654
EDWARD PODCZASKI, JOANNA CAIN. (2002) Multiple Myeloma. Clinical Obstetrics and Gynecology 45:3, 928-938
CrossRef655
Jean-Luc Harousseau. (2002) MANAGEMENT OF MULTIPLE MYELOMA. Reviews in Clinical and Experimental Hematology 6:3, 253-275
CrossRef656
Tsunayuki Kakimoto, Yutaka Hattori, Shinichiro Okamoto, Norihide Sato, Tamihiro Kamata, Masaya Yamaguchi, Kunihiko Morita, Taketo Yamada, Nobuyuki Takayama, Hideo Uchida, Naoki Shimada, Yusuke Tanigawara, Yasuo Ikeda. (2002) Thalidomide for the Treatment of Refractory Multiple Myeloma: Association of Plasma Concentrations of Thalidomide and Angiogenic Growth Factors with Clinical Outcome. Cancer Science 93:9, 1029-1036
CrossRef657
Danai D. Daliani, Christos N. Papandreou, Peter F. Thall, Xuemei Wang, Cherie Perez, Rose Oliva, Lance Pagliaro, Robert Amato. (2002) A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer 95:4, 758-765
CrossRef658
Robert Z Orlowski, Albert S Baldwin. (2002) NF-κB as a therapeutic target in cancer. Trends in Molecular Medicine 8:8, 385-389
CrossRef659
Tien Hoang, Joan H Schiller. (2002) Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy. Expert Review of Anticancer Therapy 2:4, 393-401
CrossRef660
Rita M. Cool, Jon D. Herrington. (2002) Thalidomide for the Treatment of Relapsed and Refractory Multiple Myeloma. Pharmacotherapy 22:8, 1019-1028
CrossRef661
S. V. Rajkumar, M. A. Gertz, R. A. Kyle, P. R. Greipp, . (2002) Current Therapy for Multiple Myeloma. Mayo Clinic Proceedings 77:8, 813-822
CrossRef662
B. Myers, G. Dolan. (2002) Analysis of durability of response to thalidomide treatment for relapsed myeloma patients. British Journal of Haematology 118:1, 347-347
CrossRef663
Marc Pulik, Philippe Genet, Fran
CrossRef664
Edward S. Kim, Roy S. Herbst. (2002) Angiogenesis inhibitors in lung cancer. Current Oncology Reports 4:4, 325-333
CrossRef665
Orhan Sezer, Kathrin Niemöller, Christian Jakob, Ulrike Heider. (2002) Angiogenesis in multiple myeloma. Leukemia Research 26:7, 701-702
CrossRef666
R. Alexanian. (2002) Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. Annals of Oncology 13:7, 1116-1119
CrossRef667
B. Escudier. (2002) Phase II trial of thalidomide in renal-cell carcinoma. Annals of Oncology 13:7, 1029-1035
CrossRef668
Marco Ladetto, Paola Omedè, Selina Sametti, John W. Donovan, Monica Astolfi, Daniela Drandi, Federica Volpato, Luisa Giaccone, Fulvia Giaretta, Antonio Palumbo, Benedetto Bruno, Alessandro Pileri, John G. Gribben, Mario Boccadoro. (2002) Real-time polymerase chain reaction in multiple myeloma. Experimental Hematology 30:6, 529-536
CrossRef669
(2002) Efficacy of thalidomide in the treatment of vad-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma. British Journal of Haematology 117:4, 996-996
CrossRef670
Kenichiro Yata, Takemi Otsuki, Osamu Yamada, Hideho Wada, Yoshihito Yawata, Takashi Sugihara. (2002) Synergistic Growth Inhibition of YM529 with Biologic Response Modifiers (BRMs) in Myeloma Cells. International Journal of Hematology 75:5, 534-539
CrossRef671
Michelle A. Elliott, Ruben A. Mesa, Chin-Yang Li, C. Christopher Hook, Stephen M. Ansell, Ralph M. Levitt, Susan M. Geyer, Ayalew Tefferi. (2002) Thalidomide treatment in myelofibrosis with myeloid metaplasia. British Journal of Haematology 117:2, 288-296
CrossRef672
P Richardson, T Hideshima, K Anderson. (2002) Thalidomide in multiple myeloma. Biomedicine & Pharmacotherapy 56:3, 115-128
CrossRef673
Renchi Yang, Zhong Chao Han. (2002) Angiogenesis in Hematologic Malignancies and Its Clinical Implications. International Journal of Hematology 75:3, 246-256
CrossRef674
OSCAR ARRIETA, PATRICIA GUEVARA, JOAQUÍN TAMARIZ, DANIEL REMBAO, ERIKA RIVERA, JULIO SOTELO. (2002) Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma. International Journal of Experimental Pathology 83:2, 99-104
CrossRef675
S. Kumar, T. E. Witzig, S. V. Rajkumar. (2002) Thalidomide as an anti-cancer agent. Journal of Cellular and Molecular Medicine 6:2, 160-174
CrossRef676
S Zweegman, PC Huijgens. (2002) Treatment of myeloma: recent developments. Anti-Cancer Drugs 13:4, 339-351
CrossRef677
Athanasios B.-T. Fassas, Firas Muwalla, Tanya Berryman, Riad Benramdane, Lija Joseph, Elias Anaissie, Rajesh Sethi, Raman Desikan, David Siegel, Ashraf Badros, Amir Toor, Maurizio Zangari, Christopher Morris, Edgardo Angtuaco, Sajini Mathew, Carla Wilson, Aubrey Hough, Sami Harik, Bart Barlogie, Guido Tricot. (2002) Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. British Journal of Haematology 117:1, 103-108
CrossRef678
Fran Balkwill. (2002) Tumor necrosis factor or tumor promoting factor?. Cytokine & Growth Factor Reviews 13:2, 135-141
CrossRef679
E Van Valckenborgh, H De Raeve, L Devy, S Blacher, C Munaut, A Noël, E Van Marck, I Van Riet, B Van Camp, K Vanderkerken. (2002) Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo. British Journal of Cancer 86:5, 796-802
CrossRef680
Ruben A. Mesa. (2002) Clinical and scientific advances in the philadelphia-chromosome negative chronic myeloproliferative disorders. International Journal of Hematology 76:S2, 193-203
CrossRef681
Igor Semenov, Canan Akyuz, Vera Roginskaya, Dharminder Chauhan, Seth J Corey. (2002) Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol. Leukemia Research 26:3, 271-280
CrossRef682
Ruben A. Mesa. (2002) The therapy of myelofibrosis: Targeting pathogenesis. International Journal of Hematology 76:S2, 296-304
CrossRef683
W. Michael Kuehl, P. Leif Bergsagel. (2002) Multiple myeloma: evolving genetic events and host interactions. Nature Reviews Cancer 2:3, 175-187
CrossRef684
Tsuyoshi Iwasaki, Teruaki Hamano, Atsushi Ogata, Naoaki Hashimoto, Masayasu Kitano, Eizo Kakishita. (2002) Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. British Journal of Haematology 116:4, 796-802
CrossRef685
Stephane Supiot, Alain Faivre-Chauvet, Olivier Couturier, Marie Fran
CrossRef686
Steve K Teo, Reddy S Chandula, Jill L Harden, David I Stirling, Steve D Thomas. (2002) Sensitive and rapid method for the determination of thalidomide in human plasma and semen using solid-phase extraction and liquid chromatography–tandem mass spectrometry. Journal of Chromatography B 767:1, 145-151
CrossRef687
S Singhal, J Mehta. (2002) Thalidomide in cancer. Biomedicine & Pharmacotherapy 56:1, 4-12
CrossRef688
Roberto Stasi, Sergio Amadori. (2002) The Role of Angiogenesis in Hematologic Malignancies. Journal of Hematotherapy <html_ent glyph="@amp;" ascii="&"/> Stem Cell Research 11:1, 49-68
CrossRef689
Paul Richardson, Teru Hideshima, Kenneth Anderson. (2002) T
HALIDOMIDE : Emerging Role in Cancer Medicine. Annual Review of Medicine 53:1, 629-657
CrossRef690
Douglas K. Price, Yuichi Ando, Erwin A. Kruger, Michael Weiss, William D. Figg. (2002) 5´-OH-Thalidomide, a Metabolite of Thalidomide, Inhibits Angiogenesis. Therapeutic Drug Monitoring 24:1, 104-110
CrossRef691
Robert J. Amato. (2002) Thalidomide: An antineoplastic agent. Current Oncology Reports 4:1, 56-62
CrossRef692
F Zorat, G Pozzato. (2002) Thalidomide in myelodysplastic syndromes. Biomedicine & Pharmacotherapy 56:1, 20-30
CrossRef693
Paul D Nathan, Tim G Eisen. (2002) The biological treatment of renal-cell carcinoma and melanoma. The Lancet Oncology 3:2, 89-96
CrossRef694
S. Vincent Rajkumar, Ruben A. Mesa, Ayalew Tefferi. (2002) A Review of Angiogenesis and Anti-Angiogenic Therapy in Hematologic Malignancies. Journal of Hematotherapy <html_ent glyph="@amp;" ascii="&"/> Stem Cell Research 11:1, 33-47
CrossRef695
Giovanni Barosi, Michelle Elliott, Letizia Canepa, Filippo Ballerini, Pier Paolo Piccaluga, Giuseppe Visani, Monia Marchetti, Gabriele Pozzato, Francesca Zorat, Ayalew Tefferi. (2002) Thalidomide in Myelofibrosis with Myeloid Metaplasia: A Pooled-analysis of Individual Patient Data from Five Studies. Leukemia & Lymphoma 43:12, 2301-2307
CrossRef696
Semra Paydas, Suzan Zorludemir, Fikri Baslamisli, Ilhan Tuncer. (2002) Vascular Endothelial Growth Factor (VEGF) Expression in Plasmacytoma. Leukemia & Lymphoma 43:1, 139-143
CrossRef697
Guido J. Tricot. (2002) New insights into role of microenvironment in multiple myeloma. International Journal of Hematology 76:S1, 334-336
CrossRef698
M. Offidani, A. Mele, L. Corvatta, M. Marconi, L. Malerba, A. Olivieri, S. Rupoli, F. Alesiani, P. Leoni. (2002) Gemcitabine Alone or Combined with Cisplatin in Relapsed or Refractory Multiple Myeloma. Leukemia & Lymphoma 43:6, 1273-1280
CrossRef699
Morton Coleman, John Leonard, Larry Lyons, Karen Pekle, Kenneth Nahum, Roger Pearse, Ruben Niesvizky, Joseph Michaeli. (2002) BLT-D (Clarithromycin [Biaxin], Low-Dose Thalidomide, and Dexamethasone) for the Treatment of Myeloma and Waldenström's Macroglobulinemia. Leukemia & Lymphoma 43:9, 1777-1782
CrossRef700
Megan G. Marks, Jiandong Shi, Michael O. Fry, Zili Xiao, Michelle Trzyna, Vedavalli Pokala, Michael A. Ihnat, Pui-Kai Li. (2002) Effects of Putative Hydroxylated Thalidomide Metabolites on Blood Vessel Density in the Chorioallantoic Membrane (CAM) Assay and on Tumor and Endothelial Cell Proliferation. Biological & Pharmaceutical Bulletin 25:5, 597-604
CrossRef701
Carlos G Ferreira, Cynthia Huisman, Giuseppe Giaccone. (2002) Novel approaches to the treatment of non-small cell lung cancer. Critical Reviews in Oncology/Hematology 41:1, 57-77
CrossRef702
J. Andrew Skirvin, Stuart M. Lichtman. (2002) Pharmacokinetic Considerations of Oral Chemotherapy in Elderly Patients with Cancer. Drugs & Aging 19:1, 25-42
CrossRef703
Bart Barlogie, John D. Shaughnessy. (2002) Early results of total therapy II in multiple myeloma: Implications of cytogenetics and FISH. International Journal of Hematology 76:S1, 337-339
CrossRef704
R.E. Johnston, S.H. Abdalla. (2002) Thalidomide in Low Doses is Effective for the Treatment of Resistant or Relapsed Multiple Myeloma and for Plasma Cell Leukaemia. Leukemia & Lymphoma 43:2, 351-354
CrossRef705
Richard E. Clark, William D. Fraser. (2002) Bone Turnover Following Autologous Transplantation in Multiple Myeloma. Leukemia & Lymphoma 43:3, 511-516
CrossRef706
M.D. Seftel, J. Maguire, N. Voss, W.B. Woodhurst, B.I. Dalal, J.D. Shepherd. (2002) Intra-cerebral Relapse Following Prolonged Remission after Autologous Stem Cell Transplantation for Multiple Myeloma. Leukemia & Lymphoma 43:12, 2399-2403
CrossRef707
Alessandro Pulsoni, Nicoletta Villiv??, Elena Cavalieri, Paolo Falcucci, Giacinto La Verde, Roberta Matera, Maria Teresa Petrucci, Maria Elena Tosti, Franco Mandelli. (2002) Continuous Low Dose of Melphalan and Prednisone in Patients with Multiple Myeloma of Very Old Age or Severe Associated Disease. Drugs & Aging 19:12, 947-953
CrossRef708
Kenneth C. Anderson, Lawrence H. Boise, Robert Louie, Samuel Waxman. (2002) Arsenic Trioxide in Multiple Myeloma. The Cancer Journal 8:1, 12-25
CrossRef709
Shufeng Zhou, Philip Kestell, Malcolm D. Tingle, James W. Paxton. (2002) Thalidomide in Cancer Treatment. Drugs & Aging 19:2, 85-100
CrossRef710
Michael Naughton, Joel Picus. (2002) Advanced Prostate Cancer. American Journal of Cancer 1:1, 13-22
CrossRef711
P. Leif Bergsagel, Hubert Szelényi. 2002. Multiple Myeloma. , 269-274.
CrossRef712
(2001) Diagnosis and management of multiple myeloma. British Journal of Haematology 115:3, 522-540
CrossRef713
Francesca Zorat, Vilasini Shetty, Diya Dutt, Laurie Lisak, Fabiana Nascimben, Krishnan Allampallam, Saleem Dar, Aaron York, Sefer Gezer, Parameswaran Venugopal, Azra Raza. (2001) The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. British Journal of Haematology 115:4, 881-894
CrossRef714
Bernard Combe. (2001) Thalidomide: new indications?. Joint Bone Spine 68:6, 582-587
CrossRef715
Je-Jung Lee, Ik-Joo Chung, Moo-Rim Park, Dong-Wook Ryang, Chang-Soo Park, Hyeoung-Joon Kim. (2001) Increased angiogenesis and Fas-ligand expression are independent processes in acute myeloid leukemia. Leukemia Research 25:12, 1067-1073
CrossRef716
Kai Neben, Thomas Moehler, Alwin Kraemer, Axel Benner, Gerlinde Egerer, Anthony D. Ho, Hartmut Goldschmidt. (2001) Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. British Journal of Haematology 115:3, 605-608
CrossRef717
F.A Scappaticci, N Marina. (2001) New molecular targets and biological therapies in sarcomas. Cancer Treatment Reviews 27:6, 317-326
CrossRef718
James J. Biagi, H. Miles Prince. (2001) Thalidomide is effective for extramedullary relapse of multiple myeloma post-allogeneic bone marrow transplantation. British Journal of Haematology 115:2, 484-484
CrossRef719
R Alexanian, D Weber. (2001) Recent advances in treatment of multiple myeloma and Waldenström’s macroglobulinemia. Biomedicine & Pharmacotherapy 55:9-10, 550-552
CrossRef720
Letizia Canepa, Filippo Ballerini, Riccardo Varaldo, Sabrina Quintino, Lizia Reni, Marino Clavio, Maurizio Miglino, Ivana Pierri, Marco Gobbi. (2001) Thalidomide in agnogenic and secondary myelofibrosis. British Journal of Haematology 115:2, 313-315
CrossRef721
Jennifer E. Tseng, Bonnie S. Glisson, Fadlo R. Khuri, Dong M. Shin, Jeffrey N. Myers, Adel K. El-Naggar, Jennifer S. Roach, Lawrence E. Ginsberg, Peter F. Thall, Xuemei Wang, Stephanie Teddy, Kristie N. Lawhorn, Rebecca E. Zentgraf, Ganene D. Steinhaus, James M. Pluda, James L. Abbruzzese, Waun Ki Hong, Roy S. Herbst. (2001) Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 92:9, 2364-2373
CrossRef722
J Stebbing, C Benson, T Eisen, L Pyle, K Smalley, H Bridle, I Mak, F Sapunar, R Ahern, M E Gore. (2001) The treatment of advanced renal cell cancer with high-dose oral thalidomide. British Journal of Cancer 85:7, 953-958
CrossRef723
Mark W. Kieran, Amy Billett. (2001) ANTIANGIOGENESIS THERAPY. Hematology/Oncology Clinics of North America 15:5, 835-852
CrossRef724
Thomas M. Moehler, Hans Hawighorst, Kai Neben, Gerlinde Egerer, Jens Hillengass, Regina Max, Axel Benner, Anthony D. Ho, Gerhard van Kaick, Hartmut Goldschmidt. (2001) Bone marrow microcirculation analysis in multiple myeloma by contrast-enhanced dynamic magnetic resonance imaging. International Journal of Cancer 93:6, 862-868
CrossRef725
F.M. Molloy, M.K. Floeter, N.A. Syed, F. Sandbrink, E. Culcea, S.M. Steinberg, W. Dahut, J. Pluda, E.A. Kruger, E. Reed, W.D. Figg. (2001) Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle & Nerve 24:8, 1050-1057
CrossRef726
J Blake Marriott, George Muller, David Stirling, Angus G Dalgleish. (2001) Immunotherapeutic and antitumour potential of thalidomide analogues. Expert Opinion on Biological Therapy 1:4, 675-682
CrossRef727
Giovanni Barosi, Alberto Grossi, Benedetto Comotti, Pellegrino Musto, Gabriella Gamba, Monia Marchetti. (2001) Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. British Journal of Haematology 114:1, 78-83
CrossRef728
Bart Barlogie, Maurizio Zangari, Trey Spencer, Athanasios Fassas, Elias Anaissie, Ashraf Badros, Jeana Cromer, Guido Tricot. (2001) Thalidomide in the management of multiple myeloma. Seminars in Hematology 38:3, 250-259
CrossRef729
John V. Heymach. (2001) Angiogenesis and antiangiogenic approaches to sarcomas. Current Opinion in Oncology 13:4, 261-269
CrossRef730
Kenneth C Anderson. (2001) Targeted therapy for multiple myeloma. Seminars in Hematology 38:3, 286-294
CrossRef731
Bart Barlogie. (2001) Introduction to therapies in multiple myeloma. Seminars in Hematology 38:3, 201-202
CrossRef732
Athanasios Fassas, Guido Tricot. (2001) Results of high-dose treatment with autologous stem cell support in patients with multiple myeloma. Seminars in Hematology 38:3, 231-242
CrossRef733
Osman, Keren, Comenzo, Raymond, , Rajkumar, S. Vincent, . (2001) Deep Venous Thrombosis and Thalidomide Therapy for Multiple Myeloma. New England Journal of Medicine 344:25, 1951-1952
Full Text734
Bruce D. Cheson. (2001) New drug development in non-hodgkin lymphomas. Current Oncology Reports 3:3, 250-259
CrossRef735
James R. Berenson. (2001) Bone disease in myeloma. Current Treatment Options in Oncology 2:3, 271-283
CrossRef736
Heather Schwartzbauer, Thomas A. Tami. (2001) The use of thalidomide in contemporary medical practice: revival of a medical pariah. Current Opinion in Otolaryngology & Head and Neck Surgery 9:3, 172-174
CrossRef737
Suzanne R. Hayman, Rafael Fonseca. (2001) Plasma cell leukemia. Current Treatment Options in Oncology 2:3, 205-216
CrossRef738
. (2001) Weer thalidomide. Medisch-Farmaceutische Mededelingen 39:6, 121-122
CrossRef739
S Vincent Rajkumar. (2001) Thalidomide in the treatment of multiple myeloma. Expert Review of Anticancer Therapy 1:1, 20-28
CrossRef740
Sandeep Pandit, David H. Vesole. (2001) Relapsed multiple myeloma. Current Treatment Options in Oncology 2:3, 261-269
CrossRef741
Joan Blade, Maria Perales, Laura Rosinol, Montserrat Tuset, Silvia Montoto, Jordi Esteve, Francesc Cobo, Luis Villela, Montserrat Rafel, Benet Nomdedeu, Emili Montserrat. (2001) Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. British Journal of Haematology 113:2, 422-424
CrossRef742
S Bolam, DG Oscier. 2001. Tumours of the Immune System. .
CrossRef743
O. Sezer, K. Niemoller, O. Kaufmann, J. Eucker, C. Jakob, I. Zavrski, K. Possinger. (2001) Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy. European Journal of Haematology 66:4, 238-244
CrossRef744
Bart Barlogie. (2001) High-dose therapy and innovative approaches to treatment of multiple myeloma. Seminars in Hematology 38, 21-27
CrossRef745
Robert Fowler, Kevin Imrie. (2001) Thalidomide-associated hepatitis: A case report. American Journal of Hematology 66:4, 300-302
CrossRef746
Kenneth J O’Byrne, William P Steward. (2001) Tumour angiogenesis: a novel therapeutic target in patients with malignant disease. Expert Opinion on Emerging Drugs 6:1, 155-174
CrossRef747
Kenneth C Anderson. (2001) Advances in disease biology: Therapeutic implications. Seminars in Hematology 38, 6-10
CrossRef748
Robert E. Gallagher. (2001) Co-biomodulation with arsenic trioxide in multiple myeloma. Leukemia Research 25:3, 237-239
CrossRef749
Theresa G Zogakis, Steven K Libutti. (2001) General aspects of anti-angiogenesis and cancer therapy. Expert Opinion on Biological Therapy 1:2, 253-275
CrossRef750
Orhan Sezer, Christian Jakob, Jan Eucker, Kathrin Niemoller, Frauke Gatz, Klaus-Dieter Wernecke, Kurt Possinger. (2001) Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. European Journal of Haematology 66:2, 83-88
CrossRef751
Fran Balkwill, Alberto Mantovani. (2001) Inflammation and cancer: back to Virchow?. The Lancet 357:9255, 539-545
CrossRef752
Andrea Mariani, Maurice J. Webb, Gary L. Keeney, Giliola Calori, Karl C. Podratz. (2001) Hematogenous Dissemination in Corpus Cancer. Gynecologic Oncology 80:2, 233-238
CrossRef753
B Grosbois, C Duguet. (2001) Thalidomide : le renouveau. La Revue de Médecine Interne 22:1, 5-7
CrossRef754
Seema Singhal, Jayesh Mehta. (2001) Thalidomide in Cancer. BioDrugs 15:3, 163-172
CrossRef755
Christian Meierhofer, Stefan Dunzendorfer, Christian J. Wiedermann. (2001) Theoretical Basis for the Activity of Thalidomide. BioDrugs 15:10, 681-703
CrossRef756
A.B.-T. Fassas, A.P. Rapoport, J. Bolaňos-Meade, C. Shanholtz, M. Cottler-Fox, G. Tricot. (2001) Tamoxifen-based Treatment Induces Clinically Meaningful Responses in Multiple Myeloma Patients with Relapsing Disease after Autotransplantation. Leukemia & Lymphoma 42:6, 1323-1328
CrossRef757
Todd E. Clark, Norma Edom, Janice Larson, Laura J. Lindsey. (2001) Thalomid?? (Thalidomide) Capsules. Drug Safety 24:2, 87-117
CrossRef758
Abraham Avigdor, Pia Raanani, Itai Levi, Izhar Hardan, Isaac Ben-Bassat. (2001) Extramedullary Progression Despite a Good Response in the Bone Marrow in Patients Treated with Thalidomide for Multiple Myeloma. Leukemia & Lymphoma 42:4, 683-687
CrossRef759
Philip M Ginsburg, Themistocles Dassopoulos, Eli D Ehrenpreis. (2001) Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature. Annals of Medicine 33:8, 516-525
CrossRef760
Stacy A. Rudnicki, Josep Dalmau. (2000) Paraneoplastic syndromes of the spinal cord, nerve, and muscle. Muscle & Nerve 23:12, 1800-1818
CrossRef761
Robert A. Kyle. (2000) Multiple myeloma: an odyssey of discovery. British Journal of Haematology 111:4, 1035-1044
CrossRef762
Brad L. Neiger. (2000) The re-emergence of thalidomide: Results of a scientific conference. Teratology 62:6, 432-435
CrossRef763
Julian Weldon Adlard. (2000) Thalidomide in the treatment of cancer. Anti-Cancer Drugs 11:10, 787-791
CrossRef764
Deborah A. Thomas, Hagop M. Kantarjian. (2000) Current role of thalidomide in cancer treatment. Current Opinion in Oncology 12:6, 564-573
CrossRef765
James R Berenson, Nelida N Sjak-Shie, Robert A Vescio. (2000) The role of human and viral cytokines in the pathogenesis of multiple myeloma. Seminars in Cancer Biology 10:5, 383-391
CrossRef766
Manzoor H. Mangi, Adrian C. Newland. (2000) Angiogenesis and angiogenic mediators in haematological malignancies. British Journal of Haematology 111:1, 43-51
CrossRef767
C. W. Tiplady, G. P. Summerfield. (2000) Continuous low-dose dexamethasone in relapsed or refractory multiple myeloma. British Journal of Haematology 111:1, 381-381
CrossRef768
Jørn Herrstedt. (2000) Prevention and management of mucositis in patients with cancer. International Journal of Antimicrobial Agents 16:2, 161-163
CrossRef769
S.V. Rajkumar, T.E. Witzig. (2000) A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treatment Reviews 26:5, 351-362
CrossRef770
Rajkumar, S. Vincent, Gertz, Morie A., Witzig, Thomas E., . (2000) Life-Threatening Toxic Epidermal Necrolysis with Thalidomide Therapy for Myeloma. New England Journal of Medicine 343:13, 972-973
Full Text771
Andrew L. Feldman, Steven K. Libutti. (2000) Progress in antiangiogenic gene therapy of cancer. Cancer 89:6, 1181-1194
CrossRef772
J. Gutheil, D. Finucane. (2000) Thalidomide therapy in refractory solid tumour patients. British Journal of Haematology 110:3, 754-754
CrossRef773
Susanne Schreiber, Jutta Ackermann, andreas Obermair, Hannes Kaufmann, Eleonora Urbauer, Katharina Aletaha, Heinz Gisslinger, andreas Chott, Heinz Huber, Johannes Drach. (2000) Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization. British Journal of Haematology 110:3, 605-609
CrossRef774
Francesco Bertolini, Patrizia Mancuso, Alberto Gobbi, Giancarlo Pruneri. (2000) The thin red line. Experimental Hematology 28:9, 993-1000
CrossRef775
S V Rajkumar, R Fonseca, A Dispenzieri, M Q Lacy, J A Lust, T E Witzig, R A Kyle, M A Gertz, P R Greipp. (2000) Thalidomide in the treatment of relapsed multiple myeloma.. Mayo Clinic Proceedings 75:9, 897-901
CrossRef776
O Bairey, Y Zimra, E Kaganovsky, M Shaklai, E Okon, E Rabizadeh. (2000) Microvessel density in chemosensitive and chemoresistant diffuse large B-cell lymphomas. Medical Oncology 17:4, 314-318
CrossRef777
Klaus Mross. (2000) Anti-angiogenesis therapy:concepts and importance of dosing schedules in clinical trials. Drug Resistance Updates 3:4, 223-235
CrossRef778
Ezra E.W. Cohen, Everett E. Vokes. (2000) Commentary on “Pilot and Safety Trial of Carboplatin, Paclitaxel, and Thalidomide in Advanced Non–Small-Cell Lung Cancer”. Clinical Lung Cancer 2:1, 53-54
CrossRef779
Gregory A. Masters. (2000) Commentary on “Pilot and Safety Trial of Carboplatin, Paclitaxel, and Thalidomide in Advanced Non–Small-Cell Lung Cancer”. Clinical Lung Cancer 2:1, 55
CrossRef780
Vera Peuckmann, Michael Fisch, Eduardo Bruera. (2000) Potential Novel Uses of Thalidomide. Drugs 60:2, 273-292
CrossRef781
Nelida N. Sjak-Shie, Robert A. Vescio, James R. Berenson. (2000) Recent advances in multiple myeloma. Current Opinion in Hematology 7:4, 241-246
CrossRef782
D. E. Joshua, J. Gibson. (2000) Multiple myeloma - evolving concepts of biology and treatment. Australian and New Zealand Journal of Medicine 30:3, 311-318
CrossRef783
Bruce D. Cheson, Janet Dancey, Anthony Murgo. (2000) New Drugs for the Treament of Chronic Lymphocytic Leukemia. Reviews in Clinical and Experimental Hematology 4:2, 145-166
CrossRef784
Jeffrey M Jacobson. (2000) Thalidomide: a remarkable comeback. Expert Opinion on Pharmacotherapy 1:4, 849-863
CrossRef785
D. M. Aboulafia. (2000) Inflammatory Pseudotumor Causing Small Bowel Obstruction and Mimicking Lymphoma in a Patient with AIDS: Clinical Improvement after Initiation of Thalidomide Treatment. Clinical Infectious Diseases 30:5, 826-831
CrossRef786
Philip R. Greipp. (2000) Smoldering, asymptomatic stage 1, and indolent myeloma. Current Treatment Options in Oncology 1:2, 119-126
CrossRef787
Gunnar Juliusson, Fredrik Celsing, Ingemar Turesson, Stig Lenhoff, Magnus Adriansson, Claes Malm. (2000) Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. British Journal of Haematology 109:1, 89-96
CrossRef788
(2000) Thalidomide in Multiple Myeloma. New England Journal of Medicine 342:13, 975-976
Full Text789
&NA;. (2000) SURVEY ALERT. Obstetrical & Gynecological Survey 55:3, 162
CrossRef790
Noopur Raje, Kenneth C. Anderson. (2000) Multiple myeloma. Current Treatment Options in Oncology 1:1, 73-82
CrossRef791
Olga V. Volpert. (2000) Guest Editorial: Hematopoiesis and Angiogenesis: The Same Landscape from Different Points?. Journal of Hematotherapy <html_ent glyph="@amp;" ascii="&"/> Stem Cell Research 9:1, 5-6
CrossRef792
Steve Teo, Michael Morgan, David Stirling, Steve Thomas. (2000) Assessment of the in vitro and in vivo genotoxicity of Thalomid
CrossRef793
Steve K. Teo, Michael R. Scheffler, Karin A. Kook, William G. Tracewell, Wayne A. Colburn, David I. Stirling, Steve D. Thomas. (2000) Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women. Biopharmaceutics & Drug Disposition 21:1, 33-40
CrossRef794
Guido Tricot. (2000) New insights into role of microenvironment in multiple myeloma. The Lancet 355:9200, 248-250
CrossRef795
Nikhil C Munshi, K.R Desikan, Bart Barlogie. (2000) Clinical experience with thalidomide in multiple myeloma: Phase II trial results in refractory disease and ongoing studies. Seminars in Hematology 37, 15-21
CrossRef796
Raje, Noopur, Anderson, Kenneth, . (1999) Thalidomide — A Revival Story. New England Journal of Medicine 341:21, 1606-1609
Full Text
- Letters
